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INTEGRATION OF EXTRACELLULAR AND INTRACELLULAR SIGNALS VIA THE
CALCIUM SENSING RECEPTOR (CASR)

by

CHEN ZHANG

Under the Direction of Dr. Jenny J. Yang

ABSTRACT
It has long been recognized that Ca2+ acts as a second messenger to regulate diverse crucial
cellular processes in response to external stimuli. The discovery of the parathyroid Ca2+-sensing
receptor (CaSR) has established a new paradigm of Ca2+ signaling as a first messenger. The
CaSR regulates the calcium homeostasis in the human body via sensing fluctuations in the
extracellular Ca2+ concentration. Naturally occurring mutations in the CaSR could result in
abnormal receptor responses toward [Ca2+]o which causes inherited Ca2+ regulation disorders. Lamino acids have been found to stereoselectively interact with the CaSR thus coupling protein
digestion to receptor activity. In the present study, we use several complementary approaches
including imaging [Ca2+]i response in living cells at the cellular level, measuring metal binding
affinity, making site-direct mutagenesis, examining conformational changes of purified

extracellular domains with various spectroscopic methods, and using molecular dynamic (MD)
simulations at the atomic level to provide important insights into the behavior of the receptor in
both normal and disease statuses. We demonstrated that the molecular connectivity between
[Ca2+]o–binding sites is responsible for the functional positive homotropic cooperativity in the
CaSR’s response to [Ca2+]o. Naturally occurring disease mutations near Site 1 disrupted the
cooperativity. We further identified an L-Phe-binding pocket adjacent to Ca2+-binding Site 1.
This L-Phe-binding pocket is essential for functional positive heterotropic cooperativity by virtue
of its having a global impact on all five of the predicted Ca2+-binding sites in the ECD with
regards to [Ca2+]o-evoked [Ca2+]i signaling. Furthermore, the CaSR’s ECD has been expressed
using both bacteria without glycosylation and mammalian systems with either complex glycans,
or high mannose, were characterized using the fluorescence titration spectroscopy, circular
dichroism technique as well as the NMR spectroscopy to show calcium and Phe directly bind to
the ECD domain directly and interactively. Moreover, we also demonstrated that intracellular
trafficking of the CaSR is a complex process, which involves modulation by calmodulin and can
possibly be affected by different CaSR isoforms when expressing in various cell lines. The
studies on the isolated proteins will pave the way for future protein crystallization and related
structural research.

INDEX WORDS: Ca2+, Calcium sensing receptor, L-Phe, Calmodulin, Prediction, Purification,
Fluorescence, Ca2+ Signaling, G-protein coupled receptor (GPCR)
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CHAPTER 1. INTRODUCTION
1.1 The role of Ca2+ in mammalian cells
Before Sydney Ringer serendipitously discovered calcium (Ca2+) to be essential for the
contraction of isolated hearts in 1883(1), Ca2+ had received little attention for years except the
recognition that it was an important element for the formation of bone and teeth. After the mid20th century, research on Ca2+ has grown at an exponential rate and Ca2+ became a universal
carrier for biological information(2). Ca2+ controls the matter of life and death as it modulates the
process of fertilization as well as apoptosis.
1.1.1 General principles of calcium signaling
Three major properties of Ca2+ are particularly drawing scientists’ attention: the first is that Ca2+
can both play a role as a first and as a second messenger; secondly, Ca2+ can autoregulate itself
through various signals; finally, its ambivalent nature in which it can control a number of
essential normal functions of cells and meanwhile could also be a messenger of death(2).
After thousands of years of evolution, eukaryotic cells managed to maintain a free Ca2+
concentration at the level of 10-7 M in the cytoplasm through various ways while they are
surrounded by an environment containing more than 1 mM free Ca2+ concentration. The low
level of cytosolic Ca2+ concentration is necessary in order to prevent the precipitation of Ca2+phosphate salts and prevent the extra energy that would have to be invested to change it. Those
various ways are including binding to membrane (acidic) phospholipids, interaction with low
molecular weight metabolites, formation of new compounds with inorganic ions, and binding to
specific proteins.
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The proteins that can interact with Ca2+, and thus regulate the intracellular calcium concentration,
can be categorized into two major classes: The first class belongs to intrinsic membrane proteins
which transport Ca2+ across the membrane to maintain cellular Ca2+ homeostasis. The other class
is soluble proteins. The minority of the latter is Ca2+ buffers, which mainly operate to lower the
intracellular calcium concentration. The majority of the aforementioned soluble proteins are
defined as calcium sensors as they have specific functional properties besides their Ca2+ binding
capability. These types of proteins include: the annexins, gelsolin, C-2 domain proteins as well
as EF-hand proteins.
1.1.2 Calcium as a first and a second messenger in cells
Before the discovery of the calcium sensing receptor, Ca2+ was mainly considered as a crucial
second messenger that rapidly yet efficiently regulated the intracellular calcium level and
modulated extensive molecular signaling components through calcium channels, exchangers as
well as pumps (3).
When Ca2+ acts as a second messenger, the Ca2+ signaling network can be summarized as four
components: A stimulus that induces various signals to mobilize Ca2+, The ON mechanisms that
introduce Ca2+ into the cytosol, Ca2+ functions as a message transducer and lastly, the OFF
mechanisms to remove Ca2+ via pumps or exchangers (4). When Ca2+ plays a role as first
messenger, it is also the stimulus in the first component.
The Ca2+-mobilizing second messengers are generated when certain stimuli interact with cell
surface receptors. Inositol-1,4,5-trisphosphate (Ins(1,4,5)P3) (5) is one of them that can bind to
inositol-1,4,5-trisphosphate receptor (InsP3Rs) and release Ca2+ from the ER. Sphingosine 1phosphate (S1P) is another messenger that releases Ca2+ from the ER by engaging a sphingolipid
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Ca2+ release-mediating protein of the ER (SCaMPER)(6). Cyclic ADP ribose (cADPR) (7) is a
calcium dependent activator for ryanodine receptors (RYRs).
While the InsP3Rs and RYRs are related with Ca2+ derived from internal stores, there are other
mechanisms contributing to the ON mechanisms via controlling the entry of external Ca2+. The
best-known mechanism is voltage-operated channels (VOCs). When a receptor binds to external
stimuli such as glutamate, ATP or acetylcholine, the receptor-operated channels (ROCs) will be
operated. The depletion of internal calcium stores can trigger the store-operated channels (SOCs)
(8).
The Ca2+ signal induced by the ON mechanism can then be transferred to cellular responses.
Those responses recruit numerous Ca2+ binding proteins as Ca2+ buffers and sensors. Troponin C
(TnC) and calmodulin (CaM) are two calcium sensors that have been extensively studied (4).
The OFF mechanisms will be initiated when Ca2+ needs to be removed from the system. There
are various ways the extra Ca2+ can be sequestered. The plasma membrane Ca2+-ATPase (PMCA)
pumps and Na+/Ca2+ exchangers can transfer intracellular Ca2+ to the extracellular space, the
sarco-endoplasmic reticulum ATPase (SERCA) pumps, on the other hand, pump Ca2+ back to
the internal stores (9,10).
How Ca2+ performs as a first messenger will be elucidated in the following introduction to the
calcium sensing receptor.
1.1.3 Endoplasmic reticulum dynamics and calcium signaling
A number of cellular functions such as synthesis of protein and lipid, protein folding and posttranslational modification as well as maintaining the Ca2+ concentration constant take place in
the endoplasmic reticulum (ER) (11). The calcium dynamics in the ER influence many cellular
pathways and ER functions, from gene regulation to cellular level responses, which include: cell
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differentiation and proliferation, apoptosis, from embryo development to the tissue level such as
muscle contraction and relaxation; even learning and memory, membrane excitability and energy
metabolism (12).

As mentioned in 1.1.2, the InsP3R and RyR (13,14) control the extruding of calcium from ER
while SERCA replenishes the calcium store. Besides these “in” and “out” regulations, the Ca2+
buffering system in the ER and resident chaperons control the free Ca2+ concentration in the
range of 50-500 M (15-17) although the total [Ca2+]ER is in the mM range. A number of ERlocated chaperones have been identified that buffer Ca2+ including calreticulin, glucose-regulated
protein 94 (Grp94), immunoglobulin binding protein (Grp78) (11), the family of PDI-like ER
resident proteins (18), calsequestrin (19), and reticulocalbins (11). Some of these chaperones
have weak affinity but high capacity, PDI-like proteins, while some of them have high affinity
but low capacity, such as Grp94. Proteins with very high affinity (Kd=1M), for example
reticulocalbins, are considered to play a role in maintaining certain structures or participating in
specific protein-protein interactions.

In addition to proteins locally regulating the [Ca2+]ER within the calcium store organelle, ER also
communicates with the plasma membrane for Ca2+ signaling regulation through the machinery
named as store-operated Ca2+ channel (SOC) (20). In many cell types, the inwardly rectifying
current is called ICRAC characterizing as highly Ca2+ selective, non-voltage gated current (20).
The identification stromal-interacting molecule (STIM1) connects the ER, cytoplasm, and the
Orai1 protein resident in the lumen of ER which provides reasonable explanation for the
mechanism of SOC (21-23).

5

Normally, the [Ca2+]ER is controlled at 50-400 M, which is suitable for protein and lipid
synthesis as well as protein posttranslational modification (11). Severe consequences will occur
if the [Ca2+]ER is sustained and prolonged at a low level (below 20 M ) such as disrupted protein
synthesis, accumulation of unfolded proteins, even cell apoptosis (11). On the other hand, the
overload of [Ca2+]ER stress also has negative impacts on ER function and cellular signaling
leading to congenital problems (11).

1.1.4 Spatiotemporal aspects of Ca2+ signaling
Although Ca2+ is considered as a universal signal for the regulation of cells, it could be toxic to
cells if it stays at an excessively high concentration. A pulsatile manner of Ca2+ signals has
evolved to prevent such toxicity.
Two major mechanisms are involved in the production of the temporal Ca2+ signals that would
further lead to more complex downstream signaling. The first one happens in skeletal and
cardiac cells when the Ca2+ signal pulses are produced on demand as the cells respond to
periodic stimulation that leads to membrane depolarization. This kind of signal can be observed
in muscle cells when they contract and also in nerve terminals when neurotransmitters are
released upon a brief localized pulse of Ca2+ (Calcium: A Matter of Life or Death p496). The
second type appears as an oscillation when the cells receive a continuous stimulation over a
period of time. The rhythmical Ca2+ signal has a wide range of frequencies that are tightly related
to a variety of cellular responses. The details of which will be discussed in the next paragraph.
The types of oscillations can be categorized by the oscillatory activity: membrane oscillators and
cytosolic oscillators. The membrane oscillators are usually the results of K+ outward currents
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inducing depolarization and the PMCA (plasma membrane Ca2+ ATPase) activity. The action
potentials that are set up by membrane oscillators provide rhythmical pacemaker activity that
would be responsible for processes such as cardiac contraction, neuronal activity, secretion, etc.
(24,25). The other type, the cytosolic oscillators, cause the periodic release of internal Ca2+ and
their mechanism depends on various intracellular stores. For agonist triggered cytosolic Ca2+
oscillation, the InP3/Ca2+ signaling pathway, which requires the participation of endoplasmic
reticulum, plays a crucial role in activating the oscillation. This second type of regulation has
drawn more attention to researchers since the oscillation frequencies have a large range that
varies with the type of stimulation and encode specific information regulating diverse cellular
processes. Various hormones and transmitters can induce repetitive cytosolic Ca2+ spikes in
hepatocytes in the range of 1-10 min (26-28) and this physiological process is modulated by
phorbol esters (29), protein kinase inhibitors (30), extracellular Ca2+ (27,28,31), Na+, and K+
(27,31). Ca2+ oscillations are also responsible for initiating embryonic development in both
mammalian and ascidian oocytes (32-34).

In 2001, Pasti et al. demonstrated that [Ca2+]i

oscillations could cause a pulsatile release of glutamate and the calcium signal could be mediated
by activation of AMPA/mGluRs (35). Airway epithelial cells utilize the Ca2+ oscillations to
control ciliary beat frequency as a response to ATP (36). Figure 1.1 shows a summary of the
cytosolic oscillation frequencies and their related biological functions.
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Figure 1.1 Biological Processes Regulated By [Ca2+]i oscillations.
The cytosolic oscillators would cause the periodic release of internal Ca2+ (termed [Ca2+]i
oscillation) and their mechanisms depend on various intracellular stores. The oscillation
frequencies have a large range varying with the type of stimulation and encoding specific
information to diverse cellular processes from fast reactions, such as hypertropy, to slow
physiological responses like Interleukin production (37).
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1.2 The structure and function of Calcium sensing receptor (CaSR)
1.2.1 The discovery of CaSR
It has been well known that the serum Ca2+ concentration can regulate the secretion of
parathyroid hormone (PTH). In 1993, Dr. Edward M. Brown cloned the receptor that is primarily
responsible for this type of regulation from bovine parathyroid gland (38). The receptor was
given the name “calcium sensing receptor” (CaSR/CaR). The previously observed cytosolic
calcium changes in parathyroid cells, as well as in other in vitro expression systems, was
triggered by serum calcium concentration change and is greatly attributed to the function of
CaSR (39,40). A unique characteristic of CaSR is the high cooperativity of Ca2+ dependent
activation, which tightly controls the secretion of parathyroid hormone when the receptor is
exposed to serum Ca2+ concentrations within its responsive range (38). The CaSRs expressed in
various species are highly conserved (Appendix D), indicating the biological importance of this
receptor in regulating physiological functions among living organisms.

1.2.2 Biological roles of CaSR
The major function of the CaSR is to maintain calcium homeostasis through balancing the
ingestion and absorption of calcium from the gastrointestinal tract, excretion of calcium by the
urinary system and the breakdown and formation of bone (41,42) (Figure 1.2). The CaSR is
mainly expressed in the parathyroid and thyroid glands, as well as in other tissues mentioned
above. The CaSR regulates PTH secretion from parathyroid glands and calcitonin secretion from
thyroidal C-cells upon detecting variations in the calcium concentration in the extracellular fluid
(41).
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Fgirue 1.2 Systematic regulation of Ca2+ homeostasis in human body.

Two major circulating hormones (PTH and CT) regulate Ca2+ homeostasis via several
primary organs. If the Ca2+ level is too low, PTH is released from parathyroid gland. It
then stimulates Ca2+ uptake from intestines, increases the rate of Ca2+ release from bone
and the rate of Ca2+ reabsorption in urinary system. If the Ca2+ level is too high, the
opposite regulation will occur to control the blood Ca2+ level. Thus, the blood Ca2+ is
strictly maintained between 1.1-1.4 mM.

Moreover, CaSR has its specific role in different tissues. As mentioned in the last section, the
CaSR was first discovered in parathyroid cells. The main function of the receptor is to mediate
the negative feedback of PTH secretion upon the stimulation of various agonists (38). Most of
the CaSR expressed in parathyroid cells is located in caveolae, where a significant number of
signaling molecules, as well as scaffolding proteins, reside (43). Similarly, one of the critical
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roles the CaSR expressed in the kidney plays is maintaining calcium homeostasis (44). However,
the CaSR present at different parts of the nephron (e.g. the proximal tubule, thick ascending limb,
etc.) may have specific functions (45,46).

The CaSR is also found in the gastrointestinal tract, including the esophagus, stomach, small
intestine, and colon (47,48). The activity of CaSR has been reported to be associated with
increased phosphorylation of ERK, intracellular calcium mobilization, secretion of IL-8, gastric
acid (49-51) and cell proliferation and differentiation (52,53).

The CaSR has been identified in bone, demonstrated by various techniques (54). Both
osteoblastic cell line MC3t3-E1 and osteoclasts are reported to express the CaSR. The receptor is
involved in osteoblasts proliferation likely via JNK signaling (55,56) and participates in both
differentiation and apotosis of osteoclasts through the PLC pathway (57). The CaSR stimulation
is also believed to be inhibiting bone resorbing activity of osteoclasts (58).

Experiments using immunocytochemistry showed that the CaSR is widely distributed in the
central nervous system with quite a diverse pattern (59). In the neuron system, the CaSR is also
forming heterodimers with other family C GPCRs (60,61). It has been proposed that the CaSR
may play a crucial role in regulating currents which mediates the bursting of action potentials
and the following depolarization (62). The CaSR in the hippocampus has been reported to
regulate both Ca2+-permeable, nonselective cation channels as well as Ca2+-activated K+
channels (59,63,64).
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The CaSR is also detected in cardiac tissue by various techniques including RT-PCR,
immunohistochemistry, etc. (65). A few pathological processes have been found to be associated
with an increased expression level of the CaSR, for instance the angiotensin II induced cardiac
hypertrophy (66), hypoxic-reoxygenation treated cardia myocytes, etc. (67).
1.2.3 The structure of the Calcium Sensing Receptor (CaSR)
The CaSR comprises four major parts in terms of its structure: a large N-terminal extracellular
domain (ECD), a cysteine-rich domain, a seven transmembrane domain and the intracellular Cterminal (Figure 1.2). The major function of the CaSR is regulating the calcium concentration in
the human blood.

Figure 1.3 The modeled structure of Ca2+-sensing receptor.
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The modeled CaSR extracellular domain (ECD) is based on mGluR1 (pdb: 1EWT). A
number of agonist and antagonists interact with the large ECD that forms a Venus Fly
Trap (VFT) structure. The seven transmembrane domain is linked with the ECD via a Cysrich domain. The C-terminal domain is involved in the interaction with intracellular target
proteins (68).

Members in the family C GPCR proteins possess signature large N-terminal ECDs. The low but
significant amino acid sequence similarity between the GPCR family C and a group of bacterial
periplasmic amino acid-binding proteins suggest evolutionary relevance. Indeed, the crystal
structure of the ECD of rat metabotropic glutamate receptor (mGluR1) showed a bi-lobed
Venus-flytrap-like structure (VFT) which is fully consistent with the structure of the bacterial
periplasmic amino acid-binding proteins, switching between “open” and “closed” conformational
status upon releasing or binding their endogenous agonists(69). The alignment of the amino acid
sequence of the CaSR ECD (AA36-AA513) with mGluRs and the bacterial periplasmic amino
acid-binding proteins results in a proposed VFT model of CaSR ECD with the N-terminal lobe I
connecting with C-terminal lobe II(70). However, the alignment also shows four segments in
lobe I that do not align with the bacterial periplasmic amino acid-binding protein resulting in
four unstructured loops (I~IV) (71). Only a large part of loop III (from residues 365-385) could
be deleted without reducing the activity of CaSR while truncation in the other four loops resulted
in a low surface expression of the receptor (71).
The VFT structure of mGluR1 forms a homodimers as verified by 3D structure of rat mGluR1
VFT. The intermolecular disulfide requires a conserved cysteine in loop 2, and the equivalent
residues in the CaSR are C129 and C131 (70,72). Experiments carrying out mutagenesis of the
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two cysteines suggested that disruption resulted in failure to form disulfide bonds, but did not
affect the formation of dimer (73). Other cysteines in the ECD of CaSR including C60–C101,
C358–C395 and C437–C449 form three intramolecular disulfides, which are critical for CaSR
expression and activity(74).

All members of the GPCR family C have a conserved nine-cysteine structure at the end of the Cterminal domain of the ECD and before the seven transmembrane domains except the GABAB
receptor (75). For CaSR, the region possesses about 84 residues. Mutations on any of the nine
Cys to Ser dramatically impair the surface expression and the function of CaSR. Deletion of this
Cys-rich domain results in the abrogation of CaSR activity.

The CaSR contains a seven transmembrane domain (7TM) similar to the other proteins in the
GPCR superfamily. It is believed that agonist binding to GPCRs will lead to conformational
changes of the 7TM -helices, further inducing alterations in intracellular loops as well as the Cterminal domain, thereby triggering the downstream signaling pathways. The crystal structure of
rhodopsin (a GPCR Family A protein) with 7TM domain has been reported. However, caution is
extremely needed when extrapolating the CaSR 7TM structure from rhodopsin as proteins from
family C share low sequence identity with proteins from family A. The 6 prolines in the
transmembrane domain are important to maintaining the kinks in the transmembrane helices.
Mutations of some prolines (P748R, P823A) (76,77) impair receptor function.

The intracellular domain of the CaSR contains 216 amino acids that do not show high
conservation among species (78). Two regions in this intracellular tail are homologous between
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species: one from 863-925 located at the proximal of C-tail which is pivotal in surface
expression; the other from 960-984 which is involved in interacting downstream proteins (79-81).
Three potential protein kinase C (PKC) phosphorylation sites are present in the intracellular
domain: T888, S895 and S915 are involved in regulating the receptor activity (82). Especially,
T888 plays significant role in the PKC regulation as a negative modulator of CaSR function.

Along with the PKC phosphorylation sites, two other residues participate in protein kinase A
phosphorylation: S899 and S900, but studies on these two sites indicate minor effect of PKA
phosphorylation in the modulation of CaSR (83).
1.2.4 Contribution of glycosylation to CaSR function
The attachment of sugar residues on a protein is considered to be the most complicated co- or
posttranslational modification (84). The glycosylation process is regulated by factors that vary
greatly among cell types and species (85). Mature carbohydrate units can be assembled on
protein via numerous delicate glycosylation routes and the resultant glycoproteins are secreted
out of the cells or become cellular components, including membranes, cytoplasm, or nucleus etc.
A varity of carbohydrate-peptide linkages have been found among glycoproteins in nearly all
living organisms, ranging from bacteria to eukaryotes (85). Those linkages involve 13 different
monosaccharides and 8 amino acid types and the glycopeptide bonds can be further categorized
in five distinct groups shown in Figure 1.3(85). One of the common forms of glycopeptides
bonds is N-linked glycosylation. This modification is the result of a complex process of
trimming and remodeling of the oligosaccharide that takes place in the endoplasmic reticulum
(ER) and Golgi as illustrated in Figure 1.4 (86). The synthesis of various glycopeptides bonds
takes place within different subcellular organelles (85).
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Figure 1.4 Glycan-protein linkages reported in nature.
(Updated and redrawn, with permission of Oxford University Press, from Spiro R.G.
2002. Glycobiology. 12: 43R–56R.) Diagrammatic representation of the five distinct types
of sugar-peptide bonds that have been identified in nature. (Ara) arabinose; (Rha)
rhamnose; (FucNAc) N-acetylfucosamine (2-acetamido-2,6-dideoxy-D-galactose); (Bac)
bacillosamine

(2,4-diamino-2,4,6-trideoxy-D-glucose);

(Pse)

pseudaminic

acid

(5,7-

diacetamido-3,5,7,9-tetradeoxy-L-glycero-L-manno-nonulosonic acid); (Hyl) hydroxylysine;
(Hyp) hydroxyproline; (C-term) carboxy-terminal amino acid residue. Glypiation is the
process by which a glycosylphosphatidylinositol (GPI) anchor is added to a protein. For
other details, including anomeric linkages, please see the Spiro (2002) review cited above.

Endoglycosidases can be categorized into two major types: one for deglycosylation of
asparagine-linked (N-linked) oligosaccharides; the other for O-linked oligosaccharides.
Endolycosidases F(1,2,3), Endoglycosidases H (Endo H) and peptide-N4-(N-acetyl-betaglucosaminyl) asparagine amidase (PNGase) cleave N-linked glycosylation. O-Glycosidase
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cleaves O-linked glycosylation. Among the first category, Endoglycosidases F1, F2, and F3 are
more suitable for removing the glycans of native protein due to their low sensitivity to protein
conformation while PNGase F prefers to work on denatured protein. Both Endo F1 and Endo H
can cleave asparagine-linked oligosaccharides, however, the later does not cleave sulfated highmannose

form

(i.e.

containing

5~9

mannose).

(http://www.sigmaaldrich.com/technicaldocuments/articles/biology/glycobiology/endoglycosidas
es.html). The differences between the endoglycosidases are summarized in Figure 1.5.
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Figure 1.5 Schematic representation of the generation of N-linked glycosylation.
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N-linked oligosaccharide modification takes place in the ER and Golgi. Following glucose
trimming in the ER, high mannose glycans are available for further processing and
trimming by glycosidase and mannosidases to yield high-mannose, hybrid and complex

Conformation Dependent

glycan structures.

Figure 1.6 Schematic representation of different endoglycosidases

CaSR isolated from pcDNA CaSR transfected human embryonic kidney (HEK293) cells
exhibited similar expression patterns as the CaSR proteins identified from parathyroid cells (87).
The western blot results of CaSR extracted from HEK293 cells showed several immunoreactive

18
bands using antibodies specific for the CaSR. The minor band at 120 kDa corresponds to the
nonglycosylated form of the protein, the major band at 140 kDa stands for the high mannose
form while another major band at 160 kDa represents the complex carbohydrates form of CaSR
(87,88). Additional bands at higher molecular mass (350 kDa) corresponds to the dimeric form
of the receptor. The CaSR that is expressed on the cell membrane is mature receptor that only
account for a small portion of the protein (89).

The sequon N-X-S/T is a general position at which N-Linked glycosylation can occur (90). X
can be any amino acid but not proline. The glycosylation process is completely blocked if P is at
the presence of X position. On the other hand, W, D, E and L at position X leads to inefficient
glycosylation (90). The CaSR ECD contains 11 potential N-Linked glycosylation sites and 9 of
them (N90, N130, N261, N287, N446, N468, N488, N541, N594) are highly conserved in
different species including rat (44), chicken (91), rabbit (45) and bovine (38). The other 2 (N386,
N400) are conserved in chicken, rabbit and human (88) . A mutagenesis study revealed that
N386, N400 and N594 are not efficiently glycosylated in CaSR since the replacement of those
sites with glutamine does not lead to the alteration of receptor mass or mobility as shown from
western blot, whereas, disruption of other N sites would causes a decrease in receptor mass.

The protein folding, intracellular trafficking, protein secretion as well as cell surface expression
of glycoproteins are significantly related with their carbohydrate moieties (92,93). The
carbohydrate group also plays a crucial role in protein conformation, enzymatic activity and
other structural functions. As K.Ray et al. reported, the cell surface expression of CaSR was
disrupted if as few as three glycosylation sites were mutated to glutamine (88). Substitution of
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the first five glycosylation sites with Q significantly decreased the surface expression of CaSR
(>50%) compared with other mutants. A CaSR functional study using a PI hydrolysis assay
further indicated that the mutants that exhibited impaired glycosylation had their responses to
extracellular calcium correlated with their surface expression. The maximum responses to
calcium were significantly reduced, while the EC50 of the dose response curve did not look
altered as judged from the figure, though the authors did not use it as one of the parameters.
After compensating for reduction of the surface expression level using higher DNA transfection
amount, the calcium-stimulated PI hydrolysis among the mutants were comparable with the wild
type.

1.2.5 CaSR induced intracellular calcium oscillation and signaling

The CaSR activators can be defined into several groups: Ca2+ and polycations which interact
with the Venus Fly Trap (VFT) domain (94-96) and transmembrane region(97,98) ERK; Lamino acids (12), which bind to the VFT domain; phenylalkylamine type-II calcimimetics whose
binding pockets located at transmembrane helices VI and VII (98-100). Upon stimulation with
Ca2+ or other polycations, a number of intracellular signal transduction pathways will be
activated.

Among them, the phosphoinositide-specific phospholipase C (PI-PLC) and extracellular –signalregulated kinases (ERK1/2) have been widely applied to the investigation of CaSR activity
(101,102). In 1998, McNeil et al first reported that in rat fibroblasts the activation of CaSR could
increase c-SRC kinase activity as well as the extracellular signal-regulated kinase 1/mitogen-
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activated protein kinase activity and the non-functional mutation R796W inhibited both of the
two kinases. Their results linked the activation of the SRC and ERK1 pathway to the modulation
of proliferation in different cell types by extracellular calcium (103). One year later, Hoff et al
found that, a gain-of-function mutation T151M could enhance ERK1/2 and Jun-N-terminal
kinase/stress-activated (JNK/SAPK) pathway at the presence of a physiological extracellular
calcium concentration (104). Later on, the ERK1/2 activity has been widely investigated in a
number of cells with expression of calcium sensing receptor including ovarian surface epithelial
cells (105), proximal tubular OK cells (106), Madin-Darby canine kidney cells (107), prostate
cancer cells (108), colon carcinoma cells (109), cytokine-stimulated adult human astrocytes
(110), rat neonatal ventricular cardiomyocytes (111), Xenopus melanotrope cells(112), osteoblast
(113),etc. The ERK1/2 activity has also been utilized to identify CaSR interacting proteins, for
instance, filamin A (114), 14-3-3 (115), etc.

Studies on how the L-amino acids or other type II calcimimetics affect these two major signal
pathways were conducted in different labs. It is known that those allosteric modulators require a
threshold calcium level or other agonists to active CaSR (100). However, the effect of amino
acids on calcium dependent PI-PLC activation is negligible(116). On the other hand, L-Phe
induced a significant enhancement on the extracellular calcium triggered ERK1/2 activity (100).
It has been reported that the aromatic side chain amino acids (L-Phe and L-Trp) could enhance
[Ca2+]o stimulated intracellular calcium change, while the effect of L-Phe on ERK1/2 signal were
comparatively small. Thus it has been suggested that dietary protein intake could fine tune
cellular responses to the calcium change.
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As constant exposure to serum Ca2+ would chronically activate CaSR followed by activation of
numerous cellular functions, several key questions need to be addressed, including how single
cells that expressing CaSR can adapt to such chronic exposure and what are the kinetic features
of intracellular Ca2+ response to alterations in extracellular Ca2+. In 2001, the heterologous
expression system using human embryonic kidney 293 cells was utilized to explore those
fundamental mechanisms by Gerda E.Breitwieser. Her group reported several major findings: 1,
steady-state intracellular Ca2+ concentration change was observed in CaSR expressing cells when
they are exposed to steady-state perturbations of the extracellular Ca2+ concentration (i.e.
stepwise increases of extracellular Ca2+ concentration ); 2, small changes in extracellular Ca2+
could induce intracellular calcium oscillation and the oscillation frequency was constant over the
range of 2.5~5 mM [Ca2+]o; 3, thapsigargin-sensitive intracellular Ca2+ stores contributed to the
formation of intracellular Ca2+ oscillations; 4, staurosporine, a broad-specificity protein kinase
inhibitor (inhibit protein kinases A, C, myosin light chain kinase and calmodulin kinase) did not
affect the oscillation frequency but increased the number of oscillating cells (117).

Further study of the regulation of intracellular Ca2+ oscillation was carried out by Enrique
Rozengurt’s group. Previous models explained [Ca2+]i oscillations occurring following GPCR
activation by resorting to negative feedback effects of protein kinase C (PKC) on the production
of Ins(1,4,5)P3 or the [Ca2+]i regulation on the Ins(1,4,5)P3 receptor. His group found that the
observed [Ca2+]i oscillation triggered by changes in extracellular [Ca2+] in HEK293 cells
expressing CaSR was also modulated by PKC since addition of PKC specific inhibitor
significantly decrease the number of oscillatory cells and converted the intracellular responses to
transient, non-oscillatory response. PKC activators could reduce the oscillatory frequency but
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didn’t eliminate the oscillations. Their study also demonstrated that the PKC phosphorylation
site at T888 of CaSR played crucial role in the negative feedback of [Ca2+]i oscillations.

As early as 2000, Conigrave et.al found that CaSR activity could also be regulated by aromatic
amino acids since they shifted the [Ca2+]o-[Ca2+]i response curve and lowed the EC50(118). In
2002, the aromatic amino acid induced [Ca2+]i oscillations in CaSR-transfected HEK293 cells
was further analyzed by Young et. al. (119). The [Ca2+]i oscillation induced by L-Phe or L-Trp
required a normal physiological range of [Ca2+]o (1.8 mM in their study). The average oscillation
frequency was 1/min which was much lower than [Ca2+]o induced [Ca2+]i oscillations (~ 4/min).
The two different patterns, specifically sinusoidal response induced by [Ca2+]o and transient
baseline calcium response elicited by amino acids, allow the CaSR to differentiate which agonist
was interacting with the receptor.

The mechanisms of [Ca2+]i oscillation triggered by extracellular calcium and amino acids are
considered to be different according to the studies from Dr.Rozengurt’s group(116,120) as well
as Dr.Breitwieser’s group(121). By tracking intracellular signaling markers tagged with
fluorescent proteins, including GFP-PHD (pleckstrin homology domain of PLC-1linked with
GFP in order to detect Ins(1,4,5)P3), PKC-YFP (for the indirect measurement of [Ca2+]i), and
PKD-RFP (sensing the generation of DAG), it was found that GFP-PHD and PKC-YFP
oscillatory translocated to the membrane after stimulation by high [Ca2+]o and PKD-RFP was
translocated to membrane. It was demonstrated that CaSR mediated activation of Gq and PI-PLC
(116).In contrast, [Ca2+]i change stimulated by phenylalanine did not redistribute the location of
either GFP-PHD OR PKD-RFP, but PKC-YFP exhibited cyclically redistributed pattern.
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An intact actin cytoskeleton system including the small GTP binding protein RhoA which
facilitates actin cytoskeleton organization(122), and filamin A, which is linked to the actin
cytoskeleton as a scaffold protein (123) was found to be involved in phenylalanine induced
oscillation(116) but not extracellular calcium induced [Ca2+]i change. Besides, heterotrimeric Gprotein subunits G12/13 participated in the phenylalanine regulated oscillations, but it is Gq
that mediates the [Ca2+]o induced oscillation (116). Since HEK-293 cells express TRPC1
channels (124), it is also suggested by studying of thrombin-mediated Ca2+ entry in endothelial
cells (125) that the [Ca2+]i influx stimulated by phenylalanine could due to activation of RhoA,
which further caused the translocation of Ins(1,4,5)P3 receptors and TRPC1 channels to the cell
membrane.
Phenylalkylamine allosteric regulators of CaSR could also change the [Ca2+]i oscillation patterns
(126).

1.2.6 Proteins interacting with CaSR
In addition to heterotrimeric G proteins, the CaSR needs to recruit a number of other proteins to
ensure the net work is fully functional. Recently, a few of these proteins have been identified
using yeast two-hybrid system and/or coimmunoprecipitation studies. The absence of these
proteins would influence the CaSR signaling.
Filamin A has been demonstrated to interact with the C-terminal of the CaSR in 2001 by two
individual groups (80,81). Later study using truncation and deletion mutants revealed that the
binding happened in a two -strands region from amino acid 962 to 981 of the CaSR. Blocking
the interaction between Filamin A and CaSR attenuated CaSR-induced ERK activity(80). The
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binding of the two proteins also exhibited importance in the CaSR-mediated Rho signaling
(116,127) as well as the JNK activation (128). Studies in a cell line deficient in filamin A
suggested Filamin A might protect the CaSR from degradation(114).
Potassium channels Kir4.2 and Kir4.1 have been reported to colocalize with CaSR in HEK293
cells stably expressing the CaSR and in endogenous rat kidney tissues respectively(129).
However, how and whether their function can be regulated by the CaSR still needs to be
elucidated. It is possible that Filamin A may act as a bridge that links the CaSR and either Kir4.1
or Kir4.2.
The region between amino acids 880-900 of the CaSR has been identified to interact with the
region 660-838 of an E3 ubiquitin ligase, dorfin (130). The overexpression of dorfin is believed
to increase the ubiquitination of the CaSR, resulting an accelerated degradation process (130).
Associated molecule with SH3 domain of STAM (AMSH) is an ubiquitin isopeptidase that
regulates the sorting of the receptor EGFR (131). The CaSR C-tail region from 895-1075 was
found to bind with AMSH(132). Increasing the AMSH expression level or stimulating the CaSR
with calcium could reduce the CaSR expression in HEK293 cells transfected with these two
proteins (132,133).
-Arrestins play an important role in modulating the desensitization and internalization of
GPCRs through collaborating with G protein receptor kinases (GRK) (134). Overexpression of
-Arrestins negatively regulates the inositol phosphate signaling via CaSR in HEK 293 cells. A
PKC inhibitor or mutation on the CaSR PKC phosphorylation sites reduces the effect of
overexpressing -Arrestins.
RAMP is short for receptor activity-modifying protein which has been reported to influence
receptor trafficking, glycosylation as well as second messenger production(135). Experiments in

25
COS7 cells demonstrated that RAMP1 and RAMP3 can increase the surface expression of
transfected CaSR, but not RAMP2 (136). Moreover, RAMP3 had greater influence on
modulating the receptor surface expression.
1.2.7 Trafficking of the CaSR in cells
Like many other GPCRs, the trafficking of the CaSR is a complex process that involves
interacting with various proteins to determine the final destination of the receptor. Once
synthesized at the endoplasmic reticulum (ER), those improperly folded CaSR will fail the
quality control and be lead towards the proteasome for degradation. Receptors passing the
quality control will traffic to plasma membrane or other cellular compartments via interaction
with chaperone and small GTP-binding proteins (137-140).
Several proteins interact with CaSR while the receptor exits from the ER, including p24A
(transmembrane emp24 domain trafficking protein 2(TMED2))(141); small GTP-binding protein
Sar1(142); receptor-activity-modifying proteins (RAMPs)(136); Rab1(143); calmodulin (CaM)
(82); 14-3-3(144) and Dorfin (130). p24A binds predominantly with immature form of CaSR
and cycles between the ER, the ER-Golgi intermediate compartment(ERGIC) as well as the cisGolgi membranes (145,146). Through its interaction with p24A, the stability of CaSR and the
plasma membrane targeting will be increased possibly via inceasing total cellular CaSR(141).
Sar1 is another protein that is required in releasing the receptor from the ER (141,142). RAMPs
and Rab1 are small GTP-binding proteins that localize to the cytoplasmic face of organellar
membranes. Both of them are found to facilitate CaSR trafficking from ER to Golgi (136,143).
The 14-3-3 is predicted to interact with the arginine-rich domain of CaSR (890RRxxxxRKR898)
and may lead to the retention of CaSR in the ER (115,144,147). There is also a calmodulin
binding site in the C-tail of CaSR comprising residues 874-895 (148). However, the function of
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CaM still needs to be revealed. It is reported that CaM binds to both immature and mature forms
of CaSR suggesting its role in modulating anterograde trafficking (82). On the other hand, CaM
may stabilize the surface receptor on the cell membrane (148).
Its interactions with different proteins contributes to the sub cellular localization of CaSRs. The
association of intracellular loops 1 and 3 with caveolins keeps the CaSR highly enriched in
invaginations of plasma membrane called caveolae in certain type of cells, like parathyroid chief
cells and cardiac myocytes (43,149-151). Filamin A, an adaptor protein, has also been identified
to interact with the C-terminal of CaSR, targeting the receptor to sites of Rho activity
(116,127,152). The CaSR also interacts with integrins, the latter may contribute to the regulation
of cell migration(153).
The surface expressed CaSRs may undergo endocytosis initiated with phosphorylation by G
protein coupled receptor kinase (GRKs) or protein kinase C(154,155), involving -arrestins and
facilitated by Rab7, Rab11a and adaptor protein-2 (AP2)(133,156,157). The endocytosed
receptors are either recycled to the cell membrane contributing to the receptor resensitization or
translocated to the lysosomes for degradation (158,159).
There are two mechanisms that CaSR can utilize to get degraded. One is mediated by the activity
of E3 ubiquitin ligase family member dorfin. CaSR will be targeted to proteasome after being
ubiquitinated by dorfin (160). CaSR can also be degraded in lysosomes. A deubiquitinating
enzyme specific for k63-likages (AMSH which is short for associated molecule with the SH3
domain of STAM) has been reported to be involved in the process(133). Moreover, the PESTlike sequence in the C-tail of CaSR, which are rich in proline, glutamine, serine and threonine,
can also lead the receptor to lysosome (157).

27
In the continuous presence of agonist stimulation, those secretory pathways as well as the
endocytosis mechanisms mentioned above work collaboratively (Figure 1.7), causing a net
increase in the plasma membrane expressed CaSR. This phenomenon was named AgonistDriven Insertional Signaling (ADIS)(144). However, a number of questions raised by the ADIS
mechanism remained to be explored.
1.2.8 Disease associated CaSR mutations

The discovery of CaSR and its role in maintaining physiological calcium level led to the
identification of disorders of calcium homeostasis that are related to abnormal CaSR activity.
There are more than 100 mutations of the CaSR that have been catalogued in the online database
at http://www.casrdb.mcgill.ca/. They are the primary attribution for the CaSR related disorders.
Autoimmune antibodies against the CaSR are another cause for the receptor dysfunction (161).
Mutations of the CaSR may lead to an inactive receptor or an overactive receptor. The former
includes cases of familial hypocalciuric hypercalcemia, which is a calcium disorder associated
with dominant negative activity of the mutant CaSR (162) as well as a more serious disorder
known as neonatal severe hyperparathyroidism (NSHPT) due to inactivating mutations in both
copies of the CaSR gene (161). NSHPT can cause severe hypercalcemia, multiple fractures,
neurodevelopmental disorders and even death. The latter includes autosomal dominant
hypocalcemia (ADH) (163) and Bartter syndrome type V (164). Patients with ADH usually do
not show symptoms but have mild reductions in calcium concentration in the blood. Patients
with Bartter syndrome type V show symptoms like hypokalemic metabolic alkalosis and
hyperaldosteronism along with hypocalcemia (164).
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Figure 1.7 The trafficking of CaSR.

Illustrated are the primary compartments during the trafficking of CaSR. The major
players are highlighted next to the subcellular organelles where they are expected to
interact with CaSR. Abbreviations: AP-2, adaptor protein-2; CaM
calmodulin; ER, endoplasmic reticulum; FLNA, filamin A; GRKs, G protein coupled
receptor kinases; RAMPs, receptor activity modifying proteins; VCP/p97, valosincontaining protein.
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1.3 Physiological condition of the amino acids concentration and the reational for the
dosage used in this study
In biological systems, free L-amino acids are essential molecules since they not only serve as the
building blocks of protein but are also the metabolic precursors of crucial substances that serve
as ligands for receptors (165). Evidence for the presence of amino acid sensing mechanisms in
various studies, e.g., regulating insulin secretion from pancreatic B cells, hepatic autophagy, etc.,
suggest the widespread existence of amino acid sensors, although the identities of these amino
acid sensors are in many cases unknown. These findings highlight amino acid-dependent control
of cellular signal transduction pathways. Fluctuation of the plasma levels of amino acids can,
therefore, regulate the rate of hormone synthesis and secretion as well as Ca2+ metabolism,
among other processes (165). CaSR is present throughout the gastrointestinal tract (41,166),
including in gastrin-secreting antral G cells and cholecystokinin-secreting l cells, both of which
are known to be activated by both [Ca2+]o and aromatic amino acids (166). L-amino acids,
especially aromatic amino acids, are known to enhance the sensitivity of CaSR to [Ca2+]o, which
could be one potential explanation for how dietary protein modulates [Ca2+]o homeostasis in
normal individuals as well as in patients with chronic renal failure (165,167).

The amino acids concentration in plasma before and after meal is listed in Table 1.1. All of them
are within the range of M. Even after steak meal, the peak value for certain amino acids (e.g.
Gly) is around 0.5 mM (168). However, the reported EC50 for L-Phe was 3.5 mM as measured
by intracellular calcium readout from CaSR transfected HEK293 cells (118). The discripency for
the phenomena relies on the fact that in physiological conditions, the receptors are stimulated by
a mixture of amino acids, small peptides as well as proteins instead a single amino acid. In fact,
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small peptides, for instance, -glutathione and its variants, have smaller EC50s (in the range of
M) compared with L-Phe or L-Trp (Table 1.2).

Table 1.1 Plasma amino acid concentrations before and during intravenous amino acid
infusion and after oral steak meal
Mean (±SE) plasma amino acid concentrations of phenylalanine, tryptophan, glycine,
alanine, and histidine before (basal) and in response to intravenous infusion of each
individual amino acid and after the steak meal. Each amino acid was infused in 125 ml for
1 h in increasing stepwise manner; doses of Phe, Gly, Ala, and His were 0.0125, 0.025, 0.05,
and 0.1 M, respectively, and doses of Trp were 0.005, 0.01, 0.02, and 0.04 M. The steak
meal contained 49 g protein and 405 kcal. (Table adopted from J.Clin. Invest.Vol 71. pg.
1254-1262, 1983. )

Amino acid
infused IV

Basal

0-60 min

61-120 min

121-180 min

181-240 min

Steak meal

103±14*
140±16*
417±75*
326±10
172±19

198±37*
244±38*
559±98
365±31
316±25

85±7
94±9
386±53
549±50
100±11

M
Phe
Trp
Gly
Ala
His

51±5
49±5
283±50
316±16
80±14

68±8
66±6
291±49
345±15
104±8

90±7*
97±8*
315±50*
353±25
130±10
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Table 1.2 Potencies of -glutamyl peptides for Ca2+i mobilization in CaR-expressing HEK293 cells

HEK-293 cells that stably express the CaR were loaded with fura-2AM and assayed for
receptor-dependent intracellular Ca2+ mobilization by microfluorimetry. The data were
obtained from cells perifused with physiological saline solution in the presence of 2.5 mM
Ca2+o. In accompanying experiments, the EC50 for L-Phe was 1.1 ±0.5 mM (n =4).(Table
adopted from JBC vol 286, no. 11, pp. 8786–8797, March 18, 2011)
-Glutamyl peptide

EC50 for peptide (M)

S-Methylglutathione
Glutathione

1.7 ± 0.5 (n= 4)
3.9 ± 0.7 (n = 4)
4.7 ± 0.9 (n =3)
4.8 ± 0.7 (n =3)

-Glu-Cys
-Glu-Ala

Conigrave et.al. have investigated the physiological relevance of their in vitro findings regarding
to the amino acid concentration. They mixed 20 common L-amino acids at similar concentration
comparing to those present in fasting human plasma and showed that the mixture could
reproduce the effects of high concentrations of single amino acids (Table 1.3). These findings
suggest that the CaSR sensing L-amino acid is a universal property and amino acid composition
of human plasma has a pronounced effect on the activity of CaSR compared to single amino acid
(118).
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Table 1.3 Effect of L-amino acids on the potency of Ca2+ ions as agonists of the Ca2+
receptor.
Data are shown ± SEM. All experiments were performed at pH 7.4. ∆ EC50 is defined as
control minus experimental. Unpaired t tests performed on the data set (individual amino
acids vs. control) yielded the following results: L-His, L-Phe, L-Trp, L-Tyr, L-Cys, and LThr, P ≤ 0.0001; L-Ala, P ≤ 0.0002; L-Asn, L-Gln, L-Ser, and L-Glu, P ≤ 0.01; Gly, LPro, L-Val, L-Met, L-Asp, P < 0.05; L-Lys, P = 0.05; L-Ile, P = 0.31; and L-Leu, P = 0.95.
(Data adopted from 2000 PNAS vol.97 no.9 pg 4814-4819)

Amino acid (10 mM)

EC50 for Ca2+ (n)

∆EC50 for Ca2+ (n)

L-His
L-Phe
L-Tyr
L-Trp
L-Cys
L-Ala
L-Thr
L-Asn
L-Gln
L-Ser
L-Glu
L-Pro
L-Val
L-Met
L-Asp
L-Lys
L-Arg
L-IlE
L-Leu
Control

2.4 ± 0.1 (4)
2.5 ± 0.1 (7)
2.5 ± 0.2 (3)
2.6 ± 0.3 (3)
2.8 ± 0.1 (5)
2.9 ± 0.3 (3)
3.0 ± 0.1 (3)
3.1 ± 0.2 (3)
3.2 ± 0.2 (3)
3.3 ± 0.2 (3)
3.5 ± 0.2 (3)
3.6 ± 0.3 (3)
3.6 ± 0.3 (3)
3.6 ± 0.3 (3)
3.7 ± 0.2 (3)
3.7 ± 0.1 (3)
3.7 ± 0.1 (3)
3.9 ± 0.5 (3)
4.2 ± 0.3 (3)
4.2 ± 0.1 (10)

1.9 ± 0.2 (4)
1.8 ± 0.2 (7)
1.8 ± 0.2 (3)
1.6 ± 0.2 (3)
1.6 ± 0.1 (5)
1.4 ± 0.04 (3)
1.1 ± 0.3 (3)
1.1 ± 0.2 (3)
1.0 ± 0.2 (3)
1.0 ± 0.2 (3)
0.9 ± 0.1 (3)
0.6 ± 0.2 (3)
0.6 ± 0.2 (3)
0.6 ± 0.1 (3)
0.6 ± 0.3 (3)
0.6 ± 0.2 (3)
0.5 ± 0.3 (3)
0.3 ± 0.1 (3)
0.6 ± 0.2 (3)
0±0
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Our lab utilized computational algorithms HADDOCK to dock amino acids into the CaSR ECD
and comparied the binding energies among them (Figure 1.8 ). Similarly, the calculated binding
energe correlated well with in vitro studies reported by Conigrave’s group.

10
5
0
Trp Phe Lys Tyr His Arg Glu Met Pro Asp Asn Thr Ile Leu Val Gln Ala Ser Cys
-5
-10
-15
-20
-25

Figure 1.8 Calculated binding energy for single amino acids docking into the CaSR ECD
using HADDOCK.
The blue bars show the amin acid that has a calculated binding energy level correlated
well with expectation estimated from in vitro experiments. The orange bars show the
discrepancy.

The metabolism of both Ca2+ and amin acids shall be re-appraised in the context of protein
ingestion and dietary supplements since L-amino acid and Ca2+ can potentiate the sensing
capability by CaSR for each other. It is also emphasized by Conigrave et. al. that the CaSR
should be reassessed as a potential target of aromatic L-amino acids under certain toxic
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metabolic conditions. For instance, the CaSR expressed in the CNS might be involved in
contributing to the elevated levels of L-Phe in phenylkeonuria or in hepatic encephalopathy
(118).

1.4 Challenges in studying the membrane protein with weak metal binding affinities
The challenges in studying the Calcium-sensing-receptor are multifaceted:
First, the CaSR belongs to membrane proteins, so the challenges associated with membrane
proteins may also occur to the CaSR. Membrane proteins are difficult to separate from the cells
due to their hydrophobic transmembrane domain. The heating process may cause the aggregation
of the 7TM region and thus reduce the solubility of the protein.

Although X-ray crystallography has been used as one of the major tools to study the structure of
proteins, application of this technique to the crystallization of glycosylated proteins exhibits its
own limitations. Like other glycosylated proteins, the complex form of the glycans on the CaSR
can prevent the crystallization of this protein because the chemical and conformational
heterogeneity of the glycoproteins usually inhibit crystallization.

Due to the limitation of the conditions for crystallization as well as the fast on and off rate of
Ca2+ when its interaction belongs to weak binding, even some proteins have their crystal
structure solved like mGluR1, the detection of Ca2+-binding sites in those protein may be still
elusive. Moreover, the selectivity of the CaSR for different amino acids is not clear and the
interaction between amino acids and the CaSR are relatively weak (in mM range).
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Currently, methods for direct measurement of Ca2+ and amino acid binding to the CaSR have not
yet been well established, nor are there methods for directly monitoring ligand induced
conformational changes of the proteins. Approaches for addressing these questions rely on
indirect measurements of calcium-induced intracellular signaling changes in living cells or
utilizing the Fluorescence Resonance Energy Transfer (FRET) assay for monitoring ligand
generated fluorescence changes in isolated proteins.
Last but not least, the large size of the protein (extracellular domain 612 amino acids; whole
protein 1078 amino acids) as well as the fact that the CaSR function as a dimer contribute to the
difficulties in studying the protein, especially when it possesses a high Hill coefficient which
suggests possible multiple binding sites for ligands.
1.5 Approaches and strategies
1.4.1 Prediction of Ca2+-binding sites in proteins and computational simulation
Previous studies on the known Ca2+-binding sites from thousands of proteins with X-ray
structures show that Ca2+ binding sites usually forms pentagonal or octahedral bipyramidal
geometry (169) composed by 4-7 oxygen atoms from ligand residues. The preference of the
residues in a Ca2+ binding sites falls into the following category: Acidic residues (-COOH) >
H2O> main chain carbonyl > Asn > Ser > Thr > Tyr. There are restrictions on forming certain
geometries of Ca2+ binding pockets as the distances between Ca2+ and coordinating oxygen
atoms are within the range of 2.3~2.6 Å and the average Ca-O-C angle has been reported to be
93~160°. Two major types of Ca2+-binding sites---continuous and discontinuous---are defined
based on whether a short, contiguous primary sequence can form a pocket to chelated Ca2+. The
residues composing discontinuous Ca2+-binding sites may be separated in protein sequence but
might be close enough to form a pocket in three dimensional structures. Our lab has developed a
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series of algorithms, including GG, MUG (169), MUGC (170) etc. to predict Ca2+-binding sites
from discontinuous protein sequences utilizing their 3D structures or modeled structures. While
GG algorithm focused on the geometric information of oxygen composition from a protein
structure, MUG and MUGC further define calcium center and second shell carbon atoms to
minimize the false positive and false negative results. Having a high performance with 90% site
sensitivity and 80% site selectivity (171), these approaches have been used to explore the Ca2+binding sites in modeled CaSR structure(68,172). Following the initial grafting and subdomain
approaches to verify the Ca2+ binding sites on CaSR, the immediate need is to characterize the
cooperativity among those Ca2+-binding sites and how they could be modulated by other
allosteric modulators.
1.4.2 Computational docking and molecular dynamic simulation
Molecular docking utilize computational algorithms to calculate the preferred orientation of one
molecule to another when the two form a stable complex(173). Since the interaction between
proteins and their ligands plays a crucial role in signal transduction, docking is considered as a
useful tool to predict the binding orientation of a ligand and its target protein. A scoring function
is generally used in docking programs as an attempt to approximate the standard chemical
potentials of the system (174). AutoDock Vina developed in Dr. Olson’s group, is a new
program for molecular docking. Using a sophisticated gradient optimization approach in its local
optimization procedure and the multithreading step, AutoDock Vina exhibits fast execution
capability and improved accuracy (174). AutoDock Vina has been widely used in biologically
relevant research, including studies probing the target moleculars for GPCR proteins (174).
Using this strategy, we are able to predict the L-Phenylalanine binding pocket, and further
investigate how this positive allosteric modulator regulates the function of CaSR.
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Molecular dynamics (MD) simulation provides an approach complementary to the experiments
in live cells for understanding biomolecular structure, dynamics, and function. The crystal
structures of mGluR1, a GPCR family C member, with both the ligand-free form and agonist
loaded forms available in the Protein Data Bank (PDB) [PDB entries: 1EWT, 1EWK (175), and
1ISR(176) ] are considered to be employed as a template in the simulation due to their similarity
in structure with that of the CaSR.
1.4.3 Using Ca2+ sensors to monitor intracellular calcium signaling
Monitoring the effects of Ca2+on numerous cellular processes is an essential step for
understanding the complex intracellular signaling pathways regulated by Ca2+. Several endeavors
have been made to investigate this problem, characterizing as two major categories: Ca2+-binding
dyes and genetically-encoded fluorescent proteins (177). Fura-2 is one of the representative Ca2+
binding dyes that have been widely applied in many studies. Its advantages, such as high
spatiotemporal resolution, good photostability and easy cell membrane permeability via its
acetoxymethyl ester has enabled Fura-2 to become one of the most popular cytosolic Ca2+
indicators. However, the drawbacks of these dyes are also apparent since they can not be targeted
to subcellular compartments, and the exogenous buffer they introduce during the dye mixing
process may perturb endogenous Ca2+ signaling. Moreover, their sensitivity might be reduced in
thick tissues and intact organisms (178). On the other hand, the protein-based Ca2+ sensors can
be specifically targeted to various organelles in various cell types with grafted signal peptides
(179). Aequorin, the first generation of the protein based Ca2+-sensor, has a wide dynamic range
and weak Ca2+ binding affinity, but the requirement for cofactors in order to be applied in living
cell imaging has limited its application (180). The second generation was based on the
fluorescence resonance energy transfer (FRET) between calmodulin and its binding peptide M13
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linked to two fluorescent proteins (181,182). The disadvantage of the FRET based Ca2+
indicators are mainly two folds: the linker between the donor and acceptor might disrupt the
endogenous signaling net; and quantitative analysis might be hindered by the distances and
orientation of the FRET pair (179,183,184). Our lab has developed a Ca2+ sensor named
“CATCHER” based on the enhanced green fluorescence protein (EGFP). It can target to the
endoplasmic reticulum (ER) and its weak Ca2+ binding capability as well as the minimum
perturbation of the endogenous signaling pathways provides a new way to explore calcium
changes in sub-cellular compartments (185).
1.4.4 Expression and purification of the extracellular domain of CaSR
Various studies including protein structure and function analysis, protein-protein interaction
verification, antibody generation and gene regulation exploration, rely on recombinant protein
expression technology. Hitherto, six host systems have been used for protein expression, namely
cell-free expression, bacterial expression, yeast expression, algal expression, insect expression
and mammalian expression. Among these, the bacterial, insect and mammalian systems are
widely employed in the study of GPCR proteins. Each system has its own advantages and
challenges. The bacterial expression system is best known for its low cost, simple culture
conditions and that it can easily be scaled up to generate large amounts of protein. However, it
also faces problems like protein solubility, minimal posttranslational modification and is less
tolerant to mammalian proteins. On the contrary, the mammalian expression system only
generates limited amounts of proteins and the demanding culture conditions usually make the
procedure too costly. Nevertheless, mammalian expression systems produce the highest level of
correct post-translational modification, and it is more suitable to generate functional human
proteins. Our lab routinely utilizes a variety of E.Coli strains to express engineered proteins. The
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grafted proteins and the subdomain constructs of CaSR have been successfully expressed in
bacteria system (68,172). Meanwhile, our collaborator Dr. Kelley Moremen in the University of
Georgia has abundant experience of expressing mammalian proteins in suspension culture
systems using mammalian cells (HEK293F). It will be worthwhile to study how the proteins
expressed from two different systems will vary in various biophysical characteristics (Invitrogen).
1.4.5 Monitoring intracellular signaling pathways using immunoassays
Immunoassays have been widely applied in the exploration of the intracellular molecular
signaling networks. They rely on the interaction between a certain antibody and a specific
macromolecule or low molecular weight signaling molecule. The other key feature of
immunoassays is that they provide a way to quantify the signal in response to the binding. This
feature requires a detectable label to be linked to the antibodies. The linked label either can emit
radiation, have a color change during the reaction, produce fluorescence, or can be induced to
generate light though chemiluminescence detection. Three immunoassays were used in this
project: Western Blot, immunocytochemistry (ICC) and ELISA. The Western Blot technique
utilizes chemiluminescent substrate for alkaline phosphatase (AP) to generate detectable signals.
Those signals can be measured quantitatively by comparing them with an internal control protein
such as glyceraldehyde 3-phosphate dehydrogenase (GAPDH). The secondary antibody for ICC
is conjugated with a fluorescent dye that can be excited at various wavelengths and emits lights
within a certain measurable range. On the other hand, the secondary antibody for the ELISA
assay is conjugated with horseradish peroxidase (HRP) which interacts with the substrate
tetramethylbenzidine (TMB) and subsequently generates detectable signals. Those assays can be
useful for “visualizing” molecules that play crucial roles in intracellular signaling networks.
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1.6 Major questions to be addressed in this dissertation
Several major questions need to be addressed in this dissertation:
1, How CaSR functional cooperativity is regulation by extracellular binding of Ca2+ and amino
acids?
2. How the disease associated CaSR mutants can affect the functional cooperativity mediated by
Ca2+ and amino acids?
3. How can we determine the binding of Ca2+ and L-Phe to the CaSR ECDs and detect the
potential conformational change induced by the interaction?.
4. How the multifunctional intermediate messenger protein--- CaM regulates the CaSR
trafficking and signaling?
5. How ER Ca2+ signaling regulates CaSR functional cooperativity via modulation of receptor
surface expression?

1.7 The objectives and overview of this dissertation
The overall goal of this research is to understand the mechanisms of how CaSR integrates the
Ca2+-mediated signaling and to probe the molecular basis for diseases resulting from alterations
in Ca2+ homeostasis. We will reach the goal via following 5 aims to addressing the above five
major questions.
A. Chapter 1 is to overview the background of calcium signaling and calcium sensing
receptor.
B. Chapter 2 is to describe methods and materials used in this study.
C. Chapter 3 is to understand the regulation of CaSR functional cooperativity by
extracellular binding of Ca2+ and amino acids
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A1.Predict Ca2+ and L-Phe binding sites using computational algorithms
In order to predict the Ca2+ binding sites and potential L-Phe binding site in the ECD, a modeled
structure of CaSR was generated based on the known structure of mGluR1

. GG (171) and

MetalFinder (68,186), computational algorithms developed in our lab based on utilizing
geometric characteristics of Ca2+ binding sites in proteins to identify the Ca2+ binding pockets in
ECD. And the L-Phe binding site will be predicted based on the results of molecular dynamic
simulation on the CaSR ECD docked with L-Phe. .
A2 Verify predicted Ca2+ binding pockets and L-Phe binding site by monitoring the intracellular
calcium concentration in HEK293 cells transiently transfected with wild type CaSR and its
variants using single cell fluorimetric imaging with or without the presence of L-Phe.
To study the effect of each site-specific Ca2+ binding site on the function of CaSR, the negatively
charged residues, mainly Glu and Asp, will be mutated into non-charged residues like Ile or Ala.
To confirm the L-Phe binding site, the site-directed mutagenesis strategy was applied. One of the
methods to study the effect of calcium binding sites on the function of CaSR is monitoring the
intracellular calcium release in mammalian cells. The WT CaSR and its mutants will be
transfected into HEK 293 cells and heterogeneously expressed. The intracellular calcium
concentration changes will be recorded with the aid of a ratiometric Fura-2 based method upon
stepwise increased in extracellular Ca2+. By comparing the responses of WT CaSR and its
mutants, the function of mutated calcium binding sites might be revealed. The effect of L-Phe on
WT CaSR as well as the mutants was measured by performing the assays described above.

D. Chapter 3 and 4 are to understand how the disease associated CaSR mutants can affect
the functional cooperativity mediated by Ca2+ and amino acids.
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By collaborating with Prof. Thakker’s group at University of Oxford, we will analyze how the
disease related mutations can affect the function of CaSR and how L-Phe can modulate the
receptor activity.

E. Cahpter 6 and 7 are aimed to probe the Ca2+ and L-Phe binding affinity, cooperativity,
and related conformational change of wild type ECD and its mutants by various
biophysical methods.
First, we expressed and purified the ECD and disease-related mutants and variants, which were
shown to play important role in intracellular calcium responses using bacteria and mammalian
expression systems. The native conformation of the bacterial expressed protein was compared to
the mammalian expressed protein using by immunoblotting technique and metal binding FRET
assay.
Second. The secondary structures of the purified proteins were verified using circular dichroism.
Moreover, the agonist induced conformational changes were measured using tryptophan spectral
and ANS binding assays. Next, the Tb3+ -FRET assay was applied to study the metal binding
capability of those proteins. Furthermore, the Ca2+-binding affinities were indirectly acquired
using a Ca2+ competition assay, in which Ca2+ is gradually added to compete with the bound Tb3+.

F. Chapter 8 is to study the mechanism of receptor internalization upon the stimulation of
extracellular calcium .
The regulation of cytosolic Ca2+ signaling and cell surface expression of the receptor by
calmodulin binding to the calcium-sensing receptor's proximal C-terminus was investigated in
this proposal. The hypothesis to be tested was that extracellular activation triggers the Ca2+-
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dependent association of CaM the C-terminus of CaSR in regulating cell surface expression of
the receptor and the PKC activity. We will 1) measure the cellular interaction between CaR and
CaM and the effect of CaM binding on the phosphorylation at T888 by PKC; 2), investigate the
[Ca2+]i oscillation and trafficking changes using CaSR variants with mutations of the calcium
and amino acid-binding sites and disease associated mutants and CaM variants with altered
calcium binding affinity.

G. Chapter 9 is to investigate how the CaSR regulate its functional cooperativity by
modulation of surface expression via [Ca2+]ER signaling.
We will use the ER calcium probe developed in our lab --- CatchER as well as the commercial
available ratiometric dye Mag-Fura 2 to investigate how [Ca2+]ER regulates the expression of the
receptor. We will utilize the real-time imaging system to calibrate [Ca2+]ER and the surface
expression of CaSR will be analyzed using multiple immunoassays (e.g. western blot,
immunofluorescence staining).

H. Chapter 10 summarizes major conlusions and the significance of this project.
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CHAPTER 2. MATERIALS AND METHODS
2.1 Computational prediction of Ca2+-binding sites in the ECD of CaSR
The structure of the extracellular domain of CaSR (residues 25-530) was modeled based on the
crystal structure of mGluR1 (1EWT, 1EWK and 1ISR), and the potential Ca2+-binding sites in
the CaSR ECD were predicted using MetalFinder (68,187).
2.2 Computational prediction of L-Phe-binding pocket in the ECD of CaSR
The Prediction of the L-Phe-binding site was performed by AutoDock-Vina (174). In brief, the
docking center and grid box of the model structure and the rotatable bonds of L-Phe were
defined by AutoDock tools-1.5.4. The resultant L-Phe coordinates were combined back to the
pdb file of the model structure for input into the Ligand-Protein Contacts & Contacts of
Structural Units (LPC/CSU) server to analyze interatomic contacts between the ligand and
receptor (188). The residues within 5 Å around L-Phe were considered as L-Phe-binding residues.

2.3 Computational simulation of CaSR and its mutants
2.3.1 MD simulation and correlation analysis using Amber.
MD simulation provides an approach complementary to the experiments in live cells for
understanding biomolecular structure, dynamics, and function. The initial coordinates for all the
simulations were taken from a 2.20 Å resolution x-ray crystal structure of mGluR1 with PDB ID
1EWK (175). The AMBER 10 suite of programs (189) was used to carry out all of the
simulations in an explicit TIP3P water model (190), using the modified version of the all-atom
Cornell et. al.(191) force field and the re-optimized dihedral parameters for the peptide ω-bond
(192). An initial 2 ns simulation was performed using NOE restraint during the equilibration in
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order to reorient the side chains residues in the Ca2+-binding site, but no restraints were used
during the actual simulation. A total of three MD simulations were carried out for 50 ns each on
apo-form and ligand (Ca2+ and L-Phe) loaded forms. During the simulations, an integration time
step of 0.002 ps was used to solve the Newton’s equation of motion. The long-range electrostatic
interactions were calculated using Particle Mesh Ewald method (193) and a cutoff of 9.0 Å was
applied for non-bonded interactions. All bonds involving hydrogen atoms were restrained using
the SHAKE algorithm (194). The simulations were carried out at a temperature of 300 K and a
pressure of 1 bar. A Langevin thermostat was used to regulate the temperature with a collision
frequency of 1.0 ps-1. The trajectories were saved every 500 steps (1ps). The trajectories were
analyzed using the ptraj module in Amber 10.
2.3.2 Accelerated Molecular Dynamics Simulation.

Accelerated MD (aMD) was carried out on the free CaSR ECD using the RaMD method (195)
implemented in a pmemd module of AMBER on the rotatable torsion. A boost energy, E, of
2000kcal/mol was added to the average dihedral energy and a tuning parameter, α, of 200
kcal/mol was used. The dual boost was also applied to accelerate the diffusive and solvent
dynamics as previously described (196). The simulation conditions were similar to that of the
normal MD simulations above. Principal Component Analysis was carried out on the trajectories
using the ptraj module in AMBER. The directions of the eigenvectors for the slowest modes
were visualized using the Interactive Essential Dynamics (IED) plugin (197).
2.3.3 Docking Studies of Phe, Asp, and Glutathione.
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The binding energies for the ligands were calculated using an ensemble-docking method and
Autodock vina (198). The ensemble of conformations of CaSR was generated using molecular
dynamics simulations as described above. Gasteiger charges were assigned to the ligands and
CaSR using the Autodock ADT program. The ligands were flexible during docking to each
conformation of CaSR using the following parameters: the grid spacing was 1.0 Å; the box size
was 25 Å in each dimension, and the center of the box was chosen as the center of the active site
of CaSR, with a large enough space to sample all possible ligand conformations within the box.
The maximum number of binding modes saved was set to 10. The conformation with the lowest
binding energy was used and assumed to be the best binder. Distributions of the binding energies
for each ligand were calculated based on the lowest binding energy of each ligand to each
conformation in the ensemble of CaSR conformations.
2.3.4 Principal Component Analysis (PCA)

Using the ptraj module of AMBER 10, the Principal Component Analysis (199,200) was
performed on all the atoms of the residues that are 5 Å away from Site 1 of CaSR ECD. The
covariance matrix of the x, y, and z coordinates of all the atoms obtained from each snapshot of
the combined trajectories of the ligand-free CaSR ECD, the Ca2+-loaded form, the form loaded
with only L-Phe, and the form loaded with both Ca2+ and L-Phe were calculated. The covariance
matrix was further diagonalized to produce orthonormal eigenvectors and their corresponding
eigenvalues, ranked on the basis of their corresponding variances. The first three eigenvectors,
the Principal Components, which contributed the majority of all the atomic fluctuations, were
used to project the conformational space onto them, i.e., along two dimensions.

47
2.4 Plasmid construction and protein engineering
2.4.1 L-Phe binding site related mutation construction
All of the full length CaSR mutants were generated by site-directed mutagenesis based on the
sequence of the human CaSR-pcDNA (a gift from Dr. Edward Brown from Brigham and
Women’s Hospital, Boston). Site-directed mutagenesis was performed using the QuikChangeTM
kit (Stratagene, Cedar Creek, TX) according to the manufacturer’s instructions. Briefly, a pair of
complementary primers of 27–35 bases was designed for generating each mutant with the
mutation placed at the middle of the primers. The template human CaSR in pcDNA3.1(+) was
amplified using Pfu DNA polymerase (Stratagene) with these primers for 16 cycles in a PCR
instrument (TECHNE). After digestion of the template DNA with DpnI (New England Biolabs),
the amplified mutant DNA was transformed into XL10-Gold Ultracompetent cells. All the DNA
sequences were verified by Genewiz (www.genewiz.com).
2.4.2 Disease related mutation construction
All of the full length CaSR mutants were generated by site-directed mutagenesis based on the
sequence of the human CaSR-pEGFP (a gift from Dr. Rajesh Thakker from Oxford Centre for
Diabetes, Endocrinology and Metabolism) as well as human CaSR-pcDNA. Site-directed
mutagenesis was performed using the QuikChangeTM kit (Stratagene, Cedar Creek, TX)
according to the manufacturer’s instructions as mentioned above.
2.4.3 ECD construction and its mutants
For engineering of the hCaSR-ECD, the sequence Tyr20-Phe612 was cloned from CaSR-pCDNA
3.1(+) by standard PCR methods using 5’ primer (CCGGAATTCTACGGGCCAGACCAGCG
AGCCCAA) and 3’ primer (CCCAAGCTTTTAAAAGGGCTCCGTCCACGACAGAAACT).
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The cloned sequence was then inserted into the plasmid pXLG between restriction enzymatic
sites EcoRI and HindIII. The engineered protein contains a transmembrane signal (MRLLTALF
AYFIVALILAFSVSAKS) followed by His-tag at N-terminal. The sequences were verified
through the GENEWIZ Company (www.genewiz.com).
For engineering of the bCaSR-ECD, the ECD CaSR sequence, Met1-Phe 612 was amplified from
CaSR-pCDNA 3.1(+) (2009 Nancy 27) and was further subcloned into the pRSET-A vector
between the BamHI and EcoRI restriction sites.
2.4.4 Furin tag construction and its mutants
For engineering of the Furin-CaSR-ECD, the furin cleavage site (ARRRKKRGLDV) was
inserted immediately after the FLAG tag in the pcDNA-CaSR plasmid by standard PCR methods
using 5’ primer (AAGCGAGGCTTGGACGTCACCTTTCTGAGAGGTCACGAAGAAAGT
GGC) and 3’primer (CTTTCGTCGTCGTGCCTTGTCATCGTCATCCTTGTAGTCCACAGG).
The sequences were verified through the GENEWIZ Company (www.genewiz.com). All
mutations on the Furin site containing construct were introduced using site-directed mutagenesis
via the QuikChangeTM kit (Stratagene, Cedar Creek, TX) according to the manufacturer’s
instructions as described above.
2.4.5 Construction of the Filamin A interaction region deletion mutant CaSR.
Deletion of the Filamin A interaction region was carried out on the pcDNA-CaSR plasmid. ∆860
refers to the deletion of the whole CaSR C-terminal after residue 860. ∆907-999 refers to the
deletion of the region between residue 907 and 999. ∆971 refers to a construct in which the
region between residue 971 and 1032 was deleted. All constructs were generated using standard
PCR methods.
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2.5 Protein expression and purification
2.5.1 CaSR ECD expression in bacteria system
The bacterial expression was carried out in Escherichia coli Rosetta-gamiTM pLysS cells in LB
medium with 100 mg/L of ampicillin with an initial temperature of 37°C. Isopropyl--Dthiogalacto-pyranoside (IPTG) at 300 M was added when the absorbance at 600 nm reached
0.4~0.5 to induce protein expression for overnight expression at 27C. The cells were collected
by centrifugation at 5000 rpm for 30 min and the cell pellets were lysed using a cell disruptor.
After separating the mixture by centrifugation at 17000 rpm for 15 min, the supernatant was
filtered via a 0.45 M filter and further applied to a HisPrep HP column (GE Healthcare) and the
protein was purified using AKTA FPLC (GE Healthcare). The bacterial CaSR-ECD
concentrations were determined using absorbance at 280 nm with an extinction coefficient of
110,300 M-1 cm-1.

2.5.2 CaSR ECD expression in mammalian system
One liter of Freestyle™ 293 Expression Medium (Life Technologies) was used for HEK293F or
Lec1 mutant HEK293 F cell culture. Cells were transfected with pXLG-hCaSR-ECD plasmid
using the polyethylenimine (PEI) method when the cell density achieved 8x105. The hCaSRECD was secreted into the culture media. When the cell density reached 5x106 cell/mL, the
media was collected by centrifugation 3 times at 1500xg for 10 min each. The supernatant was
diluted with dilution buffer (Tris NaCl pH=8.0) at a ratio of 1:3 and further filtered through a
0.45 m filter (Millipore, Billerica, MA). The filtered medium was applied to a 16/10 HisPrep
HP column (GE Healthcare) pre-equilibrated with Buffer A (Tris 50 mM, NaCl, 150 mM,
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Imidazole 20 mM) and a linear segmented gradient of 0–100% Buffer B (50 mM Tris, 500 mM
sodium chloride, and 500 mM imidazole, pH 7.4) was run using FPLC to elute the protein. The
hCaSR-ECD concentrations were determined using Bio-Rad protein assay.

2.6 Isotopic labeling of ECD CaSR
2.6.1 15N labeled CaSR-ECD from bacterial system
For isotopic labeling (15N-13C-2D),

15

NH4Cl and

13

C glucose were supplemented as the sole

source of nitrogen and carbon for bacteria growth in the minimal medium (K2HPO4 45 mM,
KH2PO4 32 mM, Fe(NH4)2(SO4)2·6H2O 20 M, MgSO4·7H2O 0.25mM, glucose 27.7 mM,
NH4Cl 9 mM). Escherichia coli Tuner™ strain in minimal medium with 100 mg/L of ampicillin
was cultured at 37°C at the beginning. Isopropyl--D-thiogalacto-pyranoside (IPTG) at 300
M was added when the A600 reached 0.6 to induce protein expression for overnight expression
at 27°C. The cells were collected by centrifugation at 5000 rpm for 30 min. The cell lysate was
applied to a HisPrep HP column (GE Healthcare) and protein was purified using AKTA FPLC
(GE Healthcare). The bCaSR-ECD concentrations were determined using absorption at 280 nm
with extinction coefficients of 110,300 M-1 cm-1.

2.6.2 13C Methylation labeling of ECD CaSR
The dimethylation of lysine was performed by reacting with formaldehyde under reducing
conditions at 4°C for 16 h. The reaction was optimized to allow complete dimethylation. The
formaldehyde was added twice together with DMAB for reductive methylation. For each time,
the mole ratio of formaldehyde and Lys was 3:1 and the ratio of DMAB to formaldehyde was 3:1.
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The time interval between the two additions was 3 hours. The mono-methylated peak can be
easily differentiated because the chemical shift is in the range of 30-35 ppm while the
dimethylated lysine has peaks in the range of 42-48 ppm.
2.6.3 15N labeled CaSR-ECD from mammalian system
Four~six liters of customized Freestyle™ 293 Expression Medium (Life Technologies) was used
for HEK293F cell culture. The normal L-Phe supplement in this medium was substituted by N15
labeled L-Phe. Cells were transfected with pXLG-hCaSR-ECD plasmid using the
polyethylenimine (PEI) method when the cell density reached 8x10^5. The protocol for purifying
the mammalian expressed protein was the same as purification for the non-labeled mammalian
CaSR ECD.

2.7 Circular dichroism spectroscopy
The circular dichroism spectra were recorded from 190 to 260 nm on a Jasco-810
spectropolarimeter purged with N2 and equipped with a temperature control system CTC-345.
Spectral and temperature dependent measurements were performed at a bandwidth of 2 nm using
a U-type quartz cell of path length 0.1 mm with protein concentrations ranging from 8 to 10 M
in 10 mM Tris-HCl, pH 7.4. Five spectra were recorded at a scan rate of 50 nm/min and response
time of 1s. The continuous temperature dependence of the ellipticity at 222 nm was measured
using a scan rate of 50 C/h and a delay time of 100 s. The cuvette was sealed with parafilm to
prevent solvent evaporation.
The spectra were deconvoluted using the selcon method after subtracting the spectrum of the
buffer as the blank and the CD data was depicted in units of molar ellipticity per residue. The
melting curve was fitted using equation “∆S =∆Smax/(1 + e(Tm-T)/k)” to obtain the thermal
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transition point, where ∆S and ∆Smax are the signal changes at each data point and final point, Tm
and T are the transition temperature and experimental temperature, respectively. k is a transition
rate that defines how fast the temperature-induced change occurs, which is represented by the
slope of the transition phase in the fitting curve, a smaller k results in a sharper transition (201).

2.8 Fluorescence spectroscopy
2.8.1 Intrinsic tryptophan fluorescence
A PTI lifetime fluorimeter was used to record the fluorescence spectra at room temperature using
a 1 cm path length cell. Intrinsic tryptophan emission spectra were recorded from 300 to 400 nm
with the excitation wavelength at 282 nm. The slit widths were set at 1~4 nm for excitation and
3~8 nm for emission respectively. The calcium titration was performed in 10 mM Tris with the
protein concentration of 1.5~2.0M at pH 7.4 by adding known amount of CaCl2.
2.8.2 Tb3+-FRET assay
For the Tyr/Trp-sensitized Tb3+ fluorescence energy transfer (Tb3+-FRET) assay, protein samples
(1.5~2.0M) were in 20 mM PIPES-10 mM KCl at pH 6.8. The emission spectra was collected
from 500~600 nm with the excitation at 282 nm. The slit widths for excitation and emission were
set at 1 nm and 3 nm, respectively. Secondary Rayleigh scattering was circumvented by using a
glass filter with a cutoff of 320 nm. The Tb3+ titration was performed by adding various volumes
of Tb3+ stock solutions (1 mM) stepwise into the cuvettes. The Ca2+ -Tb3+ competition
experiments were performed in solutions containing 30~50 M Tb3+ and 2 M proteins as the
starting point. The stock solution of 100 mM ~1 M CaCl2 with the same concentration of Tb3+
was gradually added into the mixture. The background fluorescence intensity was subtracted
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using logarithmic fitting and the Tb3+ binding affinity of the protein was calculated by fitting
normalized fluorescence intensity data using the Hill equation S 

[ M ]n
K d  [ M ]n
n

(Eq.2.1) where

ΔS is the total signal change in the equation, Kd is the apparent binding affinity, n is the Hill
coefficient, and [M] is the free metal concentration.
The Ca2+ competition data was first analyzed to derive the apparent dissociation constant by
Equation 1. By assuming that the samples were saturated with Tb3+at the starting point of the
competition, the Ca2+-binding affinity is further obtained by using the equation,

K d , Ca  K app

K d ,Tb
K d ,Tb  [Tb]

(Eq.2.2)

where Kd,Ca and Kd,Tb are the dissociation constants of Ca2+ and Tb3+, respectively. Kapp is the
apparent dissociation constant.

2.8.3 ANS-binding measurement
For the ANS (8-anilino-1-naphthalenesulfonic acid) binding assay, protein samples were
incubated with 40 M ANS in 50 mM Tris-HCl and 100 mM KCl (pH 7.4) with either 5 mM
EGTA or 3 mM Ca2+ at room temperature for 1 h prior to measurement. The excitation
wavelength was set at 370 nm, and the emission spectra was acquired from 400 to 600 nm. For
the Ca2+ titration, the protein concentration was 1.5 M and the Ca2+ concentration was varied
from 0 to 30 mM in 20 mM Tris- HCl and 50 mM KCl (pH 7.4).
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2.8.4 Measurement of [Ca2+]i in cell population by fluorimetry
The [Ca2+]i responses of wild type CaSR and its mutants were measured as described by Huang,
et al. (68). Briefly, CaSR-transfected HEK293 cells were grown on 13.5 × 20 mm coverslips.
After the cells reached 90% confluence, they were loaded by incubation with 4 μM Fura-2 AM
in 20 mM HEPES, containing 125 mM NaCl, 5 mM KCl, 1.25 mM CaCl2, 1 mM MgCl2, 1 mM
NaH2PO4, 1% glucose, and 1% BSA (pH 7.4) for 1 h at 37oC and then washed once with 20 mM
HEPES, pH 7.4, containing 125 mM NaCl, 5 mM KCl, 0.5 mM CaCl2, 0.5 mM MgCl2, 1%
glucose, and 1% BSA (bath buffer). The coverslips with transfected Fura-2-loaded HEK293 cells
were placed diagonally in 3 ml quartz cuvettes containing bath buffer. The fluorescence spectra
at 510 nm were measured during stepwise increases in [Ca2+]o with alternating excitation at 340
or 380 nm. The ratio of the intensities of the emitted light at 510 nm when excited at 340 or 380
nm was used to monitor changes in [Ca2+]i. The EC50 and Hill constants were fitted using the Hill
equation S 

[ M ]n
K d  [ M ]n
n

(Eq. 2.3) where ΔS is the total signal change in the equation.

2.9 Nuclear magnetic resonance (NMR) spectroscopy
NMR spectra were collected on a 900 MHz NMR spectrometer. Two-dimensional total
correlation spectra were collected using a heteronuclear single quantum coherence spectroscopy
pulse sequence with an isotropic mixing time of 75 ms at 37oC. The spectrum width was 13.3
ppm at both dimensions with a complex data point of 4096 at the first dimension and 400
increments at the second dimension. Two dimensional (15N,1H)-heteronuclear single quantum
correlation (HSQC) NMR spectra were collected with 4096 complex data points at the 1H
dimension and 128 increments at the

15

N dimension. Samples contained the protein at 10 mM
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Tris buffer, 10% D2O at pH 7.4. All of the NMR data was processed using FELIX (Accelrys) on
a Silicon Graphicscomputer.
2.10 Cell culture and transfection
For measuring cytosolic free [Ca2+], HEK293 cells were seeded on 22 × 40 mm coverslips in 60
mm culture dishes and cultured in 5% CO2 at 37oC in High Glucose Dulbecco’s modified
Eagle’s medium (DMEM) (Invitrogen) containing 10% fetal bovine serum with 100 μg/ml
penicillin-streptomycin. For fluorimetric assays, the cells were grown on 13.5×20 mm coverslips
that were placed in 6-well plates one day before the transfection. CaSR-pcDNA and its mutants
were transfected using Lipofectamine 2000TM (Invitrogen) according to the manufacturer’s
instructions. Cells were incubated for 48 h in high glucose DMEM after transfection.

2.11 Measurement of [Ca2+]i responses in single cells
Measurement of intracellular free Ca2+ was assessed as described by Huang, et al.(148). Briefly,
wild type CaSR or its mutants were transiently transfected into HEK293 cells grown on
coverslips and cultured for 48 h. The cells were subsequently loaded for 15 min using 4 μM
Fura-2 AM in 2 mL physiological saline buffer (10 mM HEPES, 140 mM NaCl, 5 mM KCl, 1.0
mM MgCl2, 1 mM CaCl2 and pH 7.4). The coverslips were mounted in a bath chamber on the
stage of a Leica DM6000 fluorescence microscope. The cells were alternately illuminated with
340 or 380 nm light, and the fluorescence at an emission wavelength 510 nm was recorded in
real time as the concentration of extracellular Ca2+ was increased in a stepwise manner in the
presence or absence of 5 mM L-Phe. The ratio of the emitted fluorescence intensities resulting
from excitation at both wavelengths was utilized as a surrogate for changes in [Ca2+]i and was
further plotted and analyzed as a function of [Ca2+]o. All experiments were performed at room
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temperature. The signals from 30 to 60 single cells were recorded for each measurement.
Oscillations were identified as three successive fluctuations in [Ca2+]i after the initial peak.

2.12 Immunoassays
2.12.1 Western Blot
2.12.1.1 Detection of membrane protein
The transfected cells grown on 60 mm plates were washed with PBS and lysed with 10 mM TrisCl (pH 7.4), 150 mM NaCl, 0.5% Nonidet P-40, 2 mM EDTA, 1 mM EGTA, and 1X protease
inhibitor cocktail on ice for 30 min. Cell debris was removed by centrifugation at 10,000 rpm for
10 min at 4 °C. The supernatants were denatured in SDS sample buffer (60 mM Tris-HCl, 2%
SDS, 10% glycerol, 5% -mercaptoethanol, 0.1% bromphenol blue) at 55°C for 10 min under
reducing conditions and subjected to 7.5% SDS-PAGE. The proteins resolved by SDS-PAGE
were subsequently electrotransferred to a nitrocellulose membrane (Thermo Scientific). The
membrane was blocked using 2% non-fat milk (Bio-Rad). The CaSR on the blot was detected by
incubation with a 1:3000 dilution of monoclonal anti-CaR antibody (ADD, Abcam) followed by
horseradish peroxidase-conjugated, goat anti-mouse secondary antibody. CaSR was visualized
with an enhanced chemiluminescence detection reagent according to the manufacturer's
instructions (Pierce Biotechnology).
2.12.1.2 ERK activity detection
Thirty-six hours post transfection of monolayers of HEK293 cells with CaSR or its mutants, cells
were incubated in serum-free high glucose DMEM medium supplemented with 0.2% w/v BSA at
37oC overnight. On the following day, cells were first incubated with HBSS for 30 min, followed
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by stimulation with varying levels of CaCl2 (0-20 mM) with or without L-Phe (5 mM) for 10 min.
At the end of the [Ca2+]o stimulation, cells were lysed with RIPA lysis buffer (Millipore, CA,
USA). In total, 150 g aliquots of lysate protein were loaded into either a 12.5% SDS-gel or a
4%-12.5% gradient gel for PAGE and analyzed by western blotting with an anti-phospho-p44/42
ERK polyclonal antibody (Cell signaling Technology, Beverly, MA, USA) diluted (1:2000). A
chemiluminescent method (AP Conjugate Substrate Kit) was employed to detect the phospop44/42 proteins. Quantitative analysis of the results was performed using ImageJ software
(National Institutes of Health). The responses were normalized to the maximal effect observed
with [Ca2+]o alone. The EC50 of [Ca2+]o-dependent responses was calculated by fitting the [Ca2+]o
concentration-response curves with the Hill equation S 

[ M ]n
K d  [ M ]n
n

where ΔS is the total signal

change in the equation, Kd is the apparent binding affinity, n is the Hill coefficient, and [M] is
the free metal concentration.

2.12.2 Immunofluorescence staining
2.12.2.1 Immunostaining of membrane protein
CaSR-transfected HEK293 cells were grown on poly(L-lysine)-coated glass coverslips for
immunofluorescence microscopy. After treatment with polyoxymethylene for 15 minutes, nonspecific antigens on the cells were blocked by incubating with 2% BSA/PBS at 37°C for 1 hr.
Anti-CaSR, mouse monoclonal antibody, ADD, was diluted 1:3000 in 1% BSA/PBS and
incubated with the coverslips overnight at 4°C. Cells were then washed with PBS for 10 minutes
at room temperature before incubating with a 1:3000 dilution of a FITC-labeled goat anti-mouse
IgG antibody (Invitrogen) at 37°C for 1 hr. Coverslips were then washed with PBS followed by
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incubation with 0.1% Triton X-100 for 15 minutes. Cells were further stained with propidium
iodide (PI) (0.5 μg/mL) for 15 minutes at room temperature before they were mounted with antifade reagent (Invitrogen). Assessment of plasma membrane staining was carried out using a 63×
objective (Zeiss 700).
2.12.2.2 ADIS experiment
HEK293 cells were transfected with WT CaSR and variant mutations. After 48 hours, cells were
first incubated with rabbit anti-flag monoclonal antibody for 1 hour at 4 oC, then stimulated with
various levels of CaCl2 (0-20 mM) for 10 min (37 oC). Cells were subsequently fixed with 3.7%
formaldehyde for 15 mins at room temperature and labeled with mouse anti-Flag monoclonal
antibody for 1 hour (room temperature). Cells were further permeabilized with 0.2% triton x-100
for 5 mins and stained with goat anti-rabbit Alexa488 and goat anti-mouse Alexa 568 conjugated
secondary antibodies. Images were collected on Zeiss LSM700 confocal microscope (Carl Zeiss,
Germany).
2.12.3 Immunoprecipitation
2.12.3.1 Biotin assay
HEK293 cells transfected with different CaSR mutants were incubated with 30 μg/ml disulfidecleavable biotin for 30 min at 4°C. Cells were subsequently washed with TBS and incubated in
Ca2+-free DMEM at 37°C for 15 min. Cells were washed three times with TBS and stimulated
with buffers containing various [Ca2+]o for 10 minutes. Next, additional calcium was removed by
washing with TBS and the cells were incubated with reducing buffer (containing 50 mM
glutathione, 75 mM NaCl, 75 mM NaOH, and 1% FBS) for 20 min at 4°C. Iodoactaminde (50
mM with 1% BSA in PBS) was added to quench residual unreacted glutathione. Cells were
washed three times with TBS and lysed in lysate buffer (10 mM Tris-HCl (pH 7.4), 150 mM
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NaCl, 0.5% Nonidet P-40, 1% Triton-X100 and a 1×protease inhibitor cocktail (EDTA-Free;
Roche)). CaSR was subsequently immunoprecipitated with anti-FLAG M2 antibody and protein
A agarose. Samples were denatured in 2× sample loading buffer and subjected to SDS-PAGE.
Biotinylated CaSR was visualized using Vectastain ABC immunoperoxidase reagent (Vector
Laboratories, Burlingame, CA).

2.12.3.2 Pull-down assay
HEK293 cells were lysed 48 hours after transient transfection with the wild type CaSR or its
truncated constructs. The lysis buffer contains 20 mM Tris-HCl (pH 7.4), 100 mM NaCl, 1%
Triton-X100. The supernatant of the cell lysates (total about 0.4mg of protein) were collected
and incubated with 5 μl of anti-flag monoclonal antibodies (Sigma) for half an hour at 4 ºC.
About 30 μl of the protein A-agarose (Santa Cruz Biotechnology, Inc) was subsequently added,
and the mixture was gently rotated for overnight at 4 ºC. After washing three times with the
respective buffers, the agarose beads were finally resuspended in 45 μl 2X SDS sample buffer
and heated at 42°C for 15 min and subjected to 7.5% SDS-PAGE. The standard western-blotting
procedure was performed to detect the CaSR, filamin or CaM using anti-FLAG antibody (Sigma)
and agarose A.

2.12.4 IP-1 ELISA assay
HEK293 cells were seeded in 24-well plates at 3 x 105 cells per well in 500 l of culture medium.
After transfection with WT CaSR, or its various mutants, cells were further cultured for 24 hours
at 37C. Cell monolayers were first washed with Ringer’s buffer without calcium (121 mM NaCl,
2.4 mM K2HPO4, 0.4 mM KH2PO4, 10 mM HEPES, 5.5 mM glucose, 1.2 mM MgCl2) and then
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incubated for 1 hour at 37C in stimulation buffer (140 mM NaCl, 5 mM KCl, 10 mM LiCl2,
0.55 mM MgCl2, 10 mM HEPES) containing varying concentrations of CaCl2. After treatment,
cells were lysed for 30 min at 37C with 50 l of 2.5% IP1 ELISA Kit Lysis Reagent (CIS Bio
International, Gif-sur-Yvette, France). The accumulation of IP1 was measured using an
immunoassay based on competition between free IP1 and horseradish peroxidase (HRP)
conjugated IP1 for binding to monoclonal anti-IP1 antibody. The results for IP1 were expressed
as percentage inhibition of IP1-HRP binding = [1-IP1-HRP binding in stimulated cells/IP1-HRP
binding in unstimulated cells] x 100.

HRP

IP1

IP1

Goat anti-mouse IgG

HRP

IP1

IP1-HRP conjugate

Anti IP1 Mab

Figure 2.1 Schematic representation of IP1 competition assay.
IP-One ELISA is a competitive immunoassay which uses IP1-HRP and an anti-IP1
monoclonal antibody. The kit comes with 96-well microplates pre-coated with an antimouse antibody. Cells are stimulated in the presence of LiCl, causing the accumulation of
IP1 upon receptor activation. The protocol consists of two steps following cell stimulation:
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addition of ELISA components and addition of TMB, the HRP substrate. The HRP
reaction

is

stopped

and

the

optical

density

(OD)

read

at

450nm

(http://www.htrf.com/usa/ip-one-elisa-assay).

2.13 Lectin Agarose Binding Assay
The ECD containing fractions after His-tag purification were mixed with 30 L of RCA-1 lectin
agarose (Vector Lab, Burlingame, CA) for overnight incubation at 4

followed by a washing

step with PBS. The ECD protein was eluted using 0.2 M galactose. The elution fractions were
analyzed by Western blot, using an anti-flag antibody.
2.14 Deglycosylation reactions
Triton X-100 was added to heat- and SDS-denatured, purified ECD protein (20 g) at a final
concentration of 2% before the protein was subjected to the PNGaseF deglycosylation procedure.
Around 1.4 units of PNGase F were added per microgram of purified protein and incubated for 2
h at 37 . The samples subjected to deglycosylation were further analyzed by Western blot using
an anti–flag antibody. For Endo F1 enzyme treatment, purified Lec1-hCaSR-ECD protein was
directly taken from FPLC fraction and incubated with Endo F1 at mass ratio 1:3 in 10 mM Tris
buffer, pH 7.4 for overnight incubation at 4

.
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CHAPTER 3. IDENTIFICATION OF AN L PHENYLALANINE BINDING SITE
ENHANCING THE COOPERATIVE RESPONSES OF THE CALCIUM SENSING
RECEPTOR TO CALCIUM
3.1 Introduction
It has long been recognized that Ca2+ acts as a second messenger that is released from
intracellular stores and/or taken up from the extracellular environment in response to external
stimuli to regulate diverse cellular processes. The discovery of the parathyroid Ca2+-sensing
receptor (CaSR) by Brown et al. has established a new paradigm of Ca2+ signaling (38). In
addition to its known role as a second messenger, extracellular Ca2+ can function as a first
messenger by CaSR-mediated triggering of multiple intracellular signaling pathways, including
activation of phospholipases C, A2, and D, and various mitogen-activated protein kinases
(MAPKs), as well as inhibition of cAMP production (121,202-206). This receptor is present in
the key tissues involved in [Ca2+]o homeostasis (e.g., parathyroid, kidney, bone) and diverse
other non-homeostatic tissues (e.g., brain, skin, etc.) (41,49,101,207). CaSR consists of a large
N-terminal extracellular domain (ECD) (~600 residues) folded into a Venus Fly Trap (VFT)
motif, followed by a 7-pass transmembrane region (7TM) and a cytosolic C-terminus. The ECD
has been shown to play an important role in the cooperative response of the CaSR to [Ca2+]o.
Elevations in [Ca2+]o activate the CaSR, evoking increases in the intracellular Ca2+ concentration
([Ca2+]i), producing [Ca2+]i oscillations, modulating the rate of parathyroid hormone (PTH)
secretion, and regulating gene expression (24,119,121,126). The pattern of [Ca2+]i oscillations is
one of the most important signatures reflecting the state of CaSR activity.
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More than two hundred naturally-occurring mutations have been identified in the CaSR
that either inactivate the receptor (reducing sensitivity to [Ca2+]o), leading to familial
hypocalciuric hypercalcemia (FHH) or neonatal severe hyperparathyroidism (NSHPT), or
activate it (increasing sensitivity to [Ca2+]o), thereby causing autosomal dominant
hypoparathyroidism (ADH) (208-210). Several of these naturally-occurring mutations of CaSR
exhibit altered functional cooperativity (208).

Functional cooperativity of CaSR (i.e., based on biological activity determined using
functional assays rather than a direct binding assay), particularly the positive homotropic
cooperative response to [Ca2+]o, is essential for the receptor’s ability to respond over a narrow
physiological range of [Ca2+]o (1.1-1.3 mM). CaSR has an estimated Hill coefficient of 3-4 for its
regulation of processes such as activating intracellular Ca2+ signaling and inhibiting PTH release.
Under physiological conditions, L-amino acids, especially aromatic amino acids (e.g., L-Phe), as
well as short aliphatic and small polar amino acids (211), are able to potentiate the high [Ca2+]o–
elicited activation of the CaSR by decreasing the EC50 values required for [Ca2+]o-evoked [Ca2+]i
responses and its functional cooperativity (118,212). The levels of amino acids in human serum
are close to those activating the CaSR in vitro (118,213) and can further enhance functional
cooperativity via positive heterotropic cooperativity. Recently, several groups have reported that
the CaSR in cells within the lumen of the gastrointestinal (GI) tract is activated by L-Phe and
other amino acids, which have long been recognized as activators of key digestive processes.
Hence, the CaSR enables the GI tract to monitor events relevant to both mineral ion and
protein/amino acid metabolism in addition to the CaSR’s sensing capability in blood and other
extracellular fluids (118,166,214). Glutathione and its -glutamylpeptides also allosterically
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modulate the CaSR at a site similar to the L-amino acid-binding pocket but with over 1,000-fold
higher potencies (212,215). Thus, CaSR is essential for monitoring and integrating information
from both mineral ions/nutrients/polyamines in blood and related extracellular fluids.
Nevertheless, we still lack a thorough understanding of the molecular mechanisms by which
CaSR is activated by [Ca2+]o and amino acids, which, in turn, regulate CaSR functional
cooperativity. In addition, in a clinical setting, the molecular basis for the alterations in this
cooperativity caused by disease-associated mutations is largely unknown due to the lack of
knowledge of this receptor’s structure and its weak binding affinities for [Ca2+]o and amino acids
(68,126,172,208).

In the present study, we use two complementary approaches--monitoring [Ca2+]i
oscillations in living cells and molecular dynamic (MD) simulations--to provide important
insights into how the CaSR functions and the behavior of the receptor at the atomic level. We
first demonstrate that the molecular connectivity between [Ca2+]o–binding sites that is encoded
within the key Ca2+-binding Site 1 in the hinge region of the CaSR’s ECD is responsible for the
functional positive homotropic cooperativity in the CaSR’s response to [Ca2+]o. We further
identify an L-Phe-binding pocket adjacent to Ca2+-binding Site 1. We show that this L-Phebinding pocket is essential for functional positive heterotropic cooperativity by virtue of its
having a marked impact on all five of the predicted Ca2+-binding sites in the ECD with regard to
[Ca2+]o-evoked [Ca2+]i signaling. Furthermore, with molecular dynamics (MD) simulations we
show that the motions of Ca2+-binding Site 1 are correlated with those of the other predicted
Ca2+-binding sites. Finally, the dynamic communication of L-Phe at its predicted binding site in
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the hinge region with the CaSR’s Ca2+–binding sites globally enhances cooperative activation of
the receptor in response to alterations in [Ca2+]o.

3.2 Results
3.2.1 Molecular connectivity among predicted calcium-binding sites is required for functional
cooperativity of CaSR
It has been documented that in several regions of the CaSR and mGluRs, the amino acid
residues are highly conserved (216). Those conserved elements provide a structural framework
for the modeling of the CaSR ECD. Among all the available crystal structures of the mGluRs,
studies on mGluR1 give concrete structural information about ligand-free as well as various
ligand-bound forms of the receptor. Moreover, CaSR and mGluR1 share similar signaling
pathways and can form heterodimers either in vivo or in vitro (61). Thus, the crystal structures of
mGluR1 were employed for modeling the CaSR ECD. By using our own computational
algorithms, we previously identified five putative Ca2+-binding sites in the modeled CaSR ECD
(Figure 3.1) (68,169,172). Among those, Site 1 is located in the hinge region of the two
subdomains in the VFT motif. Among 34 newly found naturally-occurring missense mutations
within the ECD, 18 are located within 10 Å of one or more of the predicted Ca2+-binding sites
(208). Interestingly, a few disease-associated human mutations severely alter the functional
cooperativity of CaSR (161) .

Functional positive homotropic cooperativity here refers to [Ca2+]o-induced changes in
CaSR activity that can be ascribed to interactions between the five predicted Ca2+-binding sites,
which are located in different regions of the ECD (217-219). To understand the observed
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cooperativity and the origin of changes in cooperativity caused by disease-associated mutations
at the atomic level, we have carried out MD simulations on the modeled CaSR ECD to predict
correlated motions. MD simulation provides an approach complementary to experiments in live
cells for understanding biomolecular structure, dynamics, and function (220). We calculated the
cross-correlation coefficients of each residue with all of the other residues of the CaSR ECD
from the simulations. Figure 3.1 (lower-right panel) shows the normalized correlation matrix
map of both negative (blue) and positive (red) correlated motions between each pair of residues
that indicate movements in the opposite direction or in the same direction, respectively. Positive
correlations occur between groups of residues if they are within the same domain or directly
interact with each other. Figure. 3.1 shows strong correlations amongst residues from S169 to
A324. Notably, the negative correlation motions between residues K47-L125 and residues S240A300 suggest that the two lobes undergo a dynamic change similar to that of mGluR1 upon
interactions with its ligands. Closer analysis indicates that residues involved in Ca2+-binding Site
1 exhibit negative correlations with residues in Sites 2, 3, 4 and 5 (Table 3.1).
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Figure 3.1 Delineating the molecular connectivity associated with functional positive
homotropic and positive heterotropic cooperativity of the CaSR’s ECD by molecular
modeling of L-Phe- and Ca2+-binding sites.
The hinge region is defined as locations near calcium binding site 1. Upper Left corner: The
location of the predicted calcium binding site 1 and the potential residues involved in the L-Phe
interaction. Residues in cyan: residues which are both involved in calcium and L-Phe interaction.
Residues in purple: residues are predicted to interact with L-Phe
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Table 3.1 Analysis of correlated motions of WT CaSR model structure.

Residue Pairs

Negative
Correlation

S170 (Site 1): D398 (Site 5)
D190 (Site 1): S244 (Site 2)
D190 (Site 1): D248 (Site 2)
E297 (Site 1): D248 (Site 2)
D190 (Site 1): Q253 (Site 2)
E297 (Site 1): Q253 (Site 3)
E218 (Site 1): E350 (Site 4)
E297 (Site 1): E378 (Site 5)

Positive
Correlation

E224 (Site 3): E228 (Site 3)
E228 (Site 3): E229 (Site 3)
S244 (Site 2): D248 (Site 2)
S244 (Site 2): Q253 (Site 2)
E350 (Site 4): E353 (Site 4)
E354 (Site 4): E353 (Site 4)
E378 (Site 5): E379 (Site 5)
D398 (Site 5): E399 (Site 5)

The cross-correlation coefficients of each residue to all of the other residues of the modeled
CaSR ECD structure after docking with calcium were calculated from the simulation. The
strongest positive correlation of a residue with itself is given the value 1; the strongest
negative correlation between two residues is given the value -1. A cut off at > 0.7 and < -0.4
is considered as a strong correlation between residues. Strongly correlated residues in
predicted calcium-binding sites are listed in the table.

We then predicted a putative amino acid-binding site in the modeled CaSR based on its
sequence homology to mGluR1 and its ligand-loaded form using AutoDock-Vina (174). As

69
shown in Figure 3.1 (upper-left panel), this potential amino acid-binding pocket, formed by
residues K47, L51, W70, T145, G146, S169, S170, I187, Y218, S272, H413 and R415, partially
overlaps Ca2+-binding Site 1 in the modeled CaSR ECD. Its predicted location is consistent with
previous functional studies, suggesting important roles for S170 and T145 in amino acidpotentiated intracellular calcium responses (221-223). This L-Phe-binding site is also located
within the hinge region of the ECD of CaSR with a relatively localized configuration. Other
Ca2+-binding Sites (Sites 2-5) are more than 10 Å away from the L-Phe-binding site.(172). This
partial colocalization of the predicted Ca2+- and amino acid-binding sites at the hinge domain in
the ECD of the CaSR is also observed in other members of the family C GPCRs, including
mGluRs and taste receptors, which share some degree of sequence similarity Figure 3.2a
(38,96,101,204,209,224,225). The calculated binding free energy of CaSR for various ligands (in
the order of glutathione>L-Phe>L-Asp) is in excellent agreement with previous reported
experimental results obtained by determining the EC50 of intracellular Ca2+ responses to the same
ligands Figure 3.2b (118).
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Figure 3.2 Sequence alignment and binding energy calculations based on the modeled
structure of CaSR ECD.
(a) Sequence alignment of the orthosteric binding site for Glu in mGluR1 with CaSR and
ten other GPCRs of family C. Residues involved in the predicted CaSR Ca2+-binding Site 1
are labeled at the top and corresponding residues in other group members are highlighted
in yellow. (b) The binding energies were calculated after molecular dynamics simulations.
Red line: CaSR-ECD docking with glutathione (GLUT); Black line: CaSR-ECD docking
with phenylalanine (PHE); Blue line: CaSR-ECD docking with aspartic acid (ASP).
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We define functional positive heterotropic cooperativity as that which occurs when the
functional positive cooperative effect of interaction with one ligand (e.g., Ca2+) affects the
functional response resulting from interaction of a different ligand with the protein (e.g., an
aromatic amino acid) (226). This term can be applied in the case of CaSR when it simultaneously
senses Ca2+ and L-Phe. We have also observed greater correlated motions among the multiple
Ca2+-binding sites after docking both Ca2+ and L-Phe compared with docking of L-Phe alone to
the ECD domain of the CaSR (Figure 3.3). Taking these results together, we propose that there is
molecular connectivity centered at predicted calcium-binding Site 1 that plays an essential role in
regulating the correlated motions among the multiple Ca2+-binding sites. Further communication
of this site with the amino acid-binding site is likely to mediate functional heterotropic
cooperativity of CaSR-mediated signaling, as shown later.

Figure 3.3 The correlation map of the modeled CaSR ECD structure with the L-Phe-loaded
form, calcium-loaded form and the form loaded with both calcium and L-Phe.
The cross correlation matrices show the movements of residues during MD simulation.
Positive values (in red) show residues moving in the same direction while negative values
(in blue) indicate residues moving away from one another.
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3.2.2 Functional positive homotropic cooperativity among Ca2+-binding sites.
Given that it is not readily feasible to perform radioligand binding assays on CaSR due to its low
affinities for its ligands, especially Ca2+ (e.g., mM Kd) as well as difficulty in purification of
CaSR, we monitored intracellular calcium ([Ca2+] i) responses using both a cuvette population
assay and by monitoring [Ca2+]i oscillations using single cell imaging to determine functional
cooperativity of CaSR. HEK293 cells transfected with WT CaSR exhibited sigmoidal
concentration response curves for the [Ca2+]i responses (as monitored by changes in the ratio of
fluorescence at 510 nm when excited at 340 or 380 nm) elicited by changes in [Ca2+]o with a Hill
coefficient of 3.0 ± 0.1 and a EC50 of 2.9 ± 0.2 mM, suggesting strong positive homotropic
cooperativity within its five predicted Ca2+-binding sites. The sensitivity to agonist was assessed
using the [Ca2+]o at which cells began to show [Ca2+]i oscillations and the frequency of the
oscillations at the respective levels of [Ca2+]o at which more than 50% of the cells started to
oscillate.
To seek the key determinants underlying the observed functional positive homotropic
cooperativity, mutations were introduced into the various predicted Ca2+-binding sites of the
CaSR by site-directed mutagenesis, which resulted in impaired Ca2+-sensing with altered
oscillation patterns in single cell studies and higher EC50 values compared with WT CaSR in
population studies (Figure 3.4, 3.5) (Table 3.2 & 3.3). Such population studies were also reported
in our previous studies (68,172). Results from western blot and immunocytochemistry utilizing
immunofluorescence to detect the CaSR indicated essentially equivalent expression of WT CaSR
and its variants on the cell surface (Figure 3.6). As shown in Figure 3.4a, the level of [Ca2+]o
required to initiate oscillations in mutant E297I at predicted Ca2+-binding Site 1 or D215I at Site
2 increased markedly from 3.0 ± 0.1 mM to 17.0 ± 0.4 mM and 13.9 ± 0.2 mM, respectively,
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(p<0.05). Correlating well with these results, the two mutants had significantly impaired
responses to [Ca2+]o in the population assay with increased EC50 values (Table 3.3). The Hill
coefficients in Table 3.3 & Figure 3.4b indicate that the cooperativity among the various Ca2+binding sites was impaired by mutating each of them separately. Strikingly, removal of Ca2+binding ligand residues, such as E297I and Y218Q at Site 1, converted the single process for
functional activation of the WT CaSR by [Ca2+]o to biphasic functional processes, suggesting
that the underlying cooperative binding mechanism had been substantially perturbed Figure
3.4b&Figure 3.7d.
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Figure 3.4 Intracellular Ca2+ responses of CaSR mutants involving various Ca2+-binding
sites following simulation with increases in [Ca2+]o.
a. Statistical analysis of the starting points for [Ca2+]i oscillation in HEK-293 cells
transfected with WT, E297I or D215I , respectively. The [Ca2+]o was recorded at the level of
[Ca2+]i at which single cells began to oscillate. Around 30~60 cells were analyzed and
further plotted as a bar chart. b. Population assays of WT and Ca2+-binding site-related
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mutations. HEK293 cells transfected with CaSR or its mutants were loaded with Fura-2
AM. The intracellular Ca2+ level was assessed by monitoring emission at 510 nm with
excitation alternately at 340 or 380 nm as described previously(148). The [Ca2+]i changes in
the transfected cells were monitored using fluorimetry during stepwise increases in [Ca2+]o.
The [Ca2+]i responses at various levels of [Ca2+]o were plotted and further fitted using the
Hill equation.
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Figure 3.5 Individual cellular responses of mutants in calcium-binding sites to the indicated
increments of [Ca2+]o in the presence or absence of L-Phe.
(a) Representative intracellular calcium response from a single cell. Fura-2 loaded HEK293
cells expressing CaSRs with mutations in calcium-binding sites were prepared for single
cell experiments. In each experiment, with or without 5 mM L-Phe in non-calciumcontaining Ringer’s buffer, stepwise increases in [Ca2+]o in non-calcium containing
Ringer’s buffer, in the presence or absence of L-Phe, were carried out until [Ca2+]i reached
a plateau (up to 30 mM). At least 30 cells were analyzed for each mutant. (b) Statistical
analysis of the [Ca2+]o at which CaSR-transfected single HEK293 cells started to oscillate.
Empty bar: in the absence of L-Phe; Black bar: in the presence of 5 mM L-Phe. (c) The
frequency distribution of the oscillation patterns in single cells was investigated as
described before. For experiments without L-Phe, the peaks per minute were recorded at
the level of [Ca2+]o at which the majority of cells (>50%) started to oscillate; for
experiments with 5.0 mM L-Phe, the frequency was analyzed at the same [Ca2+]o that was
used in the absence of L-Phe. Specifically, the frequency of oscillations observed with
mutant E353I was analyzed at 5.0 mM [Ca2+]o; for D398A/E399I it was investigated at 10.0
mM [Ca2+]o and E224I it was studied at 4 mM [Ca2+]o. Empty bar: in the absence of LPhe; black bar: in the presence of 5 mM L-Phe.
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Table 3.2 Summary of individual cellular responses to the indicated increments of [Ca2+]o in HEK293 cells transiently
transfected with WT CaSR or mutations in the indicated Ca2+-binding sites.
Predicted
Sites

Residues

WT

Starting Point (mM)

Ending Point (mM)

Frequency

w/o L-Phe

w L-Phe

w/o L-Phe

w L-Phe

w/o L-Phe

w L-Phe

WT

3.0 ± 0.1

2.0 ± 0.2b

6.4 ± 0.3

4.3 ± 0.2

1.5 ± 0.1

2.2 ± 0.2b

Mutants

Site 1

S147, S170,D190,
Y218, E297

E297I

17.0 ± 0.4a

7.3 ± 0.2b

N/A

N/A

1.6 ± 0.1

2.9 ± 0.1b

Site 2

D215, L242, S244,
D248, Q253

D215I

13.9 ± 0.2a

6.7 ± 0.3b

N/A

17.7 ± 0.3

1.8 ± 0.1

2.5 ± 0.2b

E224I

5.0 ± 0.2a

3.2 ± 0.1b

16.8 ± 0.3

11.0 ± 0.1b

1.4 ± 0.2

2.2 ± 0.1b

E353I

3.4 ± 0.1a

2.4 ± 0.1b

10.8 ± 0.2

4.9 ± 0.2b

1.2 ± 0.2

2.0 ± 0.2b

D398A
/E399I

9.3 ± 0.1a

5.5 ± 0.2b

N/A

N/A

1.4 ± 0.2

2.2 ± 0.2b

Site 3
Site 4
Site 5

E224, E228, E229,
E231, E232
E350, E353, E354,
N386, S388
E378,E379, T396,
D398, E399

The average [Ca2+]o was recorded at which [Ca2+]i oscillations started or terminated. Values are means ± S.E. N/A= not
available. a indicates significance with respect to wild type CaSR without L-Phe, p <0.05; b indicates significance with respect
to the corresponding experiment in the same mutant without L-Phe, p <0.05.
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Table 3.3 Summary of EC50 values and Hill coefficients predicted using Hill equation for the WT and mutant CaSRs.
Sites

Mutants

2+
Response at 30 mM [Ca ]

EC50[Ca2+]o

w/o L-Phe

w/o L-Phe

100.0 ± 2.0

WT

a

w L-Phe
104.6± 2.9

2.9 ± 0.2

Hill Coefficient
w L-Phe
1.9 ± 0.2

Phase 1:
3.2 ± 0.4

b

w L-Phe

3.0 ± 0.1

4.0 ± 0.4b

Phase 1:
2.8 ± 0.2

Site 1

E297I

78.0 ± 6.9

132.8 ± 1.9b

Site 2

D215I

88.0 ± 2.5a

147.5 ± 6.0b

14.7 ± 1.9a

9.0 ± 0.5b

2.0 ± 0.2a

2.8 ± 0.3b

Site 3

E224I

83.2 ± 5.2

a

104.2 ± 4.5b

5.3 ± 0.4a

3.1 ± 0.1b

1.9 ± 0.1a

4.3 ± 0.2b

a

b

a

Phase 2:
3.5 ± 0.1

4.2 ± 0.3b

a

88.9 ± 1.8

4.0 ± 0.1

2.6 ± 0.1

2.3 ± 0.1

3.6 ± 0.1b

a

78.3 ± 6.5

4.7 ± 0.7a

3.3 ± 0.1a

2.4 ± 0.1a

3.6 ± 0.4b

Site 4

E353I

80.7 ± 1.6

Site 5

D398A/E399I

80.9 ± 7.0

b

Phase 2:
17.8 ± 0.5

7.4 ± 0.6b

w/o L-Phe

HEK293 cells were transiently transfected with the WT CaSR or CaSRs with mutations in Ca2+-binding sites, and after 48 h
the cells were loaded with fura-2 as described under “Materials and Methods”. The cells on glass coverslips were then
transferred into the cuvette for measurement of [Ca2+]i by fluorimetry and exposed to various increases in [Ca2+]o in the
absence or presence of 5 mM L-Phe. The data were obtained from three experiments for each construct. The maximum
response for each mutant was subtracted from the baseline and normalized to the maximal cumulative [Ca2+]i response of the
WT receptor. Curve-fitting was performed using the Hill equation. a indicates significance with respect to wild type CaSR in
the absence of L-Phe, p < 0.05; b indicates significance with respect to the corresponding mutants in the absence of L-Phe, p <
0.05.
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Figure 3.6 Expression of WT CaSR and its mutants in HEK293 cells.

(a) Western blot analyses of CaSR and its mutants in transiently transfected HEK293 cells.
40 g of total protein from cellular lysates were subjected to 8.5% SDS-PAGE. Three
characteristic bands are shown in the upper panel, including the top band representing the
dimeric receptor, the middle band showing mature glycosylated CaSR monomer (150 kDa),
and the lowest band indicating immature glycosylated CaSR monomer (130 kDa). The nonglycosylated CaSR monomer form is about 110 kDa. (b) Quantification of the expression of
WT CaSR and its mutants in HEK293 cells. All the bands are shown, including the one
indicating dimeric receptor, mature glycosylated monomer and the one showing immature
CaSR monomer. The internal control GAPDH was used to standardize CaSR expression
and the mutants were further normalized to the WT CaSR expression. (c)
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Immunofluorescence analyses of surface expressed WT CaSR and its mutants in HEK293
cells. Immunostaining was done with anti-CaSR monoclonal antibody ADD (227), and
detection was carried out with Alex Fluor 488-conjugated, goat anti-mouse secondary
antibody. Red, PI staining of cell nuclei; Green, CaSR. Equivalent expression of WT CaSR
as well as its variants on the cell surface suggests that the difference in the Ca2+-sensing
capabilities among the WT and mutant receptors are due to perturbation of the cell surface
receptors’ functions, rather than, for example, impaired trafficking of the receptor proteins
to the cell surface.

3.2.3 Functional positive heterotropic cooperativity contributed by the identified L-Phe-binding
site.
Figure. 3.7a shows the effect of 5 mM L-Phe on the [Ca2+]i responses at different levels of
[Ca2+]o in HEK293 cells transiently transfected with the WT CaSR or its variants with mutations
around the predicted L-Phe-sensing site. L-Phe lowered the threshold for [Ca2+]o–induced
oscillations in the WT CaSR from 3.0 ± 0.1 mM to 2.0 ± 0.2 mM, about a 1.5-fold shift (Figure
3.7b, Table 3.2). Concurrently, L-Phe also increased the oscillation frequency from 1.5 ± 0.1 to
2.2 ± 0.2 peaks/min (p<0.05) in the presence of 3.0 mM [Ca2+]o in the single cell assay (Figure
3.7b). Meanwhile, L-Phe produced functional positive heterotropic cooperativity of the receptor,
as it facilitated the response of the WT CaSR to [Ca2+]o by significantly decreasing the EC50 from
2.9 ± 0.2 mM to 1.9 ± 0.2 mM (p<0.05) and increasing the Hill coefficient from 3.0 to 4.0 in the
cell population assay (Figure 3.7b, Table 3.3).
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We then performed detailed analyses to understand the role of residues in the modeled LPhe-binding site in the functional positive heterotropic cooperativity contributed by L-Phe
(Figure 3.7, Table 3.4). Five out of 12 residues located within 5 Å of the modeled L-Phe-binding
site exhibited impaired L-Phe-sensing ability. Mutants L51A and S170T exhibited impaired LPhe-sensing capability as indicated by the absence of any change in the starting point (Figure
3.7b) as well as constant oscillatory frequencies (~1.7 and 1.4 peaks/min) in the presence of LPhe (Figure 3.7c), while they maintained relatively unaltered calcium-sensing functions.
Consistent with the single cell assay results, cell population studies revealed that the EC50 values
of L51A, S170T and Y218Q remained the same with or without L-Phe (Figure 3.7d). The effect
of S170T on the sensing of L-Phe has previously been reported by Zhang et. al. in a cell
population assay (221). Addition of 5 mM L-Phe lowered the [Ca2+]o required to initiate
oscillations in cells transfected with mutations S272A or T145A but failed to increase the
oscillatory frequency at 2.5 mM [Ca2+]o (the level at which the majority of the cells began to
oscillate), nor did it reduce the EC50 (Table 3.4, Figure 3.8). Y218 is predicted to be involved in
binding of both L-Phe in its binding pocket and of Ca2+ in Site 1. Indeed, the mutation Y218Q
largely disrupted the functional positive homotropic cooperativity with transformation of the
single cooperative response to [Ca2+]o of the WT CaSR to a biphasic process in the cell
population assay. Y218Q also exhibited less sensitivity to [Ca2+]o, as [Ca2+]i oscillations did not
start until [Ca2+]o was increased to more than 10 mM, reflecting its role in this Ca2+-binding site.
Of note, however, addition of 5 mM L-Phe failed to restore the calcium sensitivity of this mutant
as manifested by an unchanged oscillation pattern. An oscillatory frequency of ~1.5 peaks/min
was observed at 20 mM [Ca2+]o both with and without L-Phe for this mutant. In contrast,
mutations such as K47A, Y63I, W70L, G146A, I162A, S169A, I187A, H413L, and R415A did
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not abrogate the positive allosteric effect of 5 mM L-Phe (Table 3.5). Taken together, these
results suggest that residues located at the predicted L-Phe-binding site, including L51, T145,
S170, S272, and Y218, play key roles in sensing L-Phe.

Figure 3.7 Functional studies of receptors with mutations in L-Phe-binding site in HEK293
cells.
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(a). Representative oscillation pattern from a single cell. Each experiment with or without 5
mM L-Phe began in Ca2+-free Ringer’s buffer followed by stepwise increases in [Ca2+]o
until [Ca2+]i reached a plateau (up to 30 mM [Ca2+]o). (b). The pattern of [Ca2+]i responses
in each cell (minimum of 30 cells) was analyzed, and the [Ca2+]o at which individual cells
started to oscillate was recorded and plotted as a bar chart. (c). The frequency of the
oscillation patterns of the individual cells was investigated. For experiments without L-Phe,
the peaks per minute were recorded at the level of [Ca2+]o at which the majority of the cells
(>50%) started oscillating; while for experiments with 5 mM L-Phe, the frequency was
analyzed at the same levels of [Ca2+]o as in the corresponding experiments carried out
without L-Phe. (d). Population assay for [Ca2+]i responses of HEK293 cells transiently
overexpressing WT CaSR or CaSR mutants L51A or Y218Q using Fura-2 AM during
stepwise increases in [Ca2+]o from 0.5 to 30 mM. The ratio of the intensity of light emitted
at 510 nm upon excitation with 340 or 380 nm was normalized to its maximum response.
The [Ca2+]o concentration response curves were fitted using the Hill equation.
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Table 3.4 Summary of cellular responses of HEK293 cells transiently transfected with WT CaSR or mutants in the predicted
L-Phe-binding site.

WT
L51A
T145A
S170T

w/o L-Phe
3.0 ± 0.1
2.9 ± 0.1
2.8 ± 0.1
2.1 ± 0.2a

w L-Phe
2.0 ± 0.2b
2.8 ± 0.1
2.4 ± 0.2b
2.0 ± 0.1

Frequency
(Peaks/Min)
w/o L-Phe
1.5 ± 0.1
1.7 ± 0.1
1.7 ± 0.3
1.5 ± 0.1

Y218Q

17.7± 1.0a

16.7 ± 2.2

1.5 ± 0.1

1.6 ± 0.1

S272A

2.7 ± 0.2

2.1 ± 0.1b

2.3 ± 0.1

2.4 ± 0.1

Mutant

Starting Point (mM)

EC50 (mM)
w L-Phe
2.2 ± 0.2b
1.8 ± 0.1
1.8 ± 0.2
1.4 ± 0.2

w/o L-Phe
2.9 ± 0.1
3.5 ± 0.2
3.0 ± 0.1
2.7 ± 0.2
Phase 1:
3.7 ± 0.4
Phase 2:
27.1 ± 0.8
2.4 ± 0.1

Hill Number
w L-Phe
1.8 ± 0.2b
3.2 ± 0.1
3.0 ± 0.1
2.9 ± 0.1
Phase 1:
3.6 ± 0.2
Phase 2:
24.6 ± 0.5
2.2 ± 0.1

w/o L-Phe
3.2 ± 0.3
2.4 ± 0.1
3.3 ± 0.3
2.4 ± 0.3
Phase 1:
3.8 ± 1.0
Phase 2:
3.4 ± 0.5
1.9 ± 0.1

w L-Phe
4.1 ± 0.1b
2.8 ± 0.2
3.7 ± 0.4
2.2 ± 0.1
Phase 1:
3.9 ± 0.4
Phase 2:
2.8 ± 0.8
3.0 ± 0.1

The average [Ca2+]o at which cells started to exhibit [Ca2+]i oscillations was recorded for WT or each mutant CaSR. For the
oscillation frequency in the absence of L-Phe, peaks per minute were measured at the level of [Ca2+]o at which more than 50%
cells started to oscillate; when L-Phe was added, frequencies were recorded at the same [Ca2+]o as their counterparts without
L-Phe. Specifically, the frequencies of WT and L51A was measured at 3.0 mM [Ca2+]o S272A, T145A, and S170T were
measured at 2.5 mM [Ca2+]o; and Y218Q was analyzed at 15.0 mM [Ca2+]o. Values are means ± S.E. EC50 and Hill numbers
obtained from the cell population assay by fitting plots using the Hill equation.
receptor and WT CaSR without L-Phe, p<0.05;
p<0.05.

b

a

significant difference between mutant

significant difference between cases without L-Phe and with 5 mM L-Phe,
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Figure 3.8 Individual cellular responses of mutants in the L-Phe-sensitive site to the
indicated increments of [Ca2+]o in the presence or absence of L-Phe.

HEK-293 cells transfected with wild type CaSR or mutants were loaded with Fura-2 AM
for 15 min. Each experiment with or without 5 mM L-Phe began in the same non-calciumcontaining Ringer’s buffer followed by stepwise increases in [Ca2+]o until [Ca2+]i reached a
plateau (up to 30 mM) as monitored by changes in the ratio of light emitted at 510 nm
following excitation at 340 or 380 nm. At least 30 cells were analyzed for mutants S272A
and T145A. Representative cellular responses from a single cell are shown.
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Table 3.5 Summary of cellular responses from HEK293 cells transiently transfected with WT CaSR or mutants in the
predicted L-Phe-sensing site.
The intracellular calcium responses of HEK293 cells transiently overexpressing WT CaSR or various mutants were measured
using Fura-2AM during stepwise increases in [Ca2+]o. The pattern of [Ca2+]i responses in each cell (minimum of 30 cells) was
analyzed, and the [Ca2+]o at which individual cells started to oscillate was recorded. For experiments without L-Phe, the peaks
per minute were recorded at the level of [Ca2+]o at which the majority of the cells (>50%) started oscillating; while for
experiments with 5 mM L-Phe, the frequency was analyzed at the same levels of [Ca2+]o as in the corresponding experiments
carried out without L-Phe. Specifically, WT, K47A, G146A, S169A and H413L were measured at 3.0 mM [Ca2+]o; Y63I and
R415A were measured at 3.5 mM [Ca2+]o; I187A was measured at 10.0 mM [Ca2+]o; and W70L and I162A were measured at
12.5 mM [Ca2+]o. The average fluorescence intensity ratio at each increase in the level of [Ca2+]o was plotted against [Ca2+]o
and fitted using the Hill equation, which gave EC50 and Hill numbers. Values are means ± S.E.
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Mutant
WT
K47A
Y63I
W70L
G146A
I162A
S169A
I187A
H413L
R415A

a

Starting Point (mM)
w/o L-Phe
3.0 ± 0.1
2.4 ± 0.1a
3.3 ± 0.2
13.9 ± 1.0a
2.5 ± 0.1a
13.0 ± 1.2a
3.0 ± 0.2
8.1 ± 0.4a
2.8 ± 0.2
3.5 ± 0.3

w L-Phe
2.0 ± 0.2b
1.9 ± 0.1b
2.4 ± 0.2b
9.2 ± 0.3b
1.9 ± 0.1b
9.6 ± 0.3b
2.3 ± 0.1b
3.4 ± 0.1b
1.4 ± 0.1b
2.8 ± 0.2 b

Frequency
(Peaks/Min)
w/o L-Phe
1.5 ± 0.1
1.6 ± 0.1
1.6 ± 0.2
2.7 ± 0.2
2.0 ± 0.1
1.4 ± 0.1
1.6 ± 0.1
1.8 ± 0.1
1.3 ± 0.1
1.8± 0.2

EC50 (mM)
w L-Phe
2.2 ± 0.2b
2.8 ± 0.2b
2.0 ± 0.2b
3.1 ± 0.2b
2.9 ± 0.2b
2.5 ± 0.2b
2.3 ± 0.2b
N/A
2.1 ± 0.1b
2.6 ± 0.3b

w/o L-Phe
2.9 ± 0.1
2.5 ± 0.1
2.8 ± 0.2
8.2 ± 0.3
2.6 ± 0.1
7.9 ± 0.4
3.2 ± 0.2
9.0 ± 0.3
3.4 ± 0.2
3.0 ± 0.2

Hill Number
w L-Phe
1.8 ± 0.2b
1.7 ± 0.1b
1.7 ± 0.1b
7.8 ± 0.1
1.9 ± 0.1b
11.3 ± 0.1
2.2 ± 0.1b
3.4 ± 0.1b
2.1 ± 0.1b
2.5 ± 0.1b

w/o L-Phe
3.2 ± 0.3
3.0 ± 0.1
3.0 ± 0.1
1.8 ± 0.1
2.5 ± 0.1
2.0 ± 0.1
3.3 ± 0.1
1.6 ± 0.1
3.4 ± 0.2
2.9 ± 0.2

w L-Phe
4.1 ± 0.1b
3.6 ± 0.2b
3.6 ± 0.2b
3.7 ± 0.2b
3.3 ± 0.1
1.5 ± 0.1
3.9 ± 0.1
2.6 ± 0.1b
3.6 ± 0.1
3.4± 0.1b

significant difference between mutant receptor and WT CaSR without L-Phe, p < 0.05; b significant difference between cases without

L-Phe and with 5 mM L-Phe, p<0.05
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3.2.4 Global functional positive heterotropic cooperative tuning by L-Phe of the positive
homotropic cooperative response of CaSR to [Ca2+]o.
The sensing of L-Phe at the hinge region adjacent to Site 1 has marked global effects on the five
predicted Ca2+-binding sites predicted earlier that are spread over several different locations in
the CaSR’s ECD. Interestingly, addition of 5 mM L-Phe significantly rescued the [Ca2+]i
responses of the two mutants, E297I and D215I, in Sites 1 and 2, respectively, that exhibited
disrupted cooperativity. Notably, L-Phe converted the biphasic Ca2+-response curve for E297I
back to a uniphasic curve (Figure 3.9). Figure 3.9 shows that their starting points for [Ca2+]oinitiated oscillations were reduced from 17.0 ± 0.4 mM to 7.3 ± 0.2 mM (E297I) and from 13.9 ±
0.2 mM to 6.7 ± 0.3 mM (D215I), respectively, in the presence of L-Phe (Table 1). Both of the
mutants exhibited more than 2-fold-shifts in their starting points in the presence of L-Phe. The
frequencies of their oscillations increased to more than 2 peaks/min in both cases compared to
their respective frequencies without L-Phe (Figure 3.9c and Table 3.2). Similarly, addition of LPhe decreased their EC50s in the cell population assay (Table 3.3).

Mutant E224I at Site 3 exhibited increases in the [Ca2+]o required to initiate [Ca2+]i
oscillations but manifested smaller changes (from 3.0 ± 0.1 mM to 5.0 ± 0.2 mM [Ca2+]o
(P<0.05), compared with the previous two mutants. Moreover, its elevated EC50 obtained in the
population study correlated well with results from the single cell study (Table 3.2&3.3)
suggesting an impaired ability of this mutant to sense [Ca2+]o. But addition of L-Phe not only
significantly decreased the level of [Ca2+]o required for initiating oscillations but also increased
the oscillation frequency measured at the same level of [Ca2+]o. Furthermore, the population
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assay showed that the EC50 was reduced and the maximum response was rescued by 5 mM LPhe.

Figure 3.9 [Ca2+]i responses of receptors with mutations in the Ca2+-binding sites
stimulated by increasing [Ca2+]o in the presence or absence of 5 mM L-Phe.
(a). [Ca2+]i was monitored in mutants E297I and D215I in the absence or presence of L-Phe.
[Ca2+]o was increased stepwise up to 30 mM or until [Ca2+]i reached a plateau. (b).
Statistical analysis of the [Ca2+]o at which CaSR-transfected single HEK293 cells started to
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exhibit [Ca2+]i oscillations. (c). In the single cell experiments, the frequency of the
oscillation patterns was investigated in more than 30 cells. For experiments without L-Phe,
the peaks per minute were recorded at the level of [Ca2+]o at which the majority of the cells
(>50%) started to oscillate, while for experiments with 5 mM L-Phe, the frequency was
analyzed at the same level of [Ca2+]o that was utilized in the absence of L-Phe. Empty bar:
in the absence of L-Phe; Black bar: in the presence of 5 mM L-Phe. (d). Population assay
for [Ca2+]i responses of HEK293 cells transiently transfected with CaSRs with mutanted
Ca2+-binding site-related using Fura-2 AM to measure [Ca2+]i during stepwise increases in
[Ca2+]o from 0.5 to 30 mM. [Ca2+]i responses were then fitted using the Hill equation.

E353 is predicted to be a [Ca2+]o-binding residue in Site 4 in lobe 2, while D398 and
E399 are part of Site 5 (172). Table 3.3 and Figure 3.5 show that removal of these negatively
charged residues at Sites 4 and 5 increased the level of [Ca2+]o required to initiate [Ca2+]i
oscillations and also their EC50s. L-Phe at 5 mM enhanced these mutants’ sensitivities to [Ca2+]o
toward, albeit not to normal and decreased their EC50s. Therefore, as shown in Table 3.3,
mutations not only in those predicted Ca2+-binding residues adjacent to the potential L-Phebinding site (e.g., in Sites 1 and 2) exhibited L-Phe-induced increases in their sensitivities to
[Ca2+]o as well as in their Hill coefficients, but also other in [Ca2+]o-binding residues in sites
farther away from the hinge region. These results support the concept that there are global
functional positive heterotropic cooperative interactions between L-Phe and the bindings sites for
[Ca2+]o in the CaSR ECD.
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3.2.5 The ensemble of conformations of calcium- and L-Phe-loaded CaSR ECD is
distinguishable from the non-loaded form.
To provide a more detailed description of the CaSR’s mechanism of action, , including the
interactions between the binding sites for [Ca2+]o and L-Phe at the atomic level, we analyzed the
trajectories of molecular dynamics simulations using principal component analysis (PCA), which
separates out the protein motions into principal modes ranked according to their relative
contributions(199). Projection of the trajectories of the different states of CaSR onto the first
three modes that accounted for the majority of the total fluctuations is shown in Figure 3.10. The
conformations sampled by the Ca2+-free and L-Phe-free forms of the CaSR are distinctly
different from those sampled by the Ca2+-loaded and Ca2+- and L-Phe-loaded forms of the
receptor. Interestingly, the conformations of the L-Phe-loaded and the free form of CaSR are
essentially indistinguishable as can be seen in Figure 3.10a. The results suggest that [Ca2+]o shifts
the population of conformational ensembles of CaSR to a semi-active ensemble that can
subsequently be shifted to an ensemble of more active conformations upon interaction of the
receptor with L-Phe. These results are consistent with the experiments described above and
suggest that the unbound CaSR does not respond to L-Phe alone, because L-Phe cannot
effectively shift the inactive conformations to an active ensemble of conformations. The above
results do not rule out the role of conformational selection, which implies the existence of all
relevant active and inactive conformations of the receptor before binding, in the mechanism of
activation of CaSR, but clearly indicate that the ensembles of active and inactive conformations
are distinctly different. Moreover [Ca2+]o alone and/or [Ca2+]o and L-Phe together are required to
shift the population, in agreement with previously well documented experimental results that L-
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Phe could not activate CaSR at sub-threshold levels of [Ca2+]o (below about 1.0 mM in CaSRtransfected HEK-293 cells) (165).
Based on all the results described above, we propose a model to illustrate the possible
mechanism by which Ca2+ and L-Phe regulate the function of the CaSR mainly through the
molecular connectivity encoded at the hinge region of the ECD of the protein. Our model (Figure
3.10b) suggests that a local conformational change upon interaction of the CaSR with L-Phe
might affect the overall conformation of the receptor, thereby influencing the cooperativity
between multiple Ca2+-binding sites and enhancing the receptor’s overall response to Ca2+.
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Figure 3.10 Principal component analysis (PCA) of CaSR ECD with experimental data
suggesting a model for the mechanism underlying activation of the CaSR by extracellular
Ca2+ and L-Phe.
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(a). Principal component analysis (PCA) of CaSR ECD. The trajectories of the molecular
dynamics simulations were analyzed using principal component analysis (PCA), which
separates out the motions of the CaSR ECD into principal modes ranked according to their
relative contributions. The first three principal modes were included in the present study to
analyze four different states of the protein: Ligand-free (black), presence of L-Phe-only
(Green), presence of Ca2+-only (Red) or presence of both Ca2+ and L-Phe (Blue). (b). Model
for the mechanism underlying the activation of the CaSR by extracellular Ca2+ and L-Phe.
Ca2+ and L-Phe modulate the activity as well as the cooperativity of CaSR. Higher [Ca2+]o,
around 3.0 mM, could change the conformation of CaSR into an active form (second stair
level) in a positive homotropic cooperative manner (as indicated by the change of the color
of the Ca2+-binding sites from yellow to orange) and further trigger [Ca2+]i oscillations. LPhe binds to the hinge region between Lobe 1 and Lobe 2, modulating the receptor together
with Ca2+ in a positive heterotropic cooperative way (as indicated by the change in the color
from orange to red). This could produce a conformation of the receptor that is a “superactivated” form (third stair level), associated with a higher frequency of [Ca2+]i oscillations
and a reduced EC50. CaSR mutants (lower activity stair level), especially those containing
mutations close to the hinge region between lobe 1 (LB1) and lobe 2 (LB2), could cause a
disruption of the cooperativity among the various Ca2+-binding sites (lower activity second
stair level). The impaired receptor function and the cross talk between Ca2+-binding sites
can be rescued, at least in part, by introducing L-Phe into the extracellular buffer. Red
Arrow: receptor activity.
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Figure 3.11 Docking Glutathione into the CaSR ECD.
Glutathione was docked into the CaSR ECD using Audodock Vina. The listed residue
numbers are the real sequence residue number minus 24. Yellow highilighted residues are
overlapping with Phe binding sites; Blue highlighted residues are predicted to interact with
Glutathione only.
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Figure 3.12 Docking Aspartate into the CaSR ECD.
Aspartate was docked into the CaSR ECD using Audodock Vina. The listed residue
numbers are the real sequence residue number minus 24. Yellow highilighted residues are
overlapping with Phe binding sites; Blue highlighted residues are predicted to interact with
Aspartate only.

3.3 Discussion
Several major barriers have hampered our understanding of the long-standing question of how
the CaSR integrates its activation by two different classes of nutrients, divalent cations and
amino acids as well as, to regulate the functional cooperativity of the receptor and the alterations
of this cooperativity caused by naturally occurring mutations in human diseases. These include
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“invisible” binding pockets for these two key physiological agonists of the CaSR, namely Ca2+
and amino acids, challenges in obtaining structural information associated with membrane
proteins, and the lack of direct binding methods for determining the mechanisms underlying the
cooperative activation of the CaSR by Ca2+ and amino acids (118,126,228). To overcome these
limitations, we have applied several computer algorithms and grafting approaches for identifying
and predicting Ca2+-binding sites in proteins and we have verified the intrinsic Ca2+-binding
capabilities of predicted Ca2+-binding sites in the CaSR and mGluR1α (68,124,172,229).
Our studies, shown in Figures. 3.1, 3.4 and 3.7 suggest that mutations in Ca2+-binding Site 1,
such as E2971 and Y218Q, not only disrupt the CaSR’s Ca2+-sensing capacity but also have an
impact on the positive homotropic cooperative interactions of Ca2+ with the other Ca2+-binding
sites. Such biphasic behavior with a large disruption of cooperativity, is very similar to our
previously reported metal-binding concentration response curves of subdomain 1 and its variants
with increases in [Ca2+]o (172). Subdomain 1 of CaSR contains a protein sequence encompassing
Ca2+-binding Sites 1, 2 and 3, but without Ca2+-binding Sites 4 and 5. It also exhibits both a
strong and a weak metal-binding component. This strong metal-binding process can be removed
by further mutating Site 1 (E297I). In contrast, mutations at Sites 2 and 3 have less impact on the
first binding process (172). These molecular dynamics simulation studies carried out here are
consistent with the experimental results showing that residues located within Site 1 have strong
correlated motions with other residues in Sites 2, 3, 4 and 5 (Table 3.1). These results suggest
that the dynamics of Site 1 is intricately coupled to those of the other binding sites; therefore, any
changes in the dynamics of Site 1 could affect that of the other sites. The observation of this
molecular connectivity and its relationship to positive cooperativity from the molecular
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dynamics simulations provide a description at the atomic level of the crosstalk between the
different sites of the CaSR suggested by the experimental results in live cells.

Here, we have also computationally identified an L-Phe-binding pocket formed by
residues L51, S170, T145, Y218 and S272, which is adjacent to and partially overlaps the key
Ca2+-binding Site 1 at the hinge region of the Venus Fly Trap (VFT) of the CaSR. This Ca2+binding Site is also conserved in other family C GPCRs, including the mGluR1 VFT (Figure 3.1)
(96,175,229). Y218 is involved in sensing both Ca2+ and L-Phe. The aromatic ring from residue
Y218 could form delocalized pi bonds with the side chain of L-Phe and the hydrophobic
interaction between L51 and L-Phe would further stabilize this interaction. Mutating S170 might
interfere with hydrogen-bonding of the ligated amino acid to the -amino group of S170 based
on the structure of mGluR1(223). S170T has been reported by several groups to interfere with
the CaSR’s L-Phe-sensing ability(221,223). Consideration of the crystal structure of the
glutamate-bound form of mGluR1 (175), together with our docking analysis, implies that
residues T145 and S272 may not directly participate in the interaction with L-Phe but could
possibly interact with L-Phe by ligation of water molecules, which is a relatively weaker type of
interaction.

We have observed in this study essentially equivalent expression of WT CaSR and its variants on
the cell surface (Figure 3.6). These lines of evidence suggest that the difference in the Ca2+sensing capacities among the WT and mutant receptors are due to perturbation of the cell surface
receptors’ functions, rather than, for example, impaired trafficking of the receptor proteins to the
cell surface. L-Phe restored the [Ca2+]i responses of the tested mutants located in all five
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predicted Ca2+-binding sites, and it had more dramatic rescuing effects on mutants E297I and
D215I compared with the other mutants (Figure 3.9). Thus, the importance of the hinge region,
where L-Phe likely interacts with the CaSR ECD, is once again highlighted, although we only
used [Ca2+]i responses as a read out, and the results could possibly differ if other second
messenger pathways were examined.

The PCA results suggest that the need for Ca2+ in initially activating CaSR, as suggested
by the experiments, is related to shifting the ensemble of conformations of CaSR from inactive
states to active states. The activity of the Ca2+-loaded form of CaSR is then further enhanced by
the binding of L-Phe, which produces additional changes in the ensembles of conformations of
CaSR. Therefore, the global modulation of receptor activity by Ca2+ and L-Phe might be
explained by a combination of an induced fit and population shift models (230) in which the
receptor’s overall structure could vary in the equilibrium distributions of conformations of the
receptor that can interchange dynamically in the absence of Ca2+ and L-Phe . Our experimental
results suggest that binding of Ca2+ at its various sites is associated with motions of these sites
that are highly correlated with one another. Consequently, the shift in the ensemble of
conformations of CaSR induced by the initial binding of Ca2+ at Site 1 will alter the equilibrium
population of the unbound conformations of other Ca2+-binding sites due to their crosstalk with
Site 1. The binding of Ca2+ to Site 1 and the subsequent interaction of CaSR with L-Phe can
further shift the conformations of the ECD from one part of the free energy landscape to another
in such a way that Ca2+-binding to other sites is more readily favorable. Our findings here also
enhance our understanding of the role of Ca2+ in modulating key Ca2+-binding proteins such as
calmodulin to mediate signal transduction via correlated motions among their multiple Ca2+-
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binding sites, thereby generating cooperative responses with critical biological consequences
(231,232).

The CaSR’s co-activation by these two classes of ligands may be particularly important in the
gastrointestinal tract, where high concentrations of amino acids resulting from protein digestion
ensure activation of the CaSR and its stimulation of digestive processes even when there are
relatively low levels of [Ca2+]o. Moreover, as reported in clinical studies, there are 33 diseaserelated mutations near Ca2+-binding Site 1 associated with receptor activation or inactivation and,
in some cases, with reduced cooperativity (208). Our work suggests that it is likely that such
mutations disrupt the molecular connectivity encoded in the receptor and provide a better
understanding of the molecular basis of some of the CaSR-related clinical disorders. Our finding
of the capacity of L-Phe to rescue disease-linked mutations suggests the possibility of rescuing
such mutant receptors using calcimimetics of various types as pharmacotherapy, thereby
increasing cell surface expression or intrinsic activity of the mutant CaSRs. These results,
therefore, provide insights into key factors regulating the receptor’s overall activity, which could
lay the foundation for a new generation of therapeutics.

In addition to the Ca2+-sensing receptor, [Ca2+]o regulates 14 of the other members of the
family C G protein-coupled receptors (GPCRs), including the metabotropic glutamate receptors
(mGluR), -aminobutyric acid GABAB receptors and receptors for pheromones, amino acids and
sweet substances (38,96,101,204,209,224,225,233).The observed molecular connectivity
centered at predicted calcium-binding Site 1 of the CaSR, which is adjacent to an amino acidbinding pocket at the hinge region of the receptor, may be shared by other members of the family
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C GPCRs (234,235). Besides the strong conservation of the predicted calcium-binding site 1 and
amino acid-binding pocket, several lines of evidence support this suggestion (Figure 3.2)
(68,96,172,236). We have predicted a Ca2+-binding site partially sharing the Glu-binding site in
the ECD of mGluR1α, and both of these agonists co-activate the receptor (229). A Ca2+-binding
pocket was proposed to be present in the ligand-binding site of the GABAB receptor (225). Many
animals and humans can detect the taste of calcium via a calcium taste receptor that is modulated
by an allosteric mechanism (237).

In summary, our present study provides a mechanistic view of the interplay among
extracellular Ca2+, amino acids and the CaSR via molecular connectivity that modulates the
positive homotropic and heterotropic cooperativity of CaSR-mediated intracellular Ca2+
signaling. The positive cooperative co-activation of the CaSR by Ca2+ and L-Phe and the
importance of the positive homotropic and heterotropic cooperativity, respectively, exhibited by
the two agonists may be further extended to other members of the family C GPCRs to facilitate
an understanding of the molecular basis for related human disorders and the development of new
therapeutic strategies.
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CHAPTER 4. IDENTIFICATION OF 71 CALCIUM-SENSING RECEPTOR
MUTATIONS IN HYPERCALCAEMIC AND HYPOCALCAEMIC PATIENTS:
EVIDENCE FOR CLUSTERING OF EXTRACELLULAR DOMAIN MUTATIONS AT
CALCIUM BINDING SITES
4.1 Introduction
The human calcium sensing receptor (CaSR) is a 1078 amino-acid cell-surface protein (Figure.
4.1) that is expressed predominantly in the parathyroids and kidneys, where it regulates PTH
secretion and renal calcium (Ca2+) reabsorption appropriate to the prevailing extracellular Ca2+
concentration ([Ca2+]o) (38,238). The CaSR is a member of family C of the superfamily of Gprotein coupled receptors (GPCRs) that includes the metabotropic glutamate receptors,
vomeronasal pheromone receptors V2R, taste receptors TAS1R, and the gamma-amino butyric
acid (GABA-B) receptors (239). The CaSR consists of a 612 amino-acid extracellular domain
(ECD) that is critical for co-translational processing (240), receptor dimerisation (241), binding
ligands (95,234,242), and transmitting activation signals through the 7 transmembrane domains
(TMDs), which comprises residues 613 to 862, and the intracellular domain (ICD), which
comprises residues 863 to 1078 (Figure 4.1) (243). Ligand binding by the CaSR ECD results in
the activation of multiple signalling cascades including Gq/11-protein dependent stimulation of
phospholipase C (PLC) activity, causing accumulation of inositol 1,4,5-triphosphate (IP3) and a
rapid increase of cytosolic calcium ([Ca2+]i) concentrations (101). These intracellular events
mediate a decrease in the rate of PTH secretion from the parathyroid chief cell and a reduction in
renal tubular Ca2+ reabsorption, as illustrated by CaSR mutations which result in alterations in
plasma calcium and urinary calcium excretion. For example, inactivating (i.e. loss-of-function)
CaSR mutations result in familial hypocalciuric hypercalcaemia (FHH) and neonatal severe
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primary hyperparathyroidism (NSHPT) (161,238); whereas activating (i.e. gain-of-function)
CaSR mutations result in autosomal dominant hypocalcaemia with hypercalciuria (ADHH) (244).
In addition, CaSR mutations have been reported to be associated with primary
hyperparathyroidism (PHPT) and a form of Bartter syndrome, designated type V, in rare patients
(164,245). Moreover, in vitro studies which have functionally expressed these mutant CaSRs and
determined their dose–response curves and the [Ca2+]o needed to produce a half-maximal (EC50)
response in total [Ca2+]i, have demonstrated that the inactivating CaSR mutations associated with
FHH, PHPT and NSHPT result in a rightward shift of the dose–response curve and a
significantly higher EC50; whereas the activating CaSR mutations associated with ADHH and
Bartter syndrome type V result in a leftward shift of the dose–response curve and a significantly
lower EC50 when compared to the wild-type CaSR (87,246). The identification of these diseasecausing CaSR mutations has highlighted the importance of the ECD for CaSR function, as many
mutations (i.e. 40%) which result in FHH, NSHPT or ADHH cluster in the first 300 ECD
residues (163).
The CaSR ECD three-dimensional structure has been deduced based on its homology to
the metabotropic glutamate receptor type 1 (mGluR1) whose crystal structure has been
determined (175). The CaSR ECD is considered to adopt a bilobed venus flytrap conformation.
The venus flytrap domain (VFTD), comprises residues 20 to 540, and consists of amino- and
carboxyl-terminal regions that are designated lobe 1 (residues 20 to 205 and residues 324 to 477)
and lobe 2 (residues 206 to 323 and residues 478 to 540), respectively (175). These lobes form a
large cleft, and consist of alpha helices and beta sheets that are connected by multiple loops
(175). The CaSR ECD has been proposed to be the major region for Ca2+ binding (68,172), and
an analysis of the common structural properties of Ca2+ binding sites in proteins, as well as
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studies of a CaSR model, has identified 5 putative Ca2+ binding sites (calcium binding sites-1 to 5) within the CaSR VFTD (68,172). This is consistent with the finding that the CaSR has a Hill
coefficient of around 3 (87) and binds Ca2+ in a cooperative manner. These 5 calcium binding
sitess are located at flexible loops or helical domains near the protein surface and consist of
clusters of negatively charged or neutral amino acids (68,172). Calcium binding sites-1, which is
the principal site, is located in the cleft between lobes 1 and 2 (172). To further define these
structure-function relationships of the CaSR ECD, we undertook studies to characterise
additional CaSR mutations in patients with FHH, NSHPT and ADHH and assessed the
functional consequences of those that would increase understanding of the ECD residues within
the VFTD and their relationship to the 5 Calcium binding sitess.
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Figure 4.1 Schematic representation of the location of the 72 CaSR variants.
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The CaSR comprises an extracellular domain (ECD), which is formed by residues 1-612;
seven transmembrane domains (TMDs) formed by residues 613 to 862; and an intracellular
domain (ICD), formed by residues 863 to 1078. Every 50th amino acid is indicated. The 612
amino acid ECD is consists of the following: an N-terminal signal peptide (amino acids 119); a venus fly trap domain (VFTD) (amino acids 20-540); a nine cysteine domain (NCD)
(amino acids 542-598); and a peptide linker (PL) (amino acids 599-612) that connects the
ECD to the TMD. The residues involved in forming the 5 VFTD Ca2+ binding sites (CaBSs)
are indicated by asterisks. The number preceding the asterisk indicates the respective
Calcium binding sites. The 72 CaSR variants reported in this study (Table 1) are shown in
black. The amino acid change is detailed above the mutated residue. The bracketed letter
following the amino acid change indicates whether this variant was identified in a patient
with FHH (F), NSHPT (N), ADHH (A), or in both FHH and ADHH (A/F). Boxes indicate
the mutations associated with either loss- or gain of function at codons 173 and 221. The
location of the splice site mutation (Table 1), which is predicted to lead to either a 2 amino
acid missense peptide followed by a stop at codon 167, or an in-frame deletion of exon 4 is
shown as S.S. The location of the previously reported Pro339Thr mutation (245) in relation
to calcium binding sites-4 residues is also shown.
4.2 Results
4.2.1 Overview of CaSR abnormalities and variants

DNA sequence analysis of the entire 3,236 bp coding region and 12 intron-exon boundaries
of the CASR in the 290 unrelated probands revealed the occurrence of a CASR sequence
abnormality in 82 patients (Table 4.1), thereby representing a 28% CaSR variant detection rate in
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this group of patients with hypercalcaemia and hypocalcaemia. Seven abnormalities (Pro55Leu,
Arg172Gly, Arg220Pro, Arg227Gln, Glu250Lys, Leu461Pro, Lys831Thr) occurred in more than
one patient thereby giving a total of 72 abnormalities (Table 4.1). The absence of all of these
DNA sequence abnormalities in 110 alleles from 55 unrelated normal individuals indicated that
these abnormalities were mutations or rare polymorphisms. Fifty-five CaSR abnormalities were
found in the 224 hypercalcaemic patients, representing a 25% detection rate, and 45 of these
CaSR abnormalities were in FHH patients and 10 were in NSHPT patients (Figure. 4.2) The
remaining 27 abnormalities of the CaSR were found in the 66 hypocalcaemic patients,
representing a 41% detection rate, thereby confirming ADHH as the aetiology for the
hypocalcaemia. Amongst the 72 different CaSR abnormalities, 30 (42%) had not been reported
in previous studies, and the remaining 42 (58%) had been reported to occur in other, presumably
unrelated patients (247). One variant (Glu250Lys) was found to occur in FHH and ADHH
patients, raising the possibility that this may be a polymorphic variant. Indeed, in vitro functional
expression studies demonstrated that the Glu250Lys variant represented a functionally neutral
polymorphism (Figure 4.3). Forty-five different CaSR mutations (63%) affected ECD residues
(Figure 4.1), while 22 (31%) mutations affected TMD residues and 4 (6%) mutations affected
ICD residues (Table 4.1). An analysis of the location of FHH, NSHPT and ADHH mutations
identified in this study, revealed that the majority (> 50%) of mutations associated with these
hyper- and hypocalcaemic disorders were located in the ECD (Figure 4.4A), and a similar
analysis of the 200 different previously reported CaSR mutations (248) also revealed that > 50%
of the abnormalities associated with such disorders were located in the ECD (Figure 4.4A). The
phenotypic features of FHH, NSHPT and ADHH in patients with CaSR mutations were similar
to those patients without CaSR mutations (data not shown), thereby indicating that phenotypic
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features alone are unlikely to be useful predictors for the presence or absence of a CaSR
mutation.

Table 4.1 Details of 82 CaSR abnormalities/variants identified in patients with FHH (n =
45), NSHPT (n = 10), and ADHH (n = 27).

Disorder
FHH

Codon

Nucleotide

Base

Amino

Exon

Location

25
55
55
55
55
55
69
138
158
161
163
S.S.
172
172
174
185
208
208
218
220
220
220
221
227
227
236
250
296
461
461
544
553
573
612
645
701
748

c.73
c.164
c.164
c.164
c.164
c.164
c.205
c.413
c.473
c.482
c.488
c.493-1
c.515
c.515
c.521
c.554
c.624
c.623
c.652
c.658
c.659
c.659
c.662
c.681
c.681
c.706
c.748
c.887
c.1382
c.1382
c.1631
c.1657
c.1718
c.1836
c.1934
c.2102
c.2243

CGATG
CCGCT
CCGCT
CCGCT
CCGCT
CCGCT
CGCTG
ACGAT
GGGGA
TACTG
CCCCG
agaa
AGAGG
AGAGG
CTCCG
CGACA
TGGTG
TGGTC
TATCA
CGGTG
CGGCC
CGGCC
CCGCA
CGACA
CGACA
TGCGG
GAAAA
AGCAA
CTGCC
CTGCC
CGACA
GGGAG
TATTG
TTTTTGCCGA
CGTCC
CCCCT

ArgStop
ProLeuc
ProLeuc
ProLeuc
ProLeuc
ProLeuc
ArgCysd
ThrMet
GlyGlud
Tyr Cys
Pro Arg
-d, e
ArgGlyc
ArgGlyc
LeuArg
ArgGln
TrpCysd
TrpSer
Tyr Hisd
ArgTrp
ArgProc
ArgProc
ProGln
ArgGlnc
ArgGlnc
CysGlyd
GluLysg
SerAsn
LeuProc,
LeuProc,
ArgGlnd
GlyArg
TyrCysd
Phe d, h
AlaAspd
ArgProd
ProLeu

2
2
2
2
2
2
3
3
3
3
3
IVS2f
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
5
5
6
6
6
7
7
7
7

ECD
ECD
ECD
ECD
ECD
ECD
ECD
ECD
ECD
ECD
ECD
ECD
ECD
ECD
ECD
ECD
ECD
ECD
ECD
ECD
ECD
ECD
ECD
ECD
ECD
ECD
ECD
ECD
ECD
ECD
ECD
ECD
ECD
ECD
TMD
TMD
TMD

109
748
752
778
791
798
798
816
885

c.2243
c.2255
c.2332
c.2371
c.2392
c.2393
c.2446
c.2654

CCCCG
CGCTG
GGCCG
GCCCC
CCGAC
CCGCT
ATCAC
GCTGA

ProArg
ArgCysd
GlyArgd
AlaProd
ProThr
ProLeud
IleThrd
AlaAspd

7
7
7
7
7
7
7
7

TMD
TMD
TMD
TMD
TMD
TMD
TMD
ICD

25
60
164
190
212
220
392
680
Codon

c.73
c.179
c.490
c.570
c.635
c.658
c.1174
c.2038
Nucleotide

CGATG
TGTTT
CAGTA
GATGA
ATTAG
CGGTG
CGATG
CGCTG
Base

ArgStop
CysPhe j
GlnStop i
Asp d, i, k
IleSer i
ArgTrp i
ArgStop
ArgCys j
Amino

2
2
3
4
4
4
4
7
Exon

ECD
ECD
ECD
ECD
ECD
ECD
ECD
TMD
Location

768
886

c.2303
c.2656

GGCGT
CGGTG

GlyVald,
ArgTrp i

7
7

TMD
ICD

104
116
127
131
131
151
173
221
228
241
250
419
604
610
767
767
800
824
828
831
831
832
837
843
845
883
910

c.310
c.346
c.380
c.391
c.392
c.452
c.517
c.662
c.682
c.721
c.748
c.1256
c.1810
c.1829
c.2299
c.2299
c.2399
c.2470
c.2483
c.2492
c.2492
c.2495
c.2511
c.2528
c.2534
c.2648
c.2730

GTTAT
GCTCC
GAGGG
TGCAG
TGCTA
ACGAT
CTCTT
CCGCT
GAGAA
GAAAA
GAAAA
AATAG
GAGAA
GAGGG
GAGCA
GAGAA
AACAC
GCCCC
ACCAA
AAGAC
AAGAC
TTTTC
GAGGA
GCAGA
AGCAA
GTGAT
CCTC-T

ValIled
AlaPro
GluGly
CysSerd
CysTyr
ThrMet
LeuPhed
ProLeu
GluLys
GluLys
GluLysg
AsnSer
GluLys
GluGly
GluGlnd
GluLys
AsnThrd
AlaProd
ThrAsn
LysThrc,
LysThrc,
PheSer
GluAspd
AlaGlu
SerAsn
ValMetd
Pro d, l

3
3
3
3
3
3
4
4
4
4
4
4
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7

ECD
ECD
ECD
ECD
ECD
ECD
ECD
ECD
ECD
ECD
ECD
ECD
ECD
ECD
TMD
TMD
TMD
TMD
TMD
TMD
TMD
TMD
TMD
TMD
TMD
ICD
ICD

NSHPT

Disorder
NSHPT

ADHH
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a

Nucleotide is numbered in relation to CaSR cDNA reference sequence (GenBank

accession number NM_000388) whereby nucleotide +1 corresponds to the A of the ATG –
translation initiation codon;
ICD, intracellular domain;

b
c

ECD, extracellular domain; TMD, transmembrane domain;
recurrent mutation;

d

novel mutation; e predicted to abolish

acceptor splice site (S.S.) and lead to either a 2 amino acid missense peptide followed by a
stop at codon 167, or an in-frame deletion of exon 4;

f

IVS, intervening sequence;

g

demonstrated to be a functionally neutral polymorphism (Fig. 3); h deletion/frameshift, 13
missense peptide followed by a stop at codon 626; i homozygous mutation;

j

compound

heterozygous mutation; k deletion/frameshift, 65 amino acid missense peptide followed by a
stop at codon 256; l deletion/frameshift, 27 amino acid missense peptide followed by a stop
at codon 938.
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Figure 4.2 Detection of a CaSR mutation in exon 2 in a family with neonatal severe
primary hyperparathyroidism (NSHPT).
A, DNA sequence analysis of the affected individual (II.1) revealed a C to T transition at
codon 25, thus altering the wild-type (WT) sequence CGA, encoding an arginine to the
mutant (m) sequence TGA, which is a termination (Stop) codon. This nonsense mutation

112
also resulted in the loss of the wild-type Cac8I restriction enzyme (GCN/NGC), and this
facilitated the confirmation of the mutation. B, PCR amplification and Cac8I digestion
would result in two products of 186 and 114 bp from the wild-type (WT) sequence, but a
300 bp band would be expected from the mutant (m) sequence as is illustrated in the
restriction map. This Arg25stop mutation was demonstrated to be homozygous in the
siblings affected with NSHPT (individuals II.1 and II.2), while their consanguineous
parents were both heterozygous for this mutation. The absence of this Arg25stop mutation
in 110 alleles from 55 unrelated normal individuals (N1-N3 shown) indicates that it is not a
common DNA sequence polymorphism. Individuals are represented as: male (squares),
female (circles), unaffected (open circle), affected with NSHPT (filled symbols), affected
with hypercalcaemia (half filled square).
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Figure 4.3 Functional expression of wild-type and variant codon 173, 221 and 250 CaSRs in
transfected HEK293 cells.
The [Ca2+]o-evoked increases in [Ca2+]i were measured in HEK293 cells that had been
transiently transfected with wild-type (WT) or variant codon 173, 221 and 250 CaSRs
(Wild-type sequences - Leu173 (L173), Pro221 (P221) and Glu250 (E250); variant
sequences – Phe173 (F173), Pro173 (P173), Leu221(L221), Gln221 (Q221) and Lys250
(K250). A, The mutant (m) CaSRs, F173, which occurred in an ADHH kindred (Table 1),
and P173, which occurred in an FHH kindred, resulted in a leftward and rightward shift of
the concentration-response curve, respectively, when compared to that of the wild-type
CaSR. Thus, the EC50 values of the mutant CaSRs F173 and P173 were significantly (p <
0.001) lower and higher, respectively when compared to that of the wild-type CaSR. These
findings indicate that the mutant CaSRs F173 and P173 result in a gain-of-function and a
loss-of-function of the CaSR, respectively, and this is consistent with their associated
phenotypes of ADHH and FHH in man. B, The mutant CaSRs, L221, which occurred in an
ADHH kindred (Table 1), and Q221, which occurred in an FHH kindred, resulted in a
leftward and rightward shift of the concentration-response curve, respectively, when
compared to that of the wild-type CaSR. Thus, the EC50 values of the mutant CaSRs L221
and Q221 were significantly (p < 0.01) lower and higher, respectively when compared to
that of the wild-type CaSR. These findings indicate that the mutant CaSRs L221 and Q221
result in a gain-of-function and a loss-of-function of the CaSR, respectively, and this is
consistent with their associated phenotypes of ADHH and FHH in man; C, The variant
CaSR, K250, which occurred in both ADHH and FHH kindreds, did not significantly alter
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the EC50 or concentration-response curve when compared to that of the wild-type CaSR.
These findings indicate that K250 is a functionally neutral polymorphism (poly) and not a
pathogenic mutation.
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Figure 4.4 Analysis of CaSR mutations by disease association, location and type of
mutation.
A, frequencies of ECD, TMD and ICD CaSR mutations in FHH, NSHPT and ADHH
patients observed in this study (n = 71), and in an analysis of 200 previously reported CaSR
mutations. The majority (>50%) of mutations associated with FHH, NSHPT and ADHH in
this study and amongst the previously reported CaSR mutations were located in the ECD.
Significant differences between this study and the previously reported mutations (248)
were not observed. In addition, no significant differences in the location of mutations were
observed between FHH, NSHPT and ADHH. B, frequencies of missense, truncating and
deletion/insertion CaSR mutations in FHH, NSHPT and ADHH patients observed in this
study (n = 71) and in an analysis of 200 previously reported CaSR mutations. Greater than
90% of mutations associated with FHH and ADHH were missense substitutions. However,
NSHPT was associated with a significantly (p < 0.05) higher proportion of nonsense and
frameshift mutations when compared to either FHH or ADHH. No significant difference in
the frequency of mutation types was observed between this study and all the previously
reported mutations (248).

4.2.2 NSHPT is associated with a high proportion of truncating CaSR mutations

Four of the ten NSHPT associated CaSR mutations (40%) were nonsense or frameshift
mutations that were predicted to lead to a truncated CaSR (Table 4.1, Figure 4.2). This high
proportion of truncating mutations in NSHPT differed significantly (p = 0.01) from that of FHH,
of which three (6%) mutations were predicted to lead to a truncated CaSR (Table 1, Figure 4.4B).
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An analysis of previously reported NSHPT mutations also revealed a high proportion of
truncating mutations, with >40% being nonsense or frameshift mutations (Figure 4.4B), and this
differed significantly (p < 0.01) from the previously reported FHH mutations, of which 20%
were predicted to be truncating (Figure 4.4B). All of the 10 mutations found in NSHPT patients
occurred in the homozygous (n=8) or compound heterozygous (n=2) state. The truncating
mutation located closest to the CaSR N-terminus in this study was a homozygous Arg25Stop
mutation that was present in two neonatal siblings who both presented with NSHPT and serum
calcium concentrations > 4.0 mmol/l (Figure 4.2). Restriction endonuclease analysis revealed
that the consanguineous parents were both heterozygous for the Arg25Stop mutation (Figure 4.2).
The homozygous Arg25Stop mutation was predicted to lead to a peptide that was truncated six
amino acids after the signal peptide cleavage site, and hence was not suitable for in vitro
expression and functional characterisation.
4.2.3 Functional characterisation of CaSR variants at codons 173, 221 and 250 detected in FHH
and ADHH patients
Our DNA sequence analysis of the CASR revealed that variants that would be consistent
with missense mutations at codons 173, 221 and 250 were associated with both FHH and ADHH
(Table 4.1, Figure 4.1). Thus, at codon 173, we identified a Leu173Phe variant associated with
ADHH, while, a Leu173Pro variant has been previously reported in association with FHH (249);
at codon 221, we identified Pro221Gln and Pro221Leu variants that were associated with FHH
and ADHH, respectively; at codon 250 we identified a Glu250Lys variant in a FHH proband and
an ADHH proband, and therefore the pathogenic nature of this mutation was uncertain. To
investigate the functional effects of these variants at codons 173, 221 and 250 we transiently
transfected wild-type and variant pEGFP-CaSRs into HEK293 cells and assessed the [Ca2+]i
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responses to changes in [Ca2+]o. Expression of both monomeric and dimeric forms of the wildtype and variant EGFP-CaSRs was confirmed by Western blot analysis (data not shown). An
analysis of the response curves of the wild-type and variant CaSRs (Figure 4.3) revealed that the
Leu173Phe and Pro221Leu variant CaSRs lead to a leftward shift in the concentration–response
curves and significantly (p < 0.01) reduced EC50 values (Leu173Phe versus wild-type = 1.8 ±
0.07 mM versus 2.49 ± 0.06 mM; and Pro221Leu versus wild-type = 0.87 ± 0.15 mM versus
2.74 ± 0.29 mM); and the Leu173Pro and Pro221Gln mutant CaSRs lead to a rightward shift of
the concentration–response curve and significantly (p < 0.01) raised EC50 values (Leu173Pro
versus wild-type = 11.0 ± 0.92 mM versus 2.49 ± 0.06 mM; and Pro221Leu versus wild-type =
4.3 ± 0.18 mM versus 2.74 ± 0.29 mM). In contrast, an analysis of the concentration-response
curve and EC50 of the Glu250Lys CaSR variant (Figure 4.3) revealed this not to significantly
differ (p = NS) from that of the wild-type receptor (Glu250Lys versus wild-type = 2.56 ± 0.02
mM versus 2.49 ± 0.06 mM). Thus, the Glu250Lys missense substitution, which involved
substitution of the negatively charged Glu residue for a positively charged Lys residue, did not
alter CaSR function and therefore likely represents a functionally neutral polymorphism.
However, the Leu173Phe and Pro221Leu mutations, which involved substitutions of a non-polar
residue for another non-polar residue, led to a gain of CaSR function; while the Leu173Pro,
which involved substitution of a non-polar residue for another non-polar residue, and Pro221Gln,
which involved substitution of the non-polar Pro for a polar Gln, mutations were associated with
a loss of CaSR function. This represents a very unusual situation whereby mutations of a residue
can result in two opposing functional effects on CaSR responses, such that it appears that the
residues at codons 173 and 221 when mutated act as “toggles” which either activate or inactivate
the CaSR.
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4.2.4 Three dimensional modelling of VFTD mutations

The two “toggle” residues at Leu173 and Pro221, which are associated with FHH and
ADHH, are located in the VFTD (Figure 4.1). Moreover, another 30 CaSR missense mutations
identified by our study (Table 4.1) and 93 mutations identified by previous studies (248), i.e. 47%
and 47% of all the CaSR mutations, are also located in the VFTD (Figure 4.1). We therefore
performed homology modelling of the VFTD to determine its three dimensional structure and the
functional relationships between the VFTD 5 calcium binding sitess and the 34 mutations that
included the Leu173Phe, Leu173Pro, Pro221Gln and Pro221Leu mutations (Figure 4.5). This
revealed that: nine of the mutated residues represented by 12 mutations (Thr151Met, Arg172Gly
Leu173Phe,

Leu173Pro,

Leu174Arg,

Arg185Gln,

Tyr218His

Arg220Pro,

Arg220Trp,

Pro221Leu, Pro221Gln and Ser296Asn) were located in the cleft between lobes 1 and 2 that
contained calcium binding sites-1 (Figure 4.5A); two mutations (Ile212Ser and Glu241Lys) were
adjacent to site 2 (Figure 4.5B); and six residues represented by eight mutations (Arg172Gly,
Trp208Cys, Trp208Ser, Pro221Leu, Pro221Gln, Arg227Gln, Glu228Lys and Cys236Gly) were
located within or near to the alpha helix that contained site 3 (Figure 4.5C), with three of these
(Arg172Gly, Pro221Leu, Pro221Gln) also being in close proximity to site 1. None of the VFTD
mutations in our study were present at either calcium binding sites-4 or -5, whereas, a Pro339Thr
CaSR

mutation,

that

we

have

previously

reported

in

association

with

primary

hyperparathyroidism in adulthood (245), was shown by our analysis to be located in a short
flexible loop that is linked to an alpha helix containing calcium binding sites-4 Ca2+ binding
residues (Figure 4.5D). Thus, 18 of the 34 CaSR missense mutations (i.e. > 50%) characterised
by our study were located near one or more s, with the majority (> 50%) of Calcium binding
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sites mutations located at site 1 (Table 4.2). A further analysis of the 93 previously reported
missense mutations (248) located within the CaSR VFTD revealed that 42 (27 from FHH
patients, 5 from NSHPT patients, and 10 from ADHH patients) mutations (i.e. 45%) were
predicted to be located at or near one or more of the 5 VFTD calcium binding sitescalcium
binding sites (Table 4.2) with >50% located at calcium binding sites -1; these findings are in
agreement with our observations of the 71 CaSR mutations (Table 4.1 and 4.2). In addition, FHH
calcium binding sitesCalcium binding sites mutations most commonly involved the substitution
of an Arginine residue, indicating a key role for this residue in Ca2+ binding, whereas, the
majority of ADHH mutations clustering around calcium binding sitesCalcium binding sites
involved the loss of a glutamate residue, thereby highlighting a role for glutamate in Ca2+
binding (Figure 4.1). A detailed homology modelling analysis of the locations of residues 173
and 221 at the VTFD cleft, revealed that both of these amino acid residues are situated at the
entrance to calcium binding sitesCalcium binding sites-1 at the cleft region (Figure 4.5F), and
hence mutations of these residues would be predicted to influence the entry and binding of Ca2+
into the VTFD cleft binding site. This location is consistent with the “toggle” role that these
residues were found to have in the functional expression studies (Figure 4.3) and in their clinical
phenotypic expression in being associated with both FHH and ADHH (Table 4.1).
4.3 Discussion
We report, 71 different CaSR mutations that have been identified in 80 patients with
FHH, NSHPT and ADHH (Table 4.1, Figure 4.1). The majority (>50%) of these CaSR mutations
are missense substitutions located within the ECD (Figure 4.1 and Figure 4.4). These and other
previously reported disease-causing mutations have highlighted the importance of the ECD in
CaSR function. The ECD has key roles in co-translational processing of the CaSR (240),
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receptor dimerisation (241), binding different ligands that include Ca2+ and amino acids
(95,234,242), and transmitting activation signals to the TMD and ICD (243). The CaSR ECD has
a bilobed VFTD that is predicted to contain 5 calcium binding sitescalcium binding sites, which
are located at flexible loops or helical regions close to the protein surface (172). The presence of
these multiple binding regions explains the ability of the CaSR to bind Ca2+ in a cooperative
fashion. Homology modelling of the 34 missense mutations (Table 4.1, Figure 4.1) characterised
by our study and which affect VFTD residues revealed that >50% of these mutations are situated
within 10 Å of one or more calcium binding sitess (Figure 4.5). Thus, our study of diseasecausing mutations emphasises the key role of the extracellular VFTD in binding Ca2+. The
VFTD calcium binding sitess have been previously demonstrated to exhibit differing affinities
for Ca2+ (172). In particular, VFTD calcium binding sites-2 to -5, when compared to calcium
binding sites-1 exhibit a lower affinity for Ca2+, and are considered to be involved only in
binding Ca2+ in hypercalcaemic states (172). Given the auxiliary role of sites outside the VFTD
cleft, in Ca2+ binding, mutations at these calcium binding sites would be expected to induce a
milder alteration in CaSR function than calcium binding sites-1 mutations. Homology modelling
in this study revealed that a Pro339Thr mutation (245) was situated in the proximity of Ca2+
binding site 4 that is located in lobe 1. Consistent with binding sites outside the VFTD cleft
having a minor role in Ca2+ binding, the Pro339Thr mutation has been reported to lead to a mild
loss of function and was associated with normocalcaemia in the heterozygous state (245).
Over 70% of these calcium binding sites CaSR mutations are associated with FHH or
NSHPT (Figure 4.1), and it therefore seems likely that the residues, which are within the VFTD
either participate in the binding of Ca2+, or indirectly enhance this process. Interestingly, the
most commonly mutated residue within the VFTD was found to be arginine, which is able to
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form multiple hydrogen bonds to carbonyl groups of the peptide backbone and be involved in
maintaining tertiary protein structure (250). Mutated arginine residues were located at calcium
binding sites-1 and -3, and of the 23 arginine residues, which comprise 4% of the VFTD residues,
5 (i.e. 22%) were involved in mutations that resulted in FHH or NSHPT, but not ADHH. This
observation was confirmed by our analysis of the previously reported 200 different CaSR
mutations (248) which revealed the occurrence of mutations at 30% of the VFTD arginine
residues that were associated with FHH or NSHPT, and never ADHH. Hence it is possible that
the arginine residues located at calcium binding sites-1 and -3 (Figure 4.5) promote CaSR
activation by providing a favourable VFTD conformation for Ca2+ binding. In contrast, 2 out of 5
(i.e. 40%) of the ADHH associated CaSR mutations in this study and 6 out of 10 (i.e. 60%) of
the previously reported ADHH mutations located near to a calcium binding sites involved the
substitution of a glutamate residue (Table 4.1). The mechanism of CaSR activation associated
with the loss of a glutamate binding site residue may involve a reduction in the overall negative
charge of that binding site, leading to a reduced repulsion between binding site residues that
facilitates Ca2+ binding (172).
Our identification and functional characterisation of mutations involving codons 173 and
221, which are located at the entrance to the VFTD cleft, and lead to either loss- or gain of CaSR
function, help to illustrate further the important role of this region. Indeed, the VFTD cleft is the
principal region for the binding of orthosteric ligands such as Ca2+ and amino acids, and it has
been previously demonstrated that this site has the greatest binding affinity for Ca2+ and
facilitates the cooperative binding of Ca2+ to the other four calcium binding sitess (172). Such a
role for the VFTD cleft is consistent with many of the VFTD mutations being located near to this
critical region and the observation that mutations of Glu297, which is located in the calcium

122
binding sites-1 and VFTD cleft, are also associated with opposing effects on CaSR function (96).
Our analysis of the mutations at Leu173 predicted that the introduction of a mutant
phenylalanine residue would enhance CaSR activation by increasing the area of interaction with
Ca2+ at the VTFD cleft. The importance of phenylalanine for Ca2+ binding by the CaSR has
previously been demonstrated by studies of Phe270, which is required to complete the
coordination sphere for Ca2+ at calcium binding sites-1 (96). The introduction of the mutant
Pro173 residue was predicted to disrupt an alpha helix at calcium binding sites-1 and thereby
result in a loss of CaSR function. This alpha helix is adjacent to Ser170, which is directly
involved in Ca2+ coordination, and loss of this secondary structure at calcium binding sites-1
may reduce the proximity of Ser170 to Ca2+. The predicted derangement of the architecture of
calcium binding sites-1, in the mutant Pro173 receptor, is in keeping with the severe loss of
function observed in our in vitro studies of this mutant receptor (Figure 4.3). Our analysis
mutations at Pro221 predicted that the activating Leu221 mutation would enhance Ca2+ entry into
calcium binding sites-1 due to the substitution of the rigid side chain of the wild-type proline
residue at the entrance to the VFTD cleft with the more flexible leucine side chain. In contrast,
the side chain of the mutant glutamine residue, associated with the Gln221 mutation, would be
predicted to extend across the entrance of calcium binding sites-1, thereby impairing ligand entry
and leading to a loss of CaSR function.
The value of undertaking such functional characterisation studies is demonstrated by our
analysis of the Glu250Lys variant. The Glu250Lys variant has previously been reported by
several studies to be a causative mutation in patients with FHH and PHPT (251,252), and is also
listed in the calcium sensing receptor database (CASRdb) (248) as a recurrent mutation. The
finding of this Glu250Lys variant in both FHH and ADHH patients in our study (Table 4.1),
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suggested that this variant, which involves an evolutionary conserved Glu250 residue, may not
be a mutation but instead a functionally neutral polymorphism. We therefore undertook a
functional characterisation of the wilde-type CaSR and Glu250Lys CaSRs which demonstrated
that they each had an EC50 that was similar (Figure 4.3), thereby indicating that Glu250Lys was
not a CaSR mutation but instead a polymorphism. Thus, our finding emphasises the value of
undertaking functional characterisation of CaSR variants, which is not generally performed
because of time and cost constraints. Instead variants are considered to be pathogenic mutations
on the basis of co-segregation with the disease, absence in a panel of normal individuals, and
alteration of an evolutionary conserved residue. Our findings indicate that this approach should
be used with caution for recurrent variants and especially if they are observed in FHH and
ADHH patients. Indeed, such variants should be evaluated by a functional assay as they may
represent functionally neutral polymorphisms.
The NSHPT mutations described in this study included an Arg25Stop mutation (Figure
4.2) which represents the most N-terminal truncating mutation described to date. The mutant
25Stop allele would be predicted to produce a transcript that would undergo nonsense mediated
decay (162), or result in the expression of a non-functional peptide that comprises the 19 amino
acid signal peptide and an additional 6 amino acids. However, the Arg25Stop CaSR mutation
was associated with severe hypercalcaemia in the homozygous state, while the heterozygous
affected parents had differing phenotypes, with the mother being normocalcaemic and the father
having mild hypercalcaemia. This finding of hypercalcaemia in the heterozygous father suggests
that the effects of the 25Stop mutant CaSR maybe due to haploinsufficiency rather than a
dominant-negative action on receptor dimerisation as previously reported (162,246,253). Indeed,
such an effect due to CaSR haploinsufficiency would be consistent with the observations in Casr
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+/-

mice, which have an ~50% reduction in CaSR protein expression, and exhibit mild (i.e. ~ 10%)

increases in serum calcium concentrations (227). Thus, it seems likely in the Casr +/- mice and in
humans with heterozygous null CaSR mutations that the hypercalcaemia results from a reduction
in the expression of the wild-type receptor from the normal allele, consistent with a gene dosage
effect or haploinsufficiency. The disparity in the phenotypes of individuals with the same CaSR
mutation as observed in the hypercalcaemic father and normocalcaemic mother (Figure 4.2),
which has been previously reported (254,255), may be due to the differences in genetic
background and gene modifiers.
Mutations of the CaSR gene were not identified in >70% of the probands, and the
phenotypes of these patients without CaSR mutations were similar to those with CaSR mutations.
Therefore it seems likely that other mutations involving the non-coding regions of the CaSR, or
mutations involving other mediators of calcium regulation may underlie the hyper- and
hypocalcaemic phenotypes of these patients. Indeed, the occurrence of such genetic
heterogeneity is supported by the identification of two other FHH loci located on chromosome
19p and 19q13 (256-258).
In conclusion, our study reports 71 CaSR mutations identified in patients with FHH,
NSHPT or ADHH, and demonstrates the value of functional characterisation studies by showing
that the Glu250Lys variant, which had been previously considered to be a recurrent mutation, is
instead a functionally neutral polymorphism. Our study also highlights that NSHPT is associated
with a high proportion of truncating CaSR mutations, such as Arg25Stop, which is one of the
most N-terminal truncating mutations described to date, and that haploinsufficiency of the CaSR
may have a role in the etiology of NSHPT. Furthermore, our results reveal that missense
mutations of the CaSR ECD cluster at multiple calcium binding sites, and particularly in the
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vicinity of the cleft region formed by the two lobes of the VFTD. Indeed, mutations of residues
173 and 221, located at the entrance to the VFTD cleft, were demonstrated to have opposing
effects on receptor function and likely influence receptor function through their effects on the
entry and binding of Ca2+ in the cleft region. Thus, our findings, which help to further elucidate
the structure-function relationships of the CaSR extracellular domain, provide support for the
VFTD cleft in having a major role in the binding of extracellular Ca2+ and regulation of CaSR
function.
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CHAPTER 5. DISEASE-ASSOCIATED “TOGGLE” MUTATIONS ON THE CALCIUMSENSING RECEPTOR CHANGE THE CA2+ AND L-PHE REGULATED FUNCTIONAL
COOPERATIVITY
5.1 Introduction
The human calcium (Ca2+)-sensing receptor (CaSR) is a seven transmembrane G proteincoupled receptor (GPCR) that is expressed at the highest levels in the parathyroid glands and
kidneys (38). The principal role of CaSR is to sense alterations of the extracellular calcium
concentration ([Ca2+]o) and to maintain [Ca2+]o homeostasis by regulating parathyroid hormone
(PTH) secretion as well as renal Ca2+ reabsorption. Like other members of family C in the
GPCR superfamily, including the metabotropic glutamate receptors, the V2R vomeronasal
pheromone receptors, the TAS1R taste receptors, and the gamma-amino butyric acid (GABA-B)
receptors (241), CaSR possesses a large extracellular domain (ECD) consisting of more than 600
amino acids (95). Ca2+, as the principal physiological agonist for CaSR, is thought to bind to the
ECD resulting in activation of phospholipase C (PLC), with an attendant accumulation of
inositol 1,4,5-triphosphate (IP3) followed by a resultant increase in the cytosolic calcium ([Ca2+]i)
concentration (101).
The downstream signaling pathways triggered by CaSR generally involve the interactions
of intracellular loops 2 and 3 of the receptor with heterotrimeric G-proteins, including Gq/11, Gi/o
and G12/13 (259). The Gq/11 proteins are linked to receptor-mediated activation of phospholipaseC which plays critical roles in Ca2+o-mediated PTH secretion. The Gi/o proteins inhibit adenylyl
cyclase, while the G12/13 proteins have been shown to activate monomeric G-proteins, for
instance, Rho (259). Studies have shown that CaSR stimulates phosphorylation and concomitant
activation of the extracellular signal-regulated kinases (ERK1/2) through both a pertussis toxin-
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sensitive pathway involving Gi protein as well as a pertussis toxin-insensitive pathway utilizing
Gq/11. ERK1/2 are known to modulate many cellular processes, including cell proliferation,
differentiation, apoptosis, oncogenic transformation as well as enzymatic activity (260,261).

In biological systems, free L-amino acids are essential molecules since they not only serve
as the building blocks of protein but are also the metabolic precursors of crucial substances that
serve as ligands for receptors (165). Evidence for the presence of amino acid sensing
mechanisms in various studies, e.g.,regulating insulin secretion from pancreatic beta cells,
hepatic autophagy, etc., suggest the widespread existence of amino acid sensors, although the
identities of these amino acid sensors are in many cases unknown. These findings highlight
amino acid-dependent control of cellular signal transduction pathways. Fluctuation of the plasma
levels of amino acids can, therefore, regulate the rate of hormone synthesis and secretion as well
as Ca2+ metabolism, among other processes (165). CaSR is present throughout the
gastrointestinal tract (41,166), including in gastrin-secreting antral G cells and cholecystokininsecreting l cells, both of which are known to be activated by both [Ca2+]o and aromatic amino
acids (166). L-amino acids, especially aromatic amino acids, are known to enhance the
sensitivity of CaSR to [Ca2+]o, which could be one potential explanation for how dietary protein
modulates [Ca2+]o homeostasis in normal individuals as well as in patients with chronic renal
failure (165,167).

Mutations of the CaSR can perturb intracellular signaling events (e.g., intracellular
calcium response) and disrupt the regulation of PTH secretion from the parathyroid chief cells
and of Ca2+ reabsorption in the renal tubule. Mutations that inactivate (i.e., cause loss-of-function)
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CaSR result in familial hypocalciuric hypercalcemia (FHH) and neonatal severe primary
hyperparathyroidism (NSHPT) (161,240) by producing a rightward shift in the CaSR’s
concentration–response curve, with a significantly higher EC50 in in vitro studies. On the other
hand, activating mutations of the CaSR lead to autosomal dominant hypocalcemia with
hypercalciuria (ADHH) (245), and produce a leftward shift of the concentration–response curve
and lower EC50 (163). These mutations, including the four studied here and described below that
involve the two “toggle” residues, L173 and P221, where mutations of the same residue can
either activate or inactivate the CaSR, serve as a rich source of structure-function information
and have provided important insights into how the receptor functions.
Molecular dynamics (MD) simulation provides an approach complementary to the
experiments in live cells for understanding biomolecular structure, dynamics and function (220)
and computational modeling of the GPCR 3D structures have become increasingly indispensable
tools for studying these receptors as well as discovery of the drugs which effect their behavior.
Using our previously reported computational algorithm, we have predicted five potential Ca2+binding sites in the CaSR ECD based on the charge distribution on the surface of the Venus
flytrap (VFT) domain and on the known structural properties of Ca2+-binding sites (68,172). The
CaSR ECD was modeled from the known structure of the ECD of metabotropic glutamate
receptor type 1 (mGluR1) (175),Ca2+-binding site 1 in the CaSR ECD is located in the hinge
region between lobes 1 and 2, and is proposed to be the principle site for Ca2+-binding during
receptor activation. Moreover, the putative L-Phe binding site is also predicted to be located
nearby in the hinge region (221). Interestingly, among 34 identified ECD missense mutations in
patients with FHH, NSHPT and ADHH, 18 are located within 10 Å of one or more of the
predicted Ca2+-binding sites, particularly site 1(208). Four disease-related mutations involving
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residues 173 and 221, which are located at the entrance to the Ca2+-binding site in the VFT cleft,
have been identified. Two of these are activating mutations (L173F, P221L) and two are
inactivating mutations (L173P, P221Q). These four so-called “toggle” mutations, defined as
mutations involving the same residue that lead to opposite effects on receptor function, are near
Ca2+-binding site 1 in our predicted ECD model structure, thereby highlighting the importance of
these residues for entry and binding of Ca2+ by the CaSR ECD. (161).
In the present studies, we extended Dr.Hannan’s studies to investigate whether residues
L173 and P221 are important for the CaSR’s positive homotropic cooperativity and for the
coupling of the receptor to several intracellular signaling cascades. We also utilized these four
mutations to further probe the structure-function relationships of the CaSR as they relate to the
activation of the CaSR by Ca2+ and L-Phe and how L-Phe interacts with Ca2+ to modulate
intracellular signaling. These results provide important insights into how Ca2+ and L-Phe interact
at their respective binding sites in the cleft of the VFT.
5.2 Results
5.2.1 The disease-related mutations show altered [Ca2+]i oscillation patterns compared with WT
CaSR.
The two residues involved in the four disease-associated mutations (L173, P221) are
located in the hinge region near predicted calcium-binding site 1, which is between lobes 1 and 2
as shown in Figure 4.1a. The immunostaining results suggest that all of these mutant CaSRs can
be expressed at the cell membrane (Figure 5.1b). We investigated the impact of these four
disease-associated mutations on [Ca2+]o-induced changes in [Ca2+]i to examine their effects on
the pattern of [Ca2+]i oscillations, apparent affinity and positive homotropic cooperativity of the
CaSR (Figure 5.1c). Three parameters were employed to analyze the [Ca2+]i oscillation patterns:
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the starting point, which refers to the [Ca2+]o at which a given cell starts to show at least three
continuous, sequential peaks; the ending point, which considers the [Ca2+]o at which the [Ca2+]i
reaches to a plateau, and the frequency, which is defined as the number of peaks of [Ca2+]i per
minute. A stepwise increase in [Ca2+]o induced oscillations in [Ca2+]i in some HEK293 cells
transfected with WT CaSR (Figure 5.2, WT). Frequency distribution showed that about 53% of
the cells showing oscillatory responses started to show [Ca2+]i oscillations at 2.5 mM [Ca2+]o
(Figure 5.3a). The frequency of oscillations at 2.5 mM [Ca2+]o in these cells exhibited a normal
distribution with an average frequency in the range of 1.0~1.5 peaks/min (Figure 5.3b). About 50%
of the oscillatory cells reached a [Ca2+]i plateau at 2.5 mM [Ca2+]o (Figure 5.3c). The gain-offunction mutations have an impact on the responsiveness of the cells to changes of [Ca2+]o. This
behavior was reflected in the following ways: firstly, the majority of the cells, 54% for L173F
and 40% for P221L, started to oscillate at lower levels of [Ca2+]o, 1.5 mM and 2.0 mM,
respectively, than observed with the WT CaSR. Secondly, the average frequencies at 2.5 mM
[Ca2+]o increased to 1.7 ± 0.1 peaks/min (p<0.05) and 1.6 ± 0.1 peaks/min, respectively (Table
4.1). The majority of the cells transfected with the gain-of-function mutations had oscillations
ending points at lower [Ca2+]o level (≤ 3.0 mM) than for WT CaSR. Conversely, the loss-offunction mutations had opposite effects on the respective oscillation patterns and apparent
affinities. The majority of cells transfected with the mutant containing P221Q did not oscillate
until [Ca2+]o reached 4.0 mM, and the threshold for [Ca2+]i oscillations in the cells transfected
with L173P was even higher at 15.0 mM. It was difficult to compare the [Ca2+]i oscillation
frequencies of these two mutants at any given level of [Ca2+]o, because they responded to
changes in [Ca2+]o over a substantially different range. Therefore, the frequencies were measured
at the individual EC50s of their [Ca2+]o- concentration response curves. Notably, these two

131
mutations also disrupted the cooperativity of the receptor as reflected by the decreased Hill
number (P221Q) or an alteration of the monophasic [Ca2+]o-induced [Ca2+]i concentration
response curve to a biphasic one (L173P) (Table 4.1).

Figure 5.1 The disease-related mutations are located in the hinge region near Ca2+-binding
site 1.
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(a), The model structure of the CaSR ECD, which was based on the mGluR1 crystal
structure (PDB entry: 1ISR) was generated using MODELER 9v4 and Swiss-Model. The
global view of the ECD is shown in the left panel. Spheres highlighted in red: Ca2+; residues
involved in predicted Ca2+-binding sites: purple. L-phenylalanine (in yellow) was
positioned at the hinge region between the two lobes by Autodock vina. Right panel: A
zoomed in view of the site 1 Ca2+-binding pocket. Labels highlighted in black represent
residues involved in the Ca2+-binding site 1; residues with disease-related mutations are
highlighted in purple. ( b). Surface expression of CaSR and its four disease related toggle
mutants. Green: anti-flag staining of the surface expressed CaSR. (c). Illustrated are
intracellular responses induced by Ca2+-and L-Phe, and the principle underlying the IP1
accumulation assay. The addition of Li+ impeded the degradation of IP1.
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Figure 5.2 Functional studies of disease-related CaSR mutations in HEK293 cells.
Representative oscillation pattern from a single cell. HEK-293 cells transiently transfected
with CaSR or one of its mutants were loaded with Fura-2 AM for 15 min. [Ca2+]i was
assessed by monitoring emission at 510 nm with excitation alternately at 340 or 380 nm as
described in methods. Each experiment was carried out with or without 5 mM L-Phe began
in Ca2+-free Ringer’s buffer (10 mM HEPES, 140 mM NaCl, 5 mM KCl, and 1.0 mM
MgCl2, pH 7.4), which was followed by stepwise increases in [Ca2+]o until [Ca2+]i reached a
plateau (up to 30 mM [Ca2+]o).
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Figure 5.3 The frequency distribution of the starting points, frequencies and the ending
points extracted from the [Ca2+]i oscillation patterns in HEK293 cells transfected with
CaSR or its mutants.
(a). Frequency distribution of the starting points of [Ca2+]i oscillations in HEK-293 cells
transfected with WT CaSR, or the L173F, L173P, P221L or P221Q mutants, respectively,
in the presence or absence of L-Phe. [Ca2+]o was recorded at the point when single cells
started to oscillate. Around 30~60 cells were analyzed and further plotted as a bar chart.
(b). The frequencies of the individual cell oscillation patterns were investigated. For
experiments without L-Phe, the peaks per minute were recorded at the level of [Ca2+]o at
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which the majority of the cells (>50%) started oscillating. Specifically, for the gain-offunction mutants, the peaks per minute were recorded at 2.5 mM [Ca2+]o ; while for loss-offunction mutants, the frequency was analyzed at their individual EC50s calculated from the
concentration response curves for [Ca2+]o. For experiments with 5.0 mM L-Phe, the
frequency was analyzed at the same EC50s for [Ca2+]o that were used in the absence of LPhe. Empty bar: in the absence of L-Phe; black bar: in the presence of 5 mM L-Phe. (c).
Frequency distributions of the ending points for [Ca2+]i oscillations.
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Table 5.1 Summary of [Ca2+]o-evoked [Ca2+]i concentration response data in HEK293 cells transiently transfected with WT
CaSR and its mutants.
The cells were exposed to stepwise increases in [Ca2+]o in the absence or presence of 5 mM L-Phe. For WT, L173F and P221L,
the frequency were recorded at 2.5 mM [Ca2+]o, while for L173P, the frequency was measured at 15.0 mM [Ca2+]o; and for
P221Q the frequency at 5.0 mM [Ca2+]o was chosen for comparison. The WT oscillation frequency measured at 3.0 mM [Ca2+]o
is indicated by the brackets. Curve-fitting was performed using the Hill equation. The data were obtained from three
experiments for each construct.# indicates significance with respect to wild type CaSR in the absence of L-Phe, p < 0.05;
indicates significance with respect to the corresponding mutants in the absence of L-Phe, p < 0.05.

Mutants

EC50[Ca2+]o

Hill coefficient

WT
L173F

w/o L-Phe with 5 mM L-Phe
3.0 ± 0.2
1.9 ± 0.3*
#
1.9± 0.2
1.6 ± 0.1

P221L

2.0 ± 0.1#

1.7 ± 0.1

3.2 ± 0.2

2.8 ± 0.2

L173P
(Phase 1)

3.8± 0.3

3.1 ± 0.2

3.3 ± 0.6

2.5 ± 0.2

L173P
(Phase 2)

13.0± 0.3

12.2 ± 0.2*

3.6 ± 0.4

5.8 ± 0.3

P221Q

5.2 ± 0.4#

3.7 ± 0.4*

2.4 ± 0.4*

4.1 ± 0.7*

Frequency

w/o L-Phe
3.7 ± 0.3
3.3 ± 0.1

with 5 mM L-Phe
5.0 ± 0.7*
3.7 ± 0.3

w/o L-Phe
1.3 ± 0.1
1.7 ± 0.1#

with 5 mM L-Phe
2.1± 0.1*
1.9 ± 0.1

1.6 ± 0.1#

1.8 ± 0.2

1.3 ± 0.1

1.8 ± 0.2*

1.5 ± 0.1

2.2± 0.1*

*
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5.2.2 L-Phe selectively potentiates the [Ca2+]o-evoked [Ca2+]i responses among the four mutants.
Since the potential L-Phe binding pocket, similar to that for Ca2+, is also located in the
cleft of the VFT (Figure 5.1), we next assessed the impact of L-Phe on [Ca2+]o–induced changes
in [Ca2+]i in order to study the interactions between the functional effects of [Ca2+]o and L-Phe
and the impact of the four mutations. For the majority of HEK293 cells transfected with the WT
CaSR, [Ca2+]i oscillations began at 2.0 mM [Ca2+]o and ended at 3.0 mM [Ca2+]o in the presence
of 5 mM L-Phe, and the oscillation frequency at 2.5 mM [Ca2+]o increased to 2.1 ± 0.1 peaks/min,
which was significantly higher than the 1.3 ± 0.1 peaks/min observed in the absence of L-Phe
(Figure 5.3). As shown in Figure 5.3, this allosteric activator exhibited different effects among
the four mutant receptors. For the gain-of-function mutations (L173F, P221L), L-Phe lowered
the threshold for the initiation and the termination of [Ca2+]i oscillations, but barely increased
their frequency at 2.5 mM [Ca2+]o (Figure 5.3 middle panel & Figure 5.3 right panel). In terms
of the loss-of-function mutants, cells transfected with mutant L173P started oscillating at 10.0
mM [Ca2+]o in the presence of 5.0 mM L-Phe and in most cells the [Ca2+]i oscillations stopped at
25.0 mM [Ca2+]o; in contrast, without L-Phe, 80% of the cells were still oscillating at 30 mM
[Ca2+]o. Regarding the effect of L-Phe on the frequency parameter, the level of [Ca2+]o at which
the majority of the cells (>50%) started to oscillate in the absence of L-Phe was chosen to assess
the influence of the amino acid. The L173P mutant had a frequency of 1.8 ± 0.2 peaks/min at
15.0 mM [Ca2+]o in the presence of L-Phe, which was significantly higher than the rate in the
absence of this allosteric agonist observed at the same level of [Ca2+]o (1.3 ± 0.1) (Figure 5.3b &
Table 5.1). For the P221Q mutant, the threshold for initiation of [Ca2+]i oscillations decreased
from 5.0 mM to 3.5 mM [Ca2+]o, while the ending point also decreased in the presence of L-Phe,
There was an increase in oscillation frequency for this mutant from 1.6 ± 0.1 peaks/min to 2.2 ±
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0.1 peaks/min with L-Phe at 5.0 mM [Ca2+]o.

To evaluate the impact of the mutations on the apparent affinities and the cooperativity
of the responses of the receptor to [Ca2+]o and L-Phe, the averaged [Ca2+]i response at each level
of [Ca2+]o were plotted to construct [Ca2+]o concentration-response curves for [Ca2+]I as shown in
Figure 5.4. L-Phe shifted the sigmoid curve to the left producing a lower EC50 for the [Ca2+]oevoked increase in [Ca2+]i in WT CaSR-transfected HEK293 cells as well as in cells transfected
with the P221Q mutant. Interestingly, although considered an inactivating mutation, L-Phe did
not left-shift the activation of the CaSR mutant L173P by [Ca2+]o to the same extent that it did
with the other loss-of-function mutant, P221Q, potentially because of the proximity of this
residue to the binding site for L-Phe, which might interfere with L-Phe binding. The disruption
of the positive homotropic cooperativity induced by [Ca2+]o as a result of the Leu to Pro change,
which was reflected as a biphasic concentration response curve, was also not corrected by the
addition of L-Phe (Table 4.1). Meanwhile, the addition of L-Phe barely further left-shifted the
concentration-response curves of the two gain-of-function CaSR mutants (p>0.05).
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Figure 5.4 L-Phe modulates the [Ca2+]o concentration response curves for [Ca2+]o in CaSRtransfected HEK293 cells.
The [Ca2+]i responses of HEK293 cells transiently overexpressing WT CaSR or diseaserelated mutations were measured using Fura-2AM during stepwise increases in [Ca2+]o
from 0.5 to 30 mM with or without L-Phe as above. The ratio of light emitted at 510 nm
upon alternate excitation with 340 or 380 nm was normalized to its maximum response.
And the [Ca2+]i responses at various [Ca2+]o were plotted and further fitted using the Hill
equation. Open circle: in the absence of L-Phe; Closed circles: in the presence of 5 mM LPhe.
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5.2.3 L-Phenylalanine potentiates [Ca2+]o-induced IP1 accumulation.
To determine whether the functional impact of the four mutations on [Ca2+]i extended to
other functional read-outs, we examined the effects of [Ca2+]o and L-Phe on the activation of
PLC as assessed by IP1 accumulation and, in the following section, on ERK activity. Activation
of the Gq/11 pathway by GPCRs activates phospholipase C (PLC), causing accumulation of
inositol phosphates (IPs) (101). The responses to [Ca2+]o in the absence and presence of L-Phe in
cells transiently transfected with WT CaSR or the four mutants were assessed by measuring the
accumulation of intracellular IP1 (Figure 5.5). The EC50 for the stimulation of IP1 accumulation
was 2.9 ± 0.3 mM for the WT CaSR, which agrees well with the EC50 calculated from the [Ca2+]i
responses (3.0 ± 0.2). The addition of 5 mM L-Phe significantly elevated the level of IP1
accumulation at 2.0 and 3.0 mM [Ca2+]o resulting in a left-shifted [Ca2+]o-IP1 concentration
response curve. In contrast, the two gain-of-function mutants, L173F and P221L, showed higher
levels of IP1 accumulation at 1.0, 2.0 and 3.0 mM [Ca2+]o compared with the WT CaSR, leading
to lower EC50s for the IP1 responses (1.3 ± 0.1 and 1.1 ± 0.1 respectively) (Table 4.2). On the
other hand, the loss-of-function mutations, L173P and P221Q, exhibited impaired [Ca2+]o–
stimulated IP1 accumulation as the EC50s for the [Ca2+]o-IP1 concentration response curves were
higher than with WT (10.8 ± 1.9 and 6.5 ± 0.4 respectively, vs. 2.9 ± 0.3 mM for the WT CaSR).
In the presence of L-Phe, the EC50 was reduced to 4.3 ± 0.1 (p<0.05) in the case of P221Q. 8.9 ±
1.7 (p>0.05) in the case of L173P. On the contrary, L-Phe failed to reduce the EC50 of L173P
significantly. The EC50s of the IP1 responses for the two receptors with activating mutations,
L173F and P221L, were not altered by L-Phe either. The outcome of IP1 experiments were
consistent, therefore, with the [Ca2+]o experiments in terms of EC50. However, it seems that the
alteration in the [Ca2+]o oscillation pattern for L173P was not dramatic enough to change the
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overall population response.

Figure 5.5. L-Phenylalanine potentiates [Ca2+]o-induced IP1 accumulation.
IP accumulation was measured in the IP-One ELISA Kit as detailed in Methods. Changes
in IP1 accumulation were measured in response to [Ca2+]o at 0, 1.0, 2.0, 3.0, 5.0 and 7.5 mM
in HEK293 cells transfected with WT CaSR, or with mutant L173F or P221L. For mutant
L173P, IP1 accumulation was measured at 0, 3.0, 5.0, 7.5, 10.0, 15.0, 20.0 and 25.0 mM
[Ca2+]o; for mutant P221L, the IP1 responses to [Ca2+]o at 0, 3.0, 5.0, 7.5, 10.0, 15.0 mM
[Ca2+]o were recorded. The IP1 response-[Ca2+]o concentration responses were fitted using
Hill equation as mentioned in method.
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Table 5.2 Summary of EC50s from experiments measuring IP1 accumulation and ERK1/2
phosphorylation.

Mutants

EC50 (IP1-Elisa)
Without L-Phe

EC50 (ERK1/2 activity)
With L-Phe

Without L-Phe

With L-Phe

WT

3.0 ± 0.2

2.0 ± 0.1*

3.0 ± 0.1

1.9 ± 0.1*

L173F

1.2 ± 0.1#

1.0 ± 0.1

2.7 ± 0.1#

1.6 ± 0.1*

P221L

1.1 ± 0.1#

0.9 ± 0.1

2.2 ± 0.3#

1.7 ± 0.2

L173P

10.7 ± 1.0#

9.0 ± 0.9

14.9 ± 1.0#

13.5 ± 0.8

P221Q

6.1 ± 0.3#

4.5 ± 0.4*

11.9 ± 0.3#

9.5 ± 0.4*

HEK293 cells were transiently transfected with the WT CaSR or disease-associated CaSR
mutants. Cells were then treated with various levels of [Ca2+]o. The EC50s of the IP1-[Ca2+]o
concentration responses and the ERK1/2 phosphorylation activity-[Ca2+]o concentration
responses were obtained from curve fitting using the Hill equation as described in Methods.
#

indicates significance with respect to wild type CaSR, p < 0.05;

*

indicates significance

with respect to the corresponding mutants in the absence of L-Phe, p < 0.05.

5.2.4 The ERK1/2 responses of the WT and mutants CaSRs correlate with their [Ca2+]i responses
to [Ca2+]o.
In order to understand the effects of the “toggled” mutations on the function of the CaSR
and its downstream signal pathways (Figure 5.1c) as well as to explore whether L-Phe can
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regulate these mutants as suggested by the computer simulation results, we further analyzed
[Ca2+]i oscillation patterns induced by [Ca2+]o in HEK293 cells transfected with those mutations.
Exposure of WT CaSR-transfected HEK293 cells to increasing concentrations of [Ca2+]o
in the range of 0.0-~2.0 mM for 10 minutes had little effect on the phosphorylation of p44/42
ERK. Greater increases of [Ca2+]o resulted in the accumulation of p44/42 ERK, which exhibited
a maximum response at 8.0 mM [Ca2+]o. In the presence L-Phe, the ERK1/2 activity was
enhanced. As shown in Figure 5.6 and Table 5.2, the amount of phosphorylated ERK1/2 was
increased significantly at 2.0 mM [Ca2+]o compared with that observed at the same level of
[Ca2+]o in the absence of L-Phe. The ERK1/2 activity in the presence of L-Phe reached a
maximum at 4.0 mM [Ca2+]o. For the activating mutation, L173F, the phosphorylated ERK1/2
signal could be detected at 2.0 mM [Ca2+]o which was in line with its enhanced intracellular
calcium response compared to WT CaSR. However, although L-Phe didn’t significantly shift the
[Ca2+]o triggered [Ca2+]i response curve, it enhanced the phosphorylation of ERK1/2 even at
physiological [Ca2+]o concentrations in the mutant L173F. The maximum ERK1/2 activity in cells
transfected with the L173F mutant was achieved at 3.0 mM [Ca2+]o with 5.0 mM L-Phe. The
mutation P221L enhanced ERK1/2 activity in the transfected cells, which approached a maximum
at 3.0 mM [Ca2+]o .The addition of L-Phe failed to activate the ERK1/2 signaling at lower levels
of [Ca2+]o, but the maximal p-ERK1/2 activity was enhanced ~15% in the presence of L-Phe. On
the other hand, the ERK1/2 responses of the loss-of-function mutants, L173P and P221Q,
correlated with the patterns observed for [Ca2+]i oscillations, as the phosphorylation of ERK1/2
started at 10.0 mM and 3.0 mM [Ca2+]o, respectively, similar to the initiation of [Ca2+]i
oscillations. The addition of 5 mM L-Phe shifted the [Ca2+]o-stimulated p-ERK1/2 concentration
response curves of mutant P221Q to the left but had little influence on the rescue of the mutant
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L173P activity.

Figure 5.6 L-Phe potentiates [Ca2+]o-activated ERK signaling in CaSR-transfected HEK293
cells.
HEK-293 cells transfected with WT CaSR or its mutants were incubated in serum-free
high glucose MEM medium containing 0.2% BSA overnight. Cells were washed with HBSS
and then incubated in the presence of various Ca2+ concentrations (0.0-~25.0mM) in the
absence or presence of 5 mM L-phenylalanine for 10 min at 37 C. The incubations were
stopped by exposure to the lysis buffer and processed for SDS/PAGE and Western blotting
as described in the Methods. The western blot results were further quantified using Image
J. All [Ca2+]o-concentration response curves were normalized to the maximum response in
each individual experiment. The Hill equation was employed to fit the data. Solid dots:
with L-Phe; Empty dots: [Ca2+]o only.
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5.2.5 CaSR mutants exhibit different sensitivities to L-Phe
To determine whether the four mutations impacted the apparent affinity of the receptor for L-Phe,
concentration responses for L-Phe at physiological calcium levels of 1.5 mM [Ca2+]o and 2.5 mM
[Ca2+]o (intermediate levels of [Ca2+]o at which the two gain-of-function mutants are not
desensitized based on their responses to [Ca2+]o) were compared among cells transfected with
different CaSR mutants. Figure 5.7 shows that at 1.5 mM [Ca2+]o mutant L173F has a higher
sensitivity (EC50 = 2.9 ± 0.1) than WT and the other mutants. On the contrary, the loss-offunction mutant L173P shows a lower sensitivity (EC50 = 5.5 ± 0.3 mM) to L-Phe compared to
the other mutants. P221L and P221Q do not show any differences from WT at this level of
[Ca2+]o. When analyzing the sensitivity to L-Phe at their respective EC50s for [Ca2+]o, P221Q
exhibited a reduced EC50 of the [L-Phe] response (2.5 ± 0.2 mM, p<0.05) while L173P remained
a similar sensitivity to L-Phe (4.9 ± 0.5 mM, p>0.05) (Figure 5.7, Table 5.3).

In order to explore how the four mutants have such different sensitivities to L-Phe, the solvent
accessibility at the hinge region has been analyzed. As shown in Figure 5.8, mutation L173F,
P221L and P221Q barely altered the surface potential at the predicted site of entry to the L-Phe
binding site, which is formed by residues S170, S169, and T145 (221,223); however, the
mutation from leucine to proline at position 173 contributes significantly to the clustering of
positive charges in the cleft between lobe 1 and lobe 2.On the other hand, the mutation also
decreased the original distance between residue L173 and one of the critical calcium binding site
ligand residues, Y218 from 10.8 Å to 8.7 Å (in the holo form) and from 14.2 Å to 12.2 Å (in the
apo form), which might make it more difficult for a hydrophobic amino acid to enter into its
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binding site.

Figure 5.7 Sensitivity of various CaSR mutants to L-Phe in HEK293 cells.
(a). HEK-293 cells transfected with CaSR or its mutants were loaded with Fura-2 AM for
15 min. The intracellular Ca2+ level was assessed by monitoring emission at 510 nm with
excitation alternately at 340 or 380 nm using fluorescence microscopy as above. Each
experiment started with 1.5 mM mM Ca2+ followed by stepwise increases in the level of LPhe (up to 12.0 mM) while [Ca2+]o maintained at 1.5 mM. (b). The sensitivity of P221Q to
L-Phe at 5.0 mM [Ca2+]o. The [Ca2+]i signal was measured using Frua-2 AM as mentioned
above. The experiment was carried out in the presence of 5.0 mM [Ca2+]o while increasing
the L-Phe concentration. (c). The sensitivity of L173P to L-Phe was monitored in the
presence of 15.0 mM [Ca2+]o.
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Table 5.3 Summary of EC50s of concentration-response curves for L-Phe at different
[Ca2+]o.

Mutants

EC50
(at 1.5 mM [Ca2+]o)

WT

3.7 ± 0.4

L173F

3.2 ± 0.2

P221L

4.3 ± 0.3

L173P

5.5 ± 0.3# (4.9 ± 0.5)

P221Q

4.5 ± 0.4

(2.5 ± 0.2*)

The [Ca2+]i responses of HEK-293 cells transfected with CaSR or its mutants upon
stepwise increases of L-Phe in the presence of 1.5 mM [Ca2+]o were recorded. For L173P
and P221Q, the L-Phe-induced [Ca2+]i change were also measured in the presence of high
[Ca2+]o corresponding to their EC50 values for [Ca2+]o, specifically 15.0 mM [Ca2+]o for
mutant L173P and 5.0 mM for P221Q. The results are shown in brackets. The EC50s were
calculated from the concentration-response curves fitted using the Hill equation. # indicates
significance with respect to wild type CaSR, p < 0.05; * indicates significance with respect
to the corresponding mutants in the presence of 1.5 mM [Ca2+]o, p < 0.05.
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Figure 5.8 Surface potential of the hinge region in the extracellular domain of CaSR.
The zoomed in view of the cleft between lobe1 and lobe2 of WT CaSR or its mutants was
depicted using pymol. Upper panel: using the apo form of the CaSR models; Lower panel:
using the holo form of the CaSR models. Residues involving the “toggle” disease mutations
are labeled in black. Negative potentials are shown in red, and positive potentials are
shown in blue.

5.2.6 The protein correlation profiling of the disease-related mutations as assessed by molecular
dynamic simulations.
Since it has been reported that 18 out of 34 newly found naturally-occurring missense
mutations on the ECD are within 10 Å of one or more of the predicted Ca2+-binding sites (208),
and a few disease-associated human mutations severely affect the functional cooperativity of
CaSR (161), an investigation on the mechanisms of the cooperativity alterations induced by

150
mutations as well as allosteric modulators is highly desirable. Molecular dynamic simulation
provides an approach complementary to in vitro experiments for understanding biomolecular
structure, dynamics, and function (220). To obtain additional insights into the impacts of these
various mutations on the structure and function of the CaSR, we carried out molecular dynamics
simulations, as shown in Figure 5.9. The correlation map in Figure 5.9 illustrates the protein
motions predicted using such simulations. The X- and Y-axes correspond to residue numbers of
the CaSR ECD minus 24 (in order to align with the structure of mGluR1). In the WT model, site
1 is shown to have strong correlated motions with sites 2, 3 and 4, which are shown in blue for
negative correlations ( motions between each pair of residues taking place in the opposite
direction) and red for positive correlations (movements in the same direction) (Figure 5.9). The
correlation maps of the gain-of-function mutations, L173F and P221L, exhibited dramatic
increases in the regions with either blue or red color indicating an enhancement of correlated
motions between the respective residues in these two mutants (Figure 5.9). A closer analysis of
the correlated motions of L173F and P221L revealed that the negative correlations between Site
1 and Site 3 and between Site 1 and Site 2 observed in the WT correlation map became positive
correlations in the gain-of-function mutants indicating that the mutations might have profound
impacts on the dynamic properties of the CaSR-ECD. Moreover, greater correlated motions were
observed among residues 344-454, among residues 24-124, and between these two groups of
residues. Especially for P221L, strong negative correlations between lobe 1 and lobe 2 are
observed as indicated by the abundant blue area between residues 200-300 and residues 24-170.
On the other hand, the loss-of-function mutations, L173P and P221Q, exhibit weaker correlated
motions compared to the WT CaSR (Figure 5.9).
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Since L-Phe is considered as one of the positive allosteric modulators to the CaSR, we
investigated whether L-Phe can change the dynamic features of these mutants. The introduction
of L-Phe and calcium to the simulation system dramatically changed the correlated motions of
WT (data not shown) and mutant L173F, P221L and P221Q, but had less effect on the
correlation map of L173P (Figure 5.9). These results suggested that the allosteric modulator may
have biased influences on changing the correlation motions among these mutants.

Figure 5.9 The correlation map of the modeled WT and mutant CaSR ECD structure.
The correlation map is depicted based on molecular dynamics (MD) simulations for 50 ns.
The X axis and Y axis are residue numbers of CaSR ECD sequences minus twenty four.
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The strongest negative correlation is given the value -1 while the strongest positive
correlation is defined as +1. Residues that have the strongest negative correlated motions
are shown in blue, while those involved in positive correlated motions are shown in red.
Green stands for no apparent correlated motion between the two residues.

Principal component analysis (PCA) was also applied to the four mutations and the WT
CaSR as well based on the trajectories of molecular dynamics simulations in order to predict the
effect that L-Phe could have on the CaSRs at the atomic level. PCA separates out the protein
motions into principal modes ranked according to their relative contributions (199).Projection of
the trajectories of the CaSR mutants in both the apo form (upper panel) and the holo form (lower
panel) onto the first three modes that accounted for the majority of the total fluctuations is shown
in Figure 5.10. In the Ca2+-free and L-Phe-free forms, the conformations of the CaSR mutants
sampled are similar to those of the WT CaSR. However, in the L-Phe and Ca2+-loaded forms, the
conformations of the CaSR mutant L173P is essentially distinguishable from other mutants and
WT CaSR (Figure 5.10). The results suggest that Ca2+ and L-Phe might shift the population of
conformational ensembles of mutant L173P in a different way compared with WT or the other
three mutants.
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Figure 5.10 Principal component analysis (PCA) of the wild type and mutant CaSR ECDs.

The trajectories of the molecular dynamics simulations were analyzed using principal
component analysis (PCA), which separates out the motions of different CaSR ECD
mutants into principal modes ranked according to their relative contributions. The first
three principal modes were included in the present study to analyze two different states of
the protein: upper: apo form; lower: holo form. Different colors stands for each individual
CaSR or its mutants: WT (black), L173F(Green), L173P (Red), P221L (Magenta), P221Q
(Blue).
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5.3 Discussion
The loss-of-function mutations impaired the functional cooperativity of the CaSR
We have reported 71 CaSR mutations identified in 220 patients with previously
undiagnosed hyper- or hypocalcemic disorders. More than 50% of the mutations are located
within 10 angstroms of our predicted Ca2+-binding sites (208). The hinge region is considered to
be crucial in terms of the CaSR’s sensing of its agonists (e.g., polyvalent cations and amino acids)
(68,212). Notably, 12 mutations can be mapped in the vicinity of the major Ca2+-binding site 1,
which is in the hinge region between lobes 1 and 2, linking other four potential calcium binding
sites. Thus, mutations near Ca2+-binding site 1 possibly influence the whole receptor’s functional
cooperativity (68,212).
By analyzing the changes in [Ca2+]i in individual HEK293 cell elicited by increasing
[Ca2+]o, the impact of the ’toggle’ mutations on the function of CaSR has been further evaluated.
The in vitro study showed that the L173F and P221L mutations enhance the sensitivity of the
CaSR to [Ca2+]o compared to the WT receptor, but barely change the cooperativity of the
receptor, while the L173P and P221Q mutations render a less cooperative receptor with impaired
capability to sense [Ca2+]o.

Disease related mutations change the [Ca2+]o elicited [Ca2+]i oscillation pattern and
intracellular signaling.
Oscillations have been postulated to be the result of complex responses from multiple
signaling pathways. Since the [Ca2+]o-triggered [Ca2+]i oscillation pattern is believed to be
modulated by the activity of phosphoinositide pathway (262) as well as a negative feedback loop
involving the inhibitory effect of

protein kinase C (PKC) on IP3 production (263), the
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downstream intracellular signaling responses (such as the production of IP1 and the activity of
ERK1/2,which will be discussed later) can be reflected in the oscillation patterns associated with
the different disease-related mutations. Although most research focusing on the relationship
between intracellular calcium mobilization and CaSR activation has utilized CaSR expressed
heterologously in HEK293 cells, CaSR-induced [Ca2+]i oscillations have been found in cells with
endogenously expressed CaSR, for instance in parathyroid cells (264), bovine anterior pituitary
cells (265), opossum kidney (OK) cells (106) and medullary thyroid carcinoma cells (266).
Oscillations in [Ca2+]i have been reported not only to modulate the rate of parathyroid hormone
(PTH) secretion, but also to regulate gene expression (24,119,126,130). The pattern of [Ca2+]i
oscillations is thus one of the most important signatures reflecting the state of CaSR activity. As
[Ca2+]o is increased, the [Ca2+]i oscillations reach a plateau in CaSR-transfected cells as the
desensitization process occurs and/or there is depletion of [Ca2+]i stores. Although the loss-offunction mutation L173P still oscillated at 30.0 mM [Ca2+]o, considering the elevated and broad
range of its sensitivity to [Ca2+]o it is possible that a plateau would be reached at even higher
levels of [Ca2+]o.
The studies of the accumulation IP1 (a metabolite of IP3) and the ERK pathways in
HEK293 cells transfected with the various CaSR mutants conveyed two messages: Firstly, the
mutations caused changes in the patterns of [Ca2+]i oscillations that at least partially involve
activation of the Gq/11 pathway. The changes in the accumulation of IP1 upon stimulation with
various concentrations of [Ca2+]o correlated well with the patterns of [Ca2+]i oscillations.
Secondly, stimulation of the ERK1/2 activity in CaSR transfected HEK293 cells has been reported
to involve PKC-mediated as well as a PTX-sensitive, tyrosine kinase-dependent pathways (260).
Although it is believed that the carboxyl terminus of the protein is involved in the activation of
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MAPK signaling by interacting with the scaffold protein filamin A(80,81), the data showed that
that alterations in the extracellular domain can also affect the ERK cascade which is in
agreement with previous studies(267). Since all the mutations presented similar levels of
expression on the membrane (Figure 5.1b), these downstream signaling changes may at least
partially be contributed by the disruption of cooperativity among different calcium binding sites
introduced by different mutations. On the other hand, the gain-of-function mutations may
increase the stability the receptor as suggested by other studies (268).

L-Phe induced heterotropic cooperativity rescued CaSR activity
We next investigated the effects of the positive allosteric modulator L-Phe on these four
mutations. The interaction between CaSR and L-Phe has been reported to modulate the G12/13RhoA pathway (121); however, L-Phe could also potentially enhance [Ca2+]o-induced alterations
in intracellular signaling pathways through Gq/11 pathways as reflected by the IP1 accumulation
assay. The alterations in the oscillation patterns after the introduction of the allosteric activator
could be the result of the activation of signaling downstream of G12/13 or a combined effect with
the positive heterotropic cooperativity between the multiple Ca2+ binding sites induced by L-Phe.

The present study also confirms that the ERK signaling pathway in CaSR-transfected
HEK293 cells can be modulated not only by [Ca2+]o but also by the positive allosteric modulator,
L-Phe (100). It should be noted that the ability of L-Phe to enhance the intracellular response
varied among different mutations. L-Phe enhanced the maximum response of the ERK signaling
to a greater extent than it altered the apparent affinity in the two gain-of-function mutants,
although it showed barely any influence on the [Ca2+]o-triggered [Ca2+]i and IP1 responses for
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these mutants, which may explain, in part, the dramatic changes in correlated motions from the
computational simulation results using molecular dynamics. As a signaling messenger further
downstream than either IP1 or [Ca2+]i, the phosphorylation of ERK1/2 may not merely reflect
activation of the Gq/11 pathway, but could be contributed to by other G-proteins (e.g., Gi). In
agreement with the in silico results, L-Phe exhibited less effect on the regulation of the ERK1/2
pathway in mutant L173P. The predicted L-Phe-binding site has been reported to be located near
the hinge region between lobe 1 and lobe 2 and to involve residues S169A/S170A/S171A (221).
L173 is located within 5 Å of this region. The Leu to Pro change could potentially prevent
generating additional steric effects on the closure of lobe 1 and lobe 2 so that addition of
exogenous L-Phe is has relatively little impact on the function of the CaSR’s response to changes
in [Ca2+]o. Meanwhile, the surface electrostatic charge analysis indicated that the mutation could
cause charge redistribution, leaving the Ca2+ binding pocket slightly more positive, on one hand,
and reduce the interaction between calcium and its binding site 1. Thus, the hetero-cooperativity
between the allosteric modulator and calcium binding sites could be disturbed, resulting in the
lack of a left-shifted concentration-response curve in response to [L-Phe].

Computational studies revealed different behavior of the four mutants though simulation.
Based on the known structure of the agonist-bound and apo forms of mGluR1, which is
in the same family C of the GPCRs as the CaSR, an analogous hinge motion of the CaSR is
potentially involved in forming the activated form of the latter upon interaction with ligands
binding to this region. The correlation maps generated from molecular dynamic simulations for
the model structures of the ECDs of the WT and mutant CaSRs provide a complementary
approach that is useful to compare the influence of mutations on the interaction networks within
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the CaSR ECD. In the current CaSR ECD model structure, it seems that the gain-of-function
mutations tend to have stronger correlations between the residues than the WT receptor.
Meanwhile, the loss-of-function mutations showed opposite effects on the correlation maps,
suggesting a disrupted cooperativity among different calcium binding sites. The simulation
results revealed limited effects of L-Phe on changing the correlation motions in the mutant
L173P. Meanwhile it dramatically changed other mutants as well as WT indicating that L-Phe
may not alter the cooperativity in the same way as the others which have subsequently been
confirmed by experiment data.
The results from PCA could also be an explanation for the biased L-Phe effects. L-Phe
could not effectively shift the inactive population of conformational ensembles of L173P to an
active ensemble of conformations as it did to other mutants and WT as well. However, whether
the in silico simulations provide a novel method to predict mutational effects on CaSR will
ultimately require the kind of structural detail available for the mGluRs whose structures have
been solved. Certainly, the model structure does not take into consideration the possible
interactions between the ECD and the extracellular loops and/or transmembrane domain as well
as the intracellular domains. Thus, caution is merited in applying the calculated in silico results
to those observed with the CaSR in intact cell or in vivo situations. Nevertheless, the predicted
structural motions may help to identify the mutations or ligands that have increased or
diminished coupling among specific structural elements within the CaSR ECD. While this type
of analysis is limited for the moment to the environment of the orthosteric site, this strategy
could facilitate drug design for modulating the functions of disease-related mutations in the
CaSR as well as other members of the family C GPCRs
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In conclusion, through the analysis of the [Ca2+]i oscillation and the [Ca2+]o and L-Phe
triggered downstream signaling changes, we found in the present study that the functional
cooperativity was disrupted in the identified FHH associated CaSR mutations L173P and P221Q
but not in the ADHH related mutations L173F and P221L. The addition of L-Phe rescued the
function of P221Q via the introduction of heterotropic cooperativity. The distinctive correlated
motions between the gain-of-function mutations and the loss-of-function mutations and potential
revealed by the molecular dynamic simulations provide insights into the mechanism for the
disease associated receptor functional alterations.
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CHAPTER 6. CHARATERIZE THE BIOPHYSICAL PROPERTIES OF THE
EXTRACELLULAR DOMAIN OF CALCIUM SENSING RECEPTOR
6.1 Introduction
The calcium sensing receptor (CaSR) is a seven transmembrane protein which belongs to family
C of the G protein-coupled receptor super family (269). The CaSR is named after its major
function--regulating extracellular calcium homeo stasis in the body—and its predominant
expression in parathyroid and kidney cells allows this receptor to modulate parathyroid hormone
(PTH) secretion as well as renal calcium reabsorption (38,41,270,271). The CaSR is also widely
expressed in other tissues including the gastrointestinal system(165), the central nervous
system(272), several kinds of cancer tissues etc. where it may play other crucial roles. Besides
responding to the primary physiological agonist ‘calcium’, the CaSR can also respond to various
other stimuli, such as other cations (273), amino acids(118,272), polyamines(242),
polypeptides(274) etc.
The CaSR is comprised of the three major structural features of GPCR family C: an extracellular
domain (ECD) which includes residue 20 to 612 (38); a seven-transmembrane domain (613-862)
(275) and an intracellular tail covers 216 amino acids(276) which bridge the extracellular stimuli
into intracellular signal pathways. Based on the amino acid homology of the CaSR’s ECD to
metabotropic glutamate receptor (mGluR), a modeled structure has been proposed for the
purpose of exploring the biophysical properties of the protein(68). The generated ECD model has
a bilobed Venus-fly-trap (VFT) structure (68,70), and is proposed to contain five Ca2+-binding
pockets (68). Among those calcium binding pockets, it has been demonstrated that binding site 1,
comprising residues Ser 147, Ser 170, Asp190, Tyr218 and Glu297, is critical for binding
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Ca2+(96). Eleven highly conserved putative N-linked glycosylation sites, Asn-Xaa-Ser/Thr were
identified in the ECD which are considered to be critical for cell surface expression (88).
However, due to the lack of biochemical and structural information about the ECD, how
extracellular stimuli induce conformational changes of the CaSR leading to further intracellular
downstream responses still remains to be defined. The expression of the CaSR ECD has been
reported by Goldsmith et. al. (277) and Ryan et. al. (278) using CaSR ECD stably transfected
HEK293 cell line and insect cells respectively. Both of the expressed proteins can form dimers
and are recognized by specific anti-CaSR antibodies. A few biophysical properties of the insect
cell expressed CaSR-ECD have also been explored in Ryan’s study including the secondary and
tertiary structure as well as metal-binding properties. Nevertheless, little is known about the
influence of glycosylation on this protein and the differences of the expressed proteins with
distinct glycosylation modifications.

UDP-GlcNAc:-D-mannoside-1,2-N-acetylglucosaminyltransferase I (GnTI)1(EC 2.4.1.101) is
a type II integral membrane protein, localized to medial-Golgi cisternae, and catalyzing the first
step in the conversion of high mannose N-glycans into complex and hybrid structures (279,280).
Although the complex N-glycans are essential for the viability of the developing embryo, as
mice lacking a functional GnTI gene die before birth (281,282), the complex N-glycans are not
crucial for viability of cells cultured in vitro as many mutants have been isolated which lack of
GnTI activity (283,284). One such mutant is the leuco-phytohemagglutinin (L-PHA) resistant
Lec1 HEK293F cell (285). Due to the deficiency at GnTI, Lec1 cells are unable to synthesize
complex and hybrid N-glycans and the oligosaccharides will be accumulated in the form of
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Man5-GlcNAc2-Asn-structures (286). Thus, protein expressed using Lec1 HEK293F cells could
have a uniform high mannose glycan modification at the surface.

In the present study, the ECD of CaSR was secreted from human CaSR (hCaSR)-ECD
transiently transfected HEK293F or Lec1 HEK293F cells. The protein was further purified
through affinity columns. The biophysical properties of the native CaSR ECDs were
characterized using fluorescence titration spectroscopy, circular dichroism technique as well as
NMR spectra. Our studies indicate that glycosylation could dramatically alter the protein’s
thermal stability; meanwhile it also affected the calcium induced conformational changes as well
as its metal binding capability.

6.2 Results
6.2.1 The CaSR ECD forms dimer in culture medium
HEK293F cells or the Lec1 mutant HEK293F cells were transiently transfected with engineered
hCaSR ECD cDNA (Figure 6.1). The signal peptide at the N-terminal led to the secretion of the
CaSR ECD into the culture medium. Those His-tagged CaSR ECDs were efficiently separated
from other proteins with a HisPrep column using an imidazole gradient (Figure 6.2). The
fractions containing CaSR ECD were collected and detected by SDS-PAGE under reducing
conditions (Figure 6.2). Immunoblot was further applied to verify the samples using the specific
anti-CaSR antibody. As shown in Figure 6.2 (c~e) WT CaSR ECD exhibited a smeared band in
the range from 100 kDa ~ 130 kDa suggesting various degrees of glycosylation while the Lec1
mutant hCaSR has one single band with a molecular weight of approximately 95 kDa. The nonreducing samples of WT CaSR ECD and Lec1 CaSR ECD have molecular weights at around 240
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kDa and 200 kDa, respectively, corresponding to the calculated dimerization form of the
receptor’s extracellular domain.

Figure 6.1 Schematic representation of extracellular domain of the CaSR.
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The first 25 amino acids are signal peptide from vector. The arrow indicates the beginning
of CaSR ECD sequences. The introduced stop codon mutation is immediately after residue
612, resulting in the secretion of the receptor into the cell culture medium. Putative
glycosylation sites are hightlighted using branches. Underlined and labeled regions
represent peptide sequences used to generate peptide-specific monoclonal antibody ADD.
The loop inserted between D371 and T372 is the engineered Flag-tag.

Figure 6.2 CaSR ECD protein fractions isolated from cell culture medium using FPLC

(a). HEK293F cells transfected with WT CaSR ECD were continuously cultured for 6 days.
Then cell culture medium was collected and underwent protein purification procedure
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using a nickel affinity column. Representative tracing of A280 measured in milli AU for
protein eluted by imidazole. Inset: Coomassie blue staining of the representative fractions
from the affinity column separation. The lanes marked “M” are protein molelcular weight
standards. (b). The same chromatography of protein purification using secreted proteins
from Lec1 cells transfected with the CaSR ECD. (c). WT CaSR ECD proteins (50 g) from
indicated fractions were incubated at 100 °C in sample dissociation buffer containing mercaptoethanol for 5 mins before loading on the SDS gels. (d). the same treatment as (a)
but with Lec1 CaSR ECD proteins (e). Left two lanes were loaded with WT/Lec1 CaSR
ECD incubated at 4°C for 5 mins in sample dissociation buffer without -mercaptoethanol;
the right two lanes were loaded with WT/Lec1 CaSR ECD and incubated at 100°C for 5
mins with reducing reagent.

6.2.2 The secreted CaSR ECD is stable and glycosylated
The stability of the purified extracellular domain was further investigated using immunoblot.
Samples from CaSR ECD aliquots were kept at room temperature continuously for seven days.
Both the WT CaSR ECD and the Lec1 CaSR ECD was quite stable as no degradation bands
could be detected by Western blot (Figure 6.3). In order to verify whether the secreted WT CaSR
ECD is glycosylated or not, Ricinus communis agglutinin I (RcaI) agarose beads, which
preferentially binds to oligosaccharides, were incubated with the purified protein. A high
concentration of galactose (200 mM) would compete with the glycoproteins for interaction with
the lectin agarose beads. Figure 6.4a shows that the WT CaSR ECD was able to interact with the
RcaI agarose beads which indicate that the protein was glycosylated. N-Glycosidase F, known as
PNGase F, can cleave between the innermost acetylglucosamine (GlcNAC) and asparagine
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residues of high mannose, hybrid, and complex oligosaccharides from N-linked glycoproteins
(287). Treatment with heat and detergent denatured WT CaSR ECD and exposed enzyme
cleavage sites. As shown in Figure 6.4b, with the presence of N-glycosidase, the molecular
weight of WT CaSR ECD decreased from ~100 kDa to ~80 kDa. Meanwhile, Endo F1 cleaves
asparagine-linked or free high mannose and hybrid structures but not complex oligosaccharides,
leaving a truncated sugar molecule with one N-acetylglucosamine residue on the
asparagines(288). The Lec1 CaSR ECD showed a lower band on the gel at molecular weight
around 87 kDa after treatment with Endo F1 (Figure 6.4c), suggesting that the Lec1 CaSR ECD
has homogenous high mannose form.

Figure 6.3 The stability of CaSR ECD at room temperature.
The purified ECD protein aliquots were incubated in 10 mM Tris buffer (pH 7.2) at room
temperature for the indicated number of days. Samples were then added with the sample
dissociation buffer with or without -mercaptoethanol before loading in the gel. R: without
-mercaptoethanol. (a) WT CaSR ECD; (b) Lec1 CaSR ECD.
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Figure 6.4 The secreted ECDs were glycosylated.
(a.) WT CaSR ECD protein (1.0 mg) was incubated with RCA-1 lectin agarose beads
overnight at 4

followed by washing with PBS. Lane 1: Eluted fractions using PBS without

addition of galactose. Lane 2: Eluted fractions using PBS containing 200 mM galactose.
Lane 3: 5 l of the Rca-1 lectin agarose beads after incubating with protein were loaded
into the gel as a positive control. The elution fractions were further analyzed by
immunoblot using anti-flag antibody. (b.) Denatured purified WT CaSR ECD (20 g) was
treated with PNGase F for 2 hours at 37 . Protein aliquots treated with or without
PNGase F were loaded in the gel and further analyzed by Western blot using an anti-flag
antibody. (c.) The purified Lec1-hCaSR-ECD protein was mixed with Endo F1 at mass
ratio 1:3 in 10 mM Tris buffer, pH 7.4 for overnight shaking at 4

. Samples were detected

using anti-flag antibody by immunoblot under reducing condition.
6.2.3 Calcium and glycosylation caused little secondary structure change of the CaSR ECD.
In order to analyze the secondary structure of the purified CaSR ECDs, circular dichroism
measurements were performed. Figure 6.5 shows typical far-UV CD spectra of the proteins.
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Analysis of all the spectra indicated that the purified WT and Lec1 CaSR ECD shared similar
secondary structure with  helical content of 52%~58% and -sheet content of 17% ~25%. The
addition of calcium had caused minimal changes in the spectra of both WT CaSR ECD and Lec1
CaSR ECD (Table 5.1).
The proteins were subjected to stepwise increases in temperatures to assess thermal
stability. Molar ellipticity was monitored from 4~ 95 C at 222 nm, which is considered to be a
sensitive position for proteins have >50%  helical structure. As shown in Figure 6.5 (a&b), the
WT CaSR ECD demonstrated extraordinary thermal stability as the signal at the given
wavelength did not change. The high mannose form of the CaSR ECD, the Lec1 CaSR ECD,
showed a rapid disruption of secondary structure at 92C in the absence of Ca2+. In the presence
of Ca2+, the melting points of the Lec1 CaSR ECD were decreased dramatically to 80C
possibily due to protein precipitation. However, the calcium induced alterations in melting
temperature were not observed in the WT CaSR ECD. The heating process resulted in
irreversible structural changes in the Lec1 CaSR ECD as the high temperatures caused marked
precipitation of the protein. To determine the enthalpy of the unfolding process for the CaSR
ECD, the Van’t Hoff equation could be employed for the analysis (289), however, in the present
study, the precipitation could due to calcium binding induced instability of the protein.
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Figure 6.5 Circular Dichroism measurement of purified ECD in the presence or absence of
calcium.
(a) Far-UV CD spectrum of WT CaSR ECD in 10 mM Tris, pH 7.2 with or without 2.0 mM
Ca2+, at 25

. (b) Far-UV CD spectrum of Lec1 CaSR ECD in 10 mM Tris, pH 7.2 with or

without 2.0 mM Ca2+, at 25

. (c) Temperature dependence of the molar ellipticity at 222

nm for WT CaSR ECD in 10 mM Tris, pH 7.2. (d) Temperature dependence of the molar
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ellipticity at 222 nm for Lec1 CaSR ECD in 10 mM Tris, pH 7.2. The addition of calcium
may also cause the precipitation of Lec1 protein at high temperature, resulting in a
decrease of the melting temperature.
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Table 6.1 Secondary structure of CaSR ECDs at 25 .

-Helix

-Strands

Turns

Unordered

Ca2+(-)

Ca2+(+)

Ca2+(-)

Ca2+(+)

Ca2+(-)

Ca2+(+)

Ca2+(-)

Ca2+(+)

WT
CaSR
ECD

58% ± 1%

55% ±
6%

17% ± 1%

21% ± 4%

6% ± 2%

5% ± 1%

18% ± 4%

15% ± 4%

Lec1
CaSR
ECD

52% ± 5%

60%
±4%

25% ± 3%

18% ± 1%

5% ± 1%

7% ± 2%

18% ± 3%

18% ± 3%

The secondary structure contents were estimated according to SELCON and CONTIN algorithms. Numbers in the table
show the average of secondary structure content of both algorithms.
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6.2.4 Fluorescence spectra indicate folded structure of the CaSR ECD.
There are twelve tryptophan (Trp) residues in the ECD, thus, by analyzing the intrinsic
tryptophan emission spectra from 300 to 400 nm at the excitation wavelength of 282 nm, the Trp
environment can be monitored. The emission spectrum of free Trp has a peak at around 350 nm.
The emission peak undergoes a blue-shift if the tryptophan is embedded in a hydrophobic
environment. All the Trp emission spectra of various types of ECD showed a peak at around 334
nm, indicating that the proteins retained their native structures (Figure 6.6).

Meanwhile, ANS, a fluorescence probe extensively used for the detection and analysis of protein
conformational changes, was applied to the study of the two proteins (290). This dye has low
fluorescence yield when exposed to polar environments, but a blue shift of the emission
spectrum and an increase of the fluorescence intensity would occur once its fluorophore is
located in less polar media (291). Compared to the free ANS dye, which has an emission peak at
around 500 nm, the ANS fluorescence spectra of both the CaSR ECDs underwent a more than 30
nm blue shift and further exhibited a 10-fold increase in fluorescence intensity (Figure 6.7). The
fluorescence spectra changes indicate the hydrophobic portion at the protein surface can bind
with ANS and calcium can induce a conformational change of CaSR ECDs. These results
correlate well with the Trp spectrum, demonstrating that the purified ECDs, both from WT
HEK293F cells and Lec1 mutant system, were possibily in their native forms.
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Figure 6.6 Tryptophan fluorescence titration of CaSR ECDs.
(a) Trp fluorescence spectra of WT CaSR ECD in the presence of 0 (---) or 5 mM Ca2+ (—).
(b) Trp fluorescence spectra of Lec1 CaSR ECD in the presence of 0 (---) or 5 mM Ca2+ (—).
(c) Calcium titration curve of WT CaSR ECD. (d.) Calcium titration curve of Lec1 CaSR
ECD.
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Figure 6.7 Ca2+-induced changes in ANS fluorescence in CaSR ECDs.
ANS fluorescence spectra of CaSR ECD in the presence (—) or the absence of (---) 5 mM
Ca2+. The spectrum of ANS alone is shown in gray. The fluorescence intensity at 465 nm
was recorded and plotted against calcium concentration. The data were further fitted using
Hill equation. (a) WT CaSR ECD; (b) Lec1 CaSR ECD.
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6.2.5 Ca2+-induced conformational changes in CaSR ECDs.
As shown in Figure 6.6 & 6.7, the addition of Ca2+ led to changes in both Trp fluorescence and
ANS spectrum. Binding to Ca2+ resulted in 2~3 nm blue shift of the emission maxima of the Trp
fluorescence spectra of both the WT CaSR ECD and the Lec1 CaSR ECD. Futhermore, a
decrease of 20% in Trp fluorescence intensity in WT CaSR ECD was observed upon the addition
of saturating amounts of Ca2+, while a 14% decrease in signal was shown in the case of Lec1
CaSR ECD. Compared to the calcium induced signal changes of the Trp spectra, the ANS
intensity alterations upon Ca2+ titrations rendered different patterns for the two proteins. Calcium
produced an exposure of more hydrophobic regions in the complex oligosaccharides form (WT
CaSR ECD) as there was a 25% increase in the fluorescence signal. Similar intensity
enhancements, though to lesser extents (~10%), were detected in Lec1 CaSR ECD.

The calcium induced conformational changes reflected in the Trp spectra were further assessed
by monitoring the calcium titration processes. As expected, the Kds for mammalian system
expressed CaSR ECDs were in mM range for WT CaSR ECD 3.5 ± 0.3 mM and for Lec1 CaSR
ECD 3.2 ± 0.3 mM, respectively. The Hill numbers obtained from the Trp fluorescence spectra
were 2.6 ± 0.5 for WT CaSR ECD and 2.2 ± 0.2 for Lec1 CaSR ECD, indicating that the two
proteins may share similar multiple binding processes (Table 5.2). The calcium induced ANS
spectral alterations were also fitted by the Hill equation. The WT CaSR ECD had a Kd of 3.8 ±
0.2 mM while the Lec1 CaSR ECD had a Kd value at 3.2 ± 0.1 mM. Their corresponding Hill
numbers calculated from the Ca2+-ANS titration curves were 2.6 ± 0.4 and 2.3 ± 0.5 respectively.
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Table 6.2 Summary of dissociation constants and Hill numbers for CaSR ECDs.
Trp Spectrum

ANS Spectrum

EC50

Hill number

EC50

CaSR

3.5 ± 0.3

2.6 ± 0.5

3.8 ± 0.2

Lec1 CaSR
ECD

3.2 ± 0.3

2.2 ± 0.2

3.2 ± 0.1

Mutants
WT
ECD

Hill number
4.0 ± 0.4
2.8 ± 0.4

6.2.6 Tb3+ binding process confirmed the weak binding affinity of CaSR ECD
Considering the potential presence of background Ca2+ in the buffer, which might affect the
accurate measurement of binding affinity, the metal binding capability of ECDs were further
analyzed using Tb3+ luminescence resonance energy transfer (Tb3+-LRET). There are 12 Trp
residues in the CaSR ECDs. According to the model structure of the CaSR ECD, more than 5 of
the Trp residues are within 15 Å of those potential calcium binding pockets, thus enabling
aromatic residue-sensitized Tb3+-LRET. Due to their similarities in ionic radii and coordination
chemistry, Tb3+ has been ubiquitously used to probe Ca2+ binding sites as a trivalent Ca2+
analogue. There are several advantages of using Tb3+. Firstly, the spectroscopic properties of
energy transfer between Tb3+ and the aromatic residues near the binding pockets can facilitate
the measurements of Kd as well as revealing structural information. Secondly, the higher affinity
of Tb3+ than Ca2+ also helps to probe the weak Kd values. Last, but not least, the background
contamination of Tb3+ in the titration system is lower than that of Ca2+. The Tb3+ binding
processes of the two different proteins turned out to be one binding step instead of a biphasic
process as observed in the subdomain studies (172). The Tb3+ binding affinity for WT CaSR
ECD was about 36.6 ± 0.4 M with a Hill number at 1.2 ± 0.1 suggesting a 1:1 binding mode
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(Figure 6.8). In terms of Lec1 CaSR ECD, the Kd for Tb3+ was 31.8 ± 0.3, which is comparable
with the WT CaSR ECD. On the other hand, the Ca2+-Tb3+ competition assay suggested apparent
dissociation constants for the ECDs, from which the binding constants for calcium can be
deduced (Figure 6.9). The Ca2+ binding dissociation constant calculated from Ca2+-Tb3+
competition assay, using equation; K d , Ca  K app

K d ,Tb
K d ,Tb  [Tb]

, for the WT CaSR ECD and the

Lec1 CaSR ECD were 3.7 ± 0.2 mM and 2.4 ± 0.2, respectively. This is comparable to the Kd
calculated from Ca2+ induced changes in native Trp signals as well as the ANS spectra.

Figure 6.8 Tb3+ titration curve of CaSR ECDs.
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Tb3+ titration curve of purified CaSR ECDs. The buffer for Tb3+ titration consisted of 20
mM PIPES, 135 mM NaCl, and 10 mM KCl (pH 6.8). The arrow indicates the increase in
fluorescence. The titration curve was fitted using the Hill equation. (a.) WT CaSR ECD; (b.)
Lec1 CaSR ECD.

Figure 6.9 Tb3+ competition assay of CaSR ECDs.
Tb3+-Ca2+ competition assay of purified CaSR ECDs. The buffer for Tb3+ titration
consisted of 20 mM PIPES, 135 mM NaCl, and 10 mM KCl (pH 6.8). The arrow indicates
the decrease of the fluorescence with Ca2+ addition. (a) 2.0 M of WT CaSR ECD; (b) 2.0
M of Lec1 CaSR ECD.
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Table 6.3 Summary of the Tb3+ FRET assay.
Tb3+ Titration (M)

Tb3+ Competition (M)

Mutants

EC50
number

WT CaSR
ECD

36.6 ± 0.4

1.2 ± 0.1

16.1 ± 0.2

1.8 ± 0.1

3.7 ± 0.2

Lec1 CaSR
ECD

31.8 ± 0.3

1.3 ± 0.2

10.0 ± 0.2

1.6 ± 0.1

2.4 ± 0.2

Hill

EC50

Hill number

Kd,Ca (mM)

6.2.7 NMR spectrum revealed calcium induced tertiary structure changes in CaSR ECDs
Disruptance of chemical shift can be used to monitor the interaction between metals and the
protein due to the sensitivity of the chemical shifts of protein amides to even dimunative
conformational changes occurring at the interacting interface. As depicted by Tb3+ binding
process, as well as the ANS fluorescence, a multiple binding process can be observed in both the
one-dimensional (1D) (Figure 6.10) and two-dimensional (2D) NMR (Fig. 6.11) when calcium
was titrated into both

15

N L-Phe labeled WT CaSR ECD and

15

N L-Phe labeled Lec1 mutant

CaSR ECD. The chemical shift changes for each protein are shown in Figure 6.11. During the
titration, a progressive disappearance of the amide signals at 8.05 ppm of the WT CaSR ECD
was accompanied by the concomitant emergence of a new set of peaks at 7.85 ppm as well as a
chemical shift between amide signal at 7.95ppm and 8.21ppm which move towards each other
upon titration of Ca2+ (Figure 6.11 a,b.&c), indicating complex binding states.

The chemical shifts of the peaks were further plotted into calcium response curves as shown in
Figure 6.11. The calcium induced conformational changes revealed a 1:1 ligand-protein complex
formation process, Figure 6.11 left panel. In agreement with data from fluorimetric systems, the
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binding constant was in the millimolar range (1.1 mM). Meanwhile, the analysis on the peaks in
Figure 6.11c suggested a slow exchange process in which the exchange rate of the bound and
unbound conformation could not catch up with the amide frequency. The Ca2+-concentration
response curve indicated a multiple ligand binding process with a Kd at 2.5 mM and a Hill
number at 2.5.

The Lec1 mutant CaSR ECD with its high mannose form demonstrated a less dispersed 2D
spectrum after the addition of calcium. A few peaks appeared with the addition of 3 mM calcium
with characteristics as slow chemical exchanges indicate a strong binding process (Figure 6.12).

Figure 6.10 Ca2+ titration of CaSR ECD monitored by 1D 1H NMR.
(a) Ca2+-induced, gradual chemical shift changes in WT CaSR ECD were observed at
resonances in the main chain amide proton region, such as 7.35 and 8.42 ppm . (b). Ca2+induced, gradual chemical shift changes in Lec1 CaSR ECD were observed at resonances in
the main chain amide proton region, such as 7.40 and 8.40 ppm
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Figure 6.11 (1H,15N)-HSQC spectra of WT CaSR ECD.
Left panel: Ca2+-induced chemical shift changes of WT CaSR ECD. Red: WT CaSR ECD
without addition of Ca2+; Orange: 1 mMCa2+; Yellow: 3 mM Ca2+; Green: 5 mM Ca2+; Cyan:
10 mM Ca2+. Right panel: Ca2+- chemical shift curves of peak b and peak c in WT CaSR
ECD fitted by the Hill equation.
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Figure 6.12 (1H, 15N)-HSQC spectra of Lec1CaSR ECD.
Ca2+-induced chemical shift changes of Lec1 CaSR ECD. Orange: Lec1 CaSR ECD with 5
M EGTA; Cyan: Lec1 CaSR ECD with 1 mM Ca2+
6.2.8 The binding of L-Phe to the CaSR ECD can be modulated by Ca2+
The protein yield of 15N-labeled Lec1 mutant CaSR ECD was much lower compared with 15Nlabeled WT CaSR ECD. Therefore, the application of the heteronuclear single quantum
coherence (HSQC) NMR to monitor the protein-ligand interaction with the purified 15N-labeled
Lec1 mutant CaSR ECD will be fraught with pitfalls. Recently, saturation transfer difference
(STD) NMR has become a popular NMR technique in terms of analyzing protein-ligand
interactions due to the fact that it detects the signals from the ligands and only small amount of
nonlabeled proteins or macromolecules are required. As shown in Figure 6.13, the NMR signal
change from the L-Phe STD spectrum indicated the conformational change of this CaSR positive
allosteric regulator during the interaction with CaSR ECD (Figure 6.13). This phenomenon
provides direct evidence to support the earlier hypothesis that L-Phe can bind to the extracellular
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domain of CaSR with a Kd at 4.7~6.5 mM (Figure 6.13a&b). Intriguingly, the addition of 2.5
mM calcium decreased the signal from L-Phe STD spectrum, suggesting the interaction between
Ca2+ and the receptor may influence the binding between L-Phe and the CaSR ECD (Figure 6.13
c&d).

Figure 6.13 Monitoring the ligand-protein interaction via STD NMR.
(a) STD spectrum of L-Phe titration to the CaSR ECD in the absence of Ca2+. The
increased L-Phe concentration is indicated in the figure. (b) STD spectrum of L-Phe
titration to the CaSR ECD in the presence of Ca2+. (c) The overlaid 1.0 mM L-Phe STD
spectra in the presence of Ca2+ (cyan line) and in the absence of Ca2+(red line). (d) The
intensity of the three major peaks shown in panel c was integrated respectively and further
plotted against L-Phe concentration. The plots were further fitted by a 1:1 binding
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equation. The blue line represents the left peak, red for the middle one and black for the
right one.
6.3 Discussion
It has been suggested that the ECD of the mGluRs and CaSR share similar Venus Fly Trap
structures based on several conserved amino acid regions and predicted secondary structures
(216). However, there is limited structural and biochemical information available for CaSR due
to its large molecular weight (~70 kDa as monomer) and heterogeneous glycosylation. In the
present study, we were able to purify CaSR ECDs from both normal mammalian expression
systems and the complex N-glycans deficient expression system. In the two systems, the target
protein was expressed by mammalian cells and was secreted into the cell culture media due to a
signal peptide at the beginning of the ECD sequence. It is known that CaSR functions as a dimer
on the surface of the cell membrane. Importantly, the secreted ECD proteins from both the
complex glycan and the homogenous high mannose form also present in the culture medium as a
dimer form.

Glycosylation is one of the most important posttranslational modifications occurring in protein
biosynthesis and secretary pathways. The secreted WT CaSR ECD was well glycosylated as it
can bind with lectin agarose beads and the treatment with PNGase reduced its molecular weight.
The Lec1 hCaSR ECD can be further cleaved by Endo F1 but it could not interact with the lectin
beads. The thermodynamic stability calculations indicate that the stability of a protein may be
enhanced when a glycan is covalently bound to the protein surface, which can be measured by an
increase in melting temperature (292). A stabilization by glycosylation has been reported for
other membrane proteins such as AQP2 mutants (293) and a shaker potassium channel (294).
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How the glycosylation could affect the biophysical properties of CaSR or other family C GPCR
proteins has yet to be analyzed. In the present study, the influence of the complexity of
polysaccharide on the thermal stability of CaSR-ECD is remarkable. The ECD protein with
heterogeneous saccharides was able to maintain its secondary structure at high temperature (>
90C). On the other hand, the CaSR ECD with homogenous glycan was comparatively less
stable. These phenomena would be importantly contributed to the differences of protein tertiary
structures altered by the post-translational modification since their secondary structures were
relatively similar.

Calcium, as a predominant agonist for CaSR, is believed to induce conformational changes of the
receptor to convey the extracellular signal to intracellular messengers. However, the lack of
evidence to prove such a change makes it worthwhile to analyze alteration of the receptor’s
biophysical characteristics before and after the Ca2+ binding. One of the biophysical changes on
CaSR, upon the interaction with Ca2+, is the thermal stability of its ECD. The addition of calcium
altered the structural stability of CaSR-ECD, resulting in loss of the secondary structure at much
lower temperatures. Another possible interpretation is the positive charges of the metal
accelerate the aggregation of the protein at higher temperatures. Different changes in enthalpy
corresponding to different states, measures a change in the strength of the interactions between
molecules (295). The enthalpy change of Lec1 CaSR ECD, measured in the present study, is
comparable to the results from previous subdomain studies in our lab (172), confirming the weak
binding of Ca2+ to the CaSR ECDs. These lines of evidence are also in line with results from
tryptophan spectra, as well as the ANS assay, regarding the metal-binding capability.
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The results in the present study suggested that the full length of WT CaSR ECD has Ca2+ binding
affinities (3.5~3.7 mM) comparable with the EC50s calculated from CaSR functional assays
(2.7~3.1 mM). The high mannose form of the CaSR ECD showed similar Ca2+ binding capability
as the complex N-glycans form. This indicates that the additional post-translational modification
did not impose large structural changes on the protein. There are twelve tryptophan residues in
the ECD, among them four are on the molecular surface between lobes 1 and 2. The decrease of
tryptophan intensity might be explained by a closed form of the receptor resulting from calcium
binding which could lead to a more imbedded position of those tryptophan residues. On the other
hand, the signal from the ANS spectrum decreased upon titration with Ca2+ suggesting the
ligand-induced exposure of more hydrophobic regions of the protein to interact with the ANS
probe. The Ca2+ induced ANS signal increase of the WT CaSR ECD was larger than with the
Lec1 CaSR ECD which indicated that the glycans on the WT CaSR ECD might contribute to the
hydrophobicity changes in the protein triggered by Ca2+.

Functional studies of the CaSR in cells, as well as our previous metal binding studies, using
grafting approaches have demonstrated that the CaSR has multiple Ca2+-binding sites (87). The
Hill coefficients of both the WT CaSR ECD and its Lec1 mutant, calculated from calcium
induced spectrum changes in the current study (2.2~4.0), were also in agreement with the
multiple Ca2+ binding modes. In our lab’s previous studies, when titrated with Tb3+, CaSR ECD
subdomain 1, which includes predicted Ca2+ binding site 1, site 2 and site 3, showed biphasic
binding processes while subdomain 2 (including Ca2+ binding site 2 &3) and subdomain 3
(including Ca2+ binding site 4 &5) had monophasic responses to Tb3+. However, in the present
studies, the fitted Tb3+-response curve for the WT and Lec1 CaSR ECD did not show an
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observable cooperative binding curve. It could possibly be due to the fact that in the grafting
approaches, the subdomains were not constrained by the additional structural conformations as it
would be when they are in the intact ECD structure. Concomitantly, the CaSR ECDs had much
stronger binding affinities for Tb3+ than for Ca2+ with Kds at M range. Thus the differences
between potentially weak metal-binding sites may not be detected. Moreover, the intensive
FRET signal between Tb3+ and more than one Trp residues might produce an overall strong
signal hiding behind the possible cooperativity among these metal binding sites. There are more
than 30 Phe on the ECD of CaSR, however, limited peak numbers were detected using a 900
MHz magnet, suggesting similar local environment for multiple Phe residues. Data from NMR
spectra indicated that the local environment around several Phe residues had been changed
during the calcium titration process in various ways, supporting that CaSR ECDs may interact
with calcium cooperatively.

Calcium-induced conformational changes in the intact CaSR ECD were observed in both
fluorescence and NMR spectra. Such conformational changes are fundamental initial signals for
activation of the CaSR and transduction of these signals to the cytoplasm, calling on numerous
downstream molecules that are involved in critical signaling cascades and resulting in the
regulation of numerous processes, such as the control of parathyroid hormone (PTH) secretion.
The ligand triggered tertiary structure alterations in the extracellular domain have been observed
in other GPCR family C members. Kunishima et al. have reported ligand-bound forms and
unliganded forms of mGluR1, showing alterations in the bi-lobed protomer architecture
associated with the receptor’s active and resting status through the modulation of the dimeric
interface by a packed -helical geometry (175). Ligands stabilize the mGluR1 in the active form
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by maintaining the closed bi-lobed receptor structure as the dominant form in the receptor’s
dynamic equilibrium between open and closed state. Although the changes from the Trp
spectrum and the ANS probes may, in a way, support a wrapped form of the CaSR, mutagenesis
work on the CaSR ECD will still be necessary in order to assign the peaks of the NMR spectra.
Only by gathering the detailed information about the authentic structural movements of the
CaSR, will we understand whether correcting the deviations from homeostatic balance is via
modulating the “open” and “close” form of the CaSR.

Overall, the present study provides further insights into the structure-function relationships for
the CaSR and should permit further studies to define which are the key residues involving the
interaction with the ligands for this receptor, including cations, nutrient amino acids, as well as
antibiotics. This information will be crucial to understanding how CaSR responds to variety of
stimuli and pave the way for future research works on this and other members in GPCR family C.
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CHAPTER 7. COMPARISON OF BIOPHYSICAL CHARATERISTICS OF BACTERIA
AND MAMMALIAN EXPRESSED CASR ECD
7.1 Introduction
Prokaryotic expression systems have been widely used in scientific research. It is considered
as one of the most efficient and economic ways to produce proteins. Among various prokaryotic
expression systems, including Escherichia coli (E.coli), Lactococcus lactis and other bacteria,
(e.g. Bacillus species) E.coli is the most proficiently explored organisms and has been
prevalently applied for heterologous expression of proteins (molecular biology and genomics
pg.191).
The advantages of the bacterial expression system are multifaceted. Firstly, bacterial cells
have simple physiology compared with eukaryotic cells so they are relatively easy to culture.
Secondly, their short generation time makes them grow and multiply much quicker than
eukaryotic cells, which is a characteristic favorable to large scale expression of recombinant
proteins. Moreover, it is inexpensive to culture bacterial cells. Last, but not least, the posttranslational modification in bacteria cells is different with eukaryotic cells, such as
glycosylation, the most common post-translational modifications.(296). Thus, the bacterial
expression is widely applied in protein isotopic labeling methods and the produced homogenous
samples allow structural related studies using NMR.
A number of GPCR proteins have been expressed using bacterial systems. Link et. al. have
expressed two proteins, cannabinoid receptor (CB1) and bradykinin receptor 2 (BR2), in E.Coli
system using the shake flasks culture method (297). Four GPCRs, namely chemokine receptors
(hCRs) CCR5, CCR3, CXCR4 and CX3CR1, have been discovered to be involved in HIV-1
infection, asthma and cancer metastasis. These proteins have recently been purified using a

190
bacterial system for biochemical, biophysical as well as structural studies (298). In 2013, the
functional N-terminal domain of the T1R3 taste receptor was expressed using an E. coli system
by Maitrepierre et. al (299). Similar to CaSR, T1R3 taste receptor also belongs to GPCR family
C, the successful purification of functional T1R3 taste receptor suggested feasibility to express
CaSR ECD in E. coli.

Along with the advantage in utilizing E.coli, there are also several disadvantages intrinsic to the
prokaryotic system. First, the expressed proteins may not fold properly and thus lose its
biological activity. Misfolding of disulfide bonds are one of the frequent errors observed in
manipulation with prokaryotic expression. Second, the synthesized protein, especially exogenous
protein, can be toxic to bacteria. Decreasing the bacteria cell number and/or degredation of the
expressed protein can be the following consequences. Additionally, the lack of post-translational
modification can work as double-edged sword. Protein expressed from a bacteria system is not
attached with sugar residues, which may affect its in vitro functional studies

In this chapter, the ECD of CaSR was expressed using a bacteria system (bCaSR) and was
further purified through affinity columns. The biophysical properties of the native CaSR ECDs
were characterized using the fluorescence titration spectroscopy, circular dichroism technique as
well as the NMR spectrum.
7.2 Results
7.2.1 Expression of triple labeled and non-labeled CaSR ECD in bacteria system.
The non-labeled human CaSR ECD was expressed overnight at 30C using the Rosetta-gami
(DE3) pLys bacteria strain. Since the Rosetta-gami (DE3)pLys strain does not grow or express
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well in minimum growth medium, the triple labeled protein was expressed in the Tuner strain.
Those His-tagged CaSR ECDs were efficiently separated from other proteins with a HisPrep
column using an imidazole gradient. The fractions containing CaSR ECD were collected and
revealed by SDS-PAGE under reducing conditions (Figure. 7.1a &b). Immunoblot was further
applied to verify the samples using specific anti-CaSR antibody. As shown in Figure 7.1 c&d,
the bacterial expressed CaSR ECD (bCaSR ECD) showed a clear band at around 72 kDa, which
is close to its predicted molecular weight (70 kDa). Moreover, the bCaSR ECD can not interact
with Ricinus communis agglutinin I agarose beads, which preferentially binds to
oligosaccharides, suggesting that the bCaSR ECD has minimal glycosylation modification
compared with its mammalian expressed counterpart (Figure 7.1 e). Unlike the mammalian
expressed CaSR ECD, the bCaSR ECD forms high-order polymers instead of dimer under a nonreducing environment. It is also worthwhile to notice that the bCaSR ECD was less stable when
compared with ECD expressed from mammalian cells, as there were multiple degradation bands
below 72 kDa.
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Figure 7.1 Bacterial expressed CaSR ECD isolated by FPLC is non-glycosylated
a: WT bCaSR ECD was expressed in Rosetta-gami (DE3) pLys at 30C. The cell pellet was
collected and the soluble protein was extracted by a cell disruptor. After centrifugation, the
supernatant fraction of the cell lysate then underwent protein purification procedure using
a nickel affinity column. Representative tracing of A280 measured in milli AU for protein
eluted by imidazole. Inset: Coomassie blue staining of the representative fractions from the
affinity column separation. b: The same chromatography of protein purification using
triple labeled 15N13C2D WT bCaSR ECD expressed in Tuner at 30C. c: WT bCaSR ECD
protein (50 g) from indicated fractions were incubated at 100 °C in sample dissociation
buffer containing -mercaptoethanol 5 mins before loading on the SDS gels. The band of
bCaSR ECD was detected using anti-flag antibody. d: the same treatment as (a) but with
triple labeled bCaSR ECD proteins e: WT bCaSR ECD protein (0.5 mg) was incubated
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with RCA-1 lectin agarose beads overnight at 4

followed by a washing step with PBS.

Lane 1: Elution fraction from FPLC as input protein. Lane 2: Elution fraction using PBS
containing 200 mM galactose. Lane 3: 5 l of the RCA-1 lectin agarose beads after
incubating with protein were load into the gel. The elution fractions were further analyzed
by immunoblot using anti-flag antibody.

7.2.2 Fluorescence spectra indicate folded structure of the bCaSR ECD

There are twelve tryptophan (Trp) residues on the bCaSR ECD, thus, by analyzing the intrinsic
tryptophan emission spectra from 300 to 400 nm at the excitation wavelength of 282 nm, the Trp
environment can be monitored. The emission spectrum of free Trp has a peak at around 350 nm.
The emission peak undergoes blue-shift if the tryptophan is embedded in the hydrophobic
environment. As shown in Figure 7.2, bCaSR ECD showed a peak at around 334 nm indicating
that the proteins are retained in their native structure (solid line).

Meanwhile, ANS, a fluorescence probe extensively used for the detection and analysis of protein
conformational changes, was applied to the study of bacterial expressed CaSR ECD in the same
way as in the application to the mammalian expressed proteins mentioned in Chapter 6. This dye
has low fluorescence yield when exposed to polar environments, but a blue shift of the emission
spectrum and an increase of the fluorescence intensity would occur once its fluorophore relocates
into a less polar media (291). Compared to the free ANS dye, which has an emission peak at
around 500 nm, the ANS fluorescence spectra of the bCaSR ECDs underwent a more than 30 nm
blue shift and further exhibited a 10 fold increase in fluorescence intensity (Figure 7.3). The

194
results from the ANS spectra thus correlates with the Trp spectrum in terms of demonstrating the
purified ECD from the bacterial system was at least partially folded.

Figure 7.2 Tryptophan fluorescence titration of CaSR ECDs.
Trp fluorescence spectra of WT CaSR ECD in the presence of 0 (---) and 139 M Ca2+ (—).
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Figure 7.3 Ca2+-induced changes in ANS fluorescence in bCaSR ECDs.
ANS fluorescence spectra of CaSR ECD in the presence (—) or the absence of (---) 1 mM
Ca2+. The spectrum of ANS alone is shown in gray.

7.2.3 Calcium induced little secondary structure change of the bCaSR ECD.

In order to analyze the secondary structure of the bacterial expressed protein, the far-UV circular
dichroism measurements were performed as shown in Figure 7.4. Analysis of all the spectra
indicated that the purified bCaSR ECD shared similar secondary structure with CaSR ECD
expressed from a mammalian expression system, possessing  helical content of 47%~58% and
-sheet content of 17% ~27%. The addition of 200 M calcium did not change the spectrum of
bCaSR ECD significantly (Figure 7.4).
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The proteins were subjected to step-wise increasing temperatures to measure the thermal stability.
The molar ellipticity signal was monitored from 4~95 C at 222 nm, which is considered to be a
sensitive position for proteins that have >50% of the  helical structure. As shown in Figure 7.4,
the melting point (Tm) of bCaSR ECD is around 80 C in the absence of calcium. Interestingly,
in the presence of Ca2+, the melting point of bCaSR ECD was dramatically dropped to 55C and
80C respectively. The heat denaturation is irreversible as the high temperatures lead to the
formation of precipitation of the bCaSR ECD. In the presence of 200 M Ca2+, the tendency of
protein precipitation at lower temperatures was seen.

Figure 7.4 Circular Dichroism measurement of purified ECD in the presence or absence of
calcium.
Left panel: Far-UV CD spectrum of bCaSR ECD in 10 mM Tris, pH 7.2 with or without
200 M Ca2+, at 25

. Right panel: Temperature dependence of the molar ellipticity at 222

nm for bCaSR ECD in 10 mM Tris, pH 7.2. In the presence of 200 M Ca2+, bCaSR ECD
tended to form precipitants.
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7.2.4 Metals induced conformational changes in bCaSR ECD
As shown in Figure 7.2 & 7.3, the addition of Ca2+ leaded to changes in both the Trp
fluorescence and the ANS spectrum. Binding to Ca2+ resulted in 2~3 nm blue shift of the
emission maximum on the Trp fluorescence spectrum of the bCaSR ECD. Futhermore, similar to
mammalian expressed CaSR ECDs, a decrease of 17% in Trp fluorescence intensity in bCaSR
ECD was observed upon the addition of saturating amounts of Ca2+. Compared to the calcium
induced signal changes on the Trp spectra, the ANS intensity alterations upon Ca2+ titrations
rendered different patterns between the proteins generated from the two expression systems. For
bCaSR ECD, calcium caused less hydrophobic areas interacting with ANS, resulting in a 34%
decrease of the fluorescence peak value; on the contrary, it induced exposure of more
hydrophobic regions in the complex oligosaccharides form (WT hCaSR ECD) as there was a 25%
increase in the fluorescence signal. Similar intensity enhancements, though to lesser extents
(~10%), were detected in Lec1 hCaSR ECD (Figure 6.7).

The calcium induced conformational changes reflected in the Trp spectra were further assessed
by monitoring the calcium titration processes. The calcium titrating bCaSR ECD step could be
fitted by the Hill equation with a dissociate constant (Kd ) of 0.8 ± 0.2 mM and a Hill coefficient
of 1.1 ± 0.2, indicating a similar 1:1 binding process as bCaSR ECD (Figure 7.5). Meanwhile,
the calcium induced ANS spectra alterations were also fitted by the Hill equation. The Kd of
bCaSR ECD measured via ANS spectra was 0.9 ± 0.2 mM with a Hill coefficient of 1.1± 0.2.
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Figure 7.5 Ca2+-induced changes in native tryptophan and ANS fluorescence
(a.) Left panel: Trp fluorescence spectra of WT bCaSR ECD in the presence of 0.0 (---)
and 2.0 mM Ca2+ (—). Right panel: Calcium titration curve of WT bCaSR ECD. The
fluorescence intensity was normalized to the initial read-out when the calcium
concentration was 0.0 mM and further plotted against calcium concentration. The plot was
fitted using the Hill equation. (b.) Left panel: ANS fluorescence spectra of CaSR ECD in
the presence (—) or the absence of (---) 1 mM Ca2+. The spectrum of ANS alone is shown in
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gray. Right panel: Calcium titration curve of WT bCaSR ECD. Curve was fitted as
mentioned above.

Considering the potential background Ca2+ in the buffer, which might affect the accurate
measurement of binding affinity, the metal binding capability of bCaSR ECD was further
analyzed using Tb3+ luminescence resonance energy transfer (Tb3+-LRET). There are 13 residues
on the bCaSR ECD and according to the modeled structure of the CaSR ECD, some of the Trp
residues are within 10 Å of those potential calcium binding pockets, thus enabling the aromatic
residue-sensitized Tb3+-LRET. Due to their similarities in ionic radii and coordination chemistry,
Tb3+ has been ubiquitously used to probe Ca2+ binding sites as a trivalent Ca2+ analogue. The
advantages of using Tb3+ have been elucidated earlier in Chapter 6. The Tb3+ binding processes
of the bCaSR ECD turned out to be one binding step instead of a biphasic process as observed in
the subdomain studies (Huang 2009). The Tb3+ binding affinity for bCaSR ECD was about 5.1 ±
0.3 M with a Hill coefficient of 1.2 ± 0.2 (Figure 7.6). The Ca2+-Tb3+ competition assay gave
the apparent dissociation constant for the ECD. For bCaSR ECD, the Ca2+ binding dissociation
constant calculated from Ca2+-Tb3+ competition assay using equation 2 was 38.4 ± 2.2 M
(Figure 7.7).
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Figure 7.6 Tb3+ titration curve of bCaSR ECDs.
Tb3+ titration curve of purified CaSR ECDs. The buffer for Tb3+ titration consisted of 20
mM PIPES, 10 mM KCl (pH 6.8).The arrow indicates the increase of the fluorescence with
increasing [Tb3+]. The titration curve was fitted using Hill equation.

Figure 7.7 Tb3+ competition assay of CaSR ECDs.
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Tb3+-Ca2+ competition assay of purified bCaSR ECD. The buffer for Tb3+ titration
consisted of 20 mM PIPES, 135 mM NaCl, and 10 mM KCl (pH 6.8). The arrow indicates
the decrease of the fluorescence with increasing [Tb3+].

7.2.5 NMR spectrum revealed calcium induced tertiary structure changes in bCaSR ECD.

The fluctuationsin the chemical shift can be used to monitor the interaction between metals and
the protein due to the sensitivity of chemical shifts of protein amides to even subtle
conformational changes occurring at the interacting interface. Figure 7.8 depicts the onedimensional (1D) NMR of the N15 labeled bCaSR-ECD expressed from the Tuner strain. The
proton signal from the aromatic group and side chain HN (chemical shift from 8 ppm~6ppm)
indicated that the bacterial protein was at least partially folded. However, the large size of the
protein (72 kDa) may also influence the resolution as well as the dispersion of spectrum.
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Figure 7.8 1D 1H spectrum of 15N labeled bCaSR ECD.
The bCaSR ECD was expressed in the Tuner Strain at 25C. The protein sample was
prepared in 10 mM Tris buffer with pH at 7.4. The NMR spectrum was collected from an
800 MHz magnet.

The chemical shifts observed in the 2D spectrum of bCaSR-ECD showed a more
complicated pattern compared with the mammalian expressed ECDs. The calcium induced
chemical shift changes suggested multiple binding processes instead of 1:1 binding as
demonstrated in fluorescence spectroscopy. As shown in Figure 7.8, the concentration
bCaSR ECD is constantly maintained at 100 M while the calcium concentration is
increased stepwise. When the ratio of protein concentration versus [Ca2+] equals 1:4, the
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spectrum appeared similar as the ratio was 10:1. The spectrum of 1:0 is similar to the one
with 1: 1 (Figure 7.8).

Figure 7.9 (1H,15N)-HSQC spectra of bCaSR ECD with Ca2+ titration.
15

N labeled CaSR ECD was expressed in the Tuner strain at 25C. The sample was initially

prepared in 10 mM Tris buffer with a pH at 7.2. Calcium was introduced to the system
stepwise before each scan of the HSQC spectra using a 900 MHz NMR instrument.
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7.2.6 Optimization for the expression condition of CaSR ECD

Due to the fact that the bacterial expressed CaSR ECD tends to degrade within a short time,
efforts have been made to optimize the expression conditions using different cell strains,
temperature, as well as expression time. By collaborating with Dr. Jian Hu from Michigan State
University, we designed mutations on several cysteine residues and changed the rare codon in
the human CaSR sequence. The optimized CaSR ECD sequence was then synthesized from the
Genscript Company. Figure 7.10 shows the sequence alignment of the CaSR among different
species.
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-----------------------------MAFYSCCWVLLALTWHTSAYGPDQRAQ----------------------------MNPLTGLVPPLLFLLCLVPHGSAYGPDKRAQ--------------------------------MRFYLYYLVLLGFSSVISTYGPHQRAQ--------------------------------MRLLLYYLTLLGSSYVISTYGPHQRAQ---MNFGAGLRTGSRNGNEKWKRMTFCRSSAFCHMFSSTLYLISSMARHAVVLRAGACQLQGR
-------------------------------MIPNTMPVLE------------------:
::
60
-------KKGDIILGGLFPIHFGVAAKDQDLKSRPESVECIRYNFRGFRWLQAMIFAIEE
-------KKGDIILGGLFPIHFGVASKDEDLESRPESLECVRYNFRGFRWLQAMIFAIEE
-------KTGDILLGGLFPMHFGVTSKDQDLAARPESTECVRYNFRGFRWLQAMIFAIEE
-------MTGDILLGGLFPLHFGIASKDQDLAARPESTQCVRFNFRGFRWLQAMIFAIEE
FRLNGMYQDGDVILGGLFEAHFFTLFPELTFRTEPAPPYCEIFNMESFQYAQTMAFAINE
-------KKGDIILGGLFSLHDMVEEQSLPFTSHPPKSKCTRFNFRTFRWMQTMIFAIEE
**::***** *
. : :.*
* :*:. *:: *:* ***:*
101
129131
INSSPALLPNLTLGYRIFDTCNTVSKALEATLSFVAQNKIDSLNLDEFCNCSEHIPSTIA
INSSPTLLPNITLGYRIFDTCNTVSKALEATLSFVAQNKIDSLNLDEFCNCSEHMPSTIA
INNSSTLLPNITLGYRIFDTCNTVSKALEATLSFVAQNKIDSLNLDEFCNCTDHIPSTIA
INNSSTLLPNITLGYRIFDTCNTVSKALEATLSFVAQNKIDSLNLDEFCNCTDHIPSTIA
INRNPSLLPNISLGYHLYDNCVMLGMALRAAMSLVSGIEES----FLNLNCTGPPP-IIG
INKEGKLLPNITVGYKIYDSCSTPHQALKAAMELMGGEKSSEVGEKTQRNSTCNES-VPL
** . ****:::**:::*.*
**.*::.::. : .
*.:
.

27
31
27
27
60
10

VVGATGSGVSTAVANLLGLFYIPQVSYASSSRLLSNKNQFKSFLRTIPNDEHQATAMADI
VVGATGSGVSTAVANLLGLFHIPQVSYASSSRLLSNKNQYKSFLRTMPNDEHQATGMADI
VVGASGSAVSTAVANLLGLFYIPQISYASSSRLLSNKNQFKSFMRTIPTDEHQATAMADI
VVGAAGSAVSTAVANLLGLFYIPQISYASSSRLLSNKNQYKSFMRTIPTDEYQATAMADI
VVGDPSSTPSIAISSVLGLFRVPIVSHYATCSCLSDRKKYPSFFRTIPSDAFQVRAMIQL
VIGDGGSTQSLVVARFLGVFTVPQISYFSSCACLSDKKQFPAFLRTMPSDFFQVDALVQL
*:* .* * .:: .**:* :* :*: ::. **::::: :*:**:*.* .*. .: ::
236
IEYFRWNWVGTIAADDDYGRPGIEKFREEAEERDICIDFSELISQYSDEEEIQHVVEVIQ
IEYFQWNWVGTIAADDDYGRPGIEKFREEAEEREICFDFSELISQYMEEEEIDRVASVIQ
IDYFQWNWVIAVASDDEYGRPGIEKFEKEMEERDICIHLSELISQYFEEWQIQGLVDRIE
IEYFQWNWVIAVASDDEYGRPGIEKFENEMEERDICIHLNELISQYFEDHEIKALVDRIE
ISHFGWTWIGLLYSDDDYGTYAAQSFHQEMQLFGFCIAFSEPLRYDSNPRDIQRLMEVIQ
VKHFGWTWVGVIAGDDAYGRGGANIFANEVTNLGVCIAFHRIIPKNRQQAEILSIISVIR
:.:* *.*: : .** ** . : * :*
.*: : . :
: :* : . *.

200
204
200
200
235
182

80
84
80
80
120
63

140
144
140
140
175
122

260
264
260
260
295
242
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NSTAKVIVVFSSGPDLEPLIKEIVRRNITGKIWLASEAWASSSLIAMPQ-YFHVVGGTIG 319
NSTARVIVVFSSGPDLEPLIKEIVKRNITGRIWLASEAWASSSLIALPN-FFDVMGGTIG 323
NSSAKVIVVFASGPDIEPLIKEMVRRNITDRIWLASEAWATTSLIAKPE-YLDVVVGTIG 319
NSTAKVIVVFASGPDVEPLIKEMVRRNITDRIWLASEAWAISSLVAKPE-YLDVMAGTIG 319
ASTSTVVVVFSPSTLVIPLMNEVVLQNMTGRQWIASESWATSPVFYTPR-FLPFLGGTLG 354
LSGAKVILVFAVEQDAAALFDEVQRSELTGIQWLASEAWSTAAVLSTPEKYHNILQGTVG 302
* : *::**:
.*:.*:
::*. *:***:*: :.:. *. : .: **:*
358
FALKAGQIPGFREFLKKVHP--RKSVHNGFAKEFWEETFNCHLQEGAKGPLPVDTFLRGH 377
FALRAGQIPGFREYLRNVNV--KMSNVNGFLKEFWEETFNCHLPS---KSLSSPSSFMGS 378
FALRAGEIPGFKDFLQEVTP--KKSSHNEFVREFWEETFNCYLED--------SQRLRDS 369
FALKAGRIPGFREFLQHVQP--KKDSHNEFVREFWEETFNCYLED--------SPRFQES 369
IAIRRGEIEGLREFLLQLRP-KNDPRNN-MLKIFWENMFGCSF----------------- 395
FAIQQANIPGLRDFLLRLNPSRSDAQTDPFLVSFWEEVFQCSLGV--------------- 347
:*:: ..* *::::* .:
: :
***: * * :
395
437
EESGDRFSNSSTAFRPLCTGDENISSVETPYIDYTHLRISYNVYLAVYSIAHALQDIYTC 437
PEDPNRWGNSS-SFRLPCSGKENISSVETPYLDFTHLRISYNVYLAVYSIAYALQDIYSC 437
E-------NGSTSFRPLCTGEEDIMGAETPYLDYTHLRISYNVYVAVHSIAQALQDILTC 422
E-------NGSTSFRPLCSGEEDIASVETPYLDYKHLRISYNVYVAVYSIAQALQDILTC 422
--------ETGPHVKNVCTGQEDLSTTNTPYTDVSELRAANNVYKAVYALAHALHDLMKC 447
---QTESREKEGESKPPCSGKEDLGNVTNIYSDVSQLRISYNVYKAVYAVAYALKAMKSC 404
:
: *:*.*:: . . * * ..** : *** **:::* **: : .*
449
482
LPGRGLFTNGSCADIKKVEAWQVLKHLRHLNFTNNMGEQVTFDECGDLVGNYSIINWHLS 497
TPGKGLFANNSCADIKKVEAWQLLKHLRHLNFTNNMGEQVDFNDSGDLVGNYSIINWHLS 497
IPGRGLFSNNSCADIKKIEAWQVLKQLRHLNFSNSMGEKVHFDENADPSGNYTIINWHRS 482
TPGRGLFANNSCADIKKMEAWQVLKQLRHLNYTNSMGEKMRFDENSDMEANYTIINWHRS 482
EEGKGPFSKNSCAEISNLKPWQLVHYLQKVNFSTRFGDHVSFNKNGDALAIYDVMNWQPG 507
VKGEGPFFQRSCADPDVIQPWQLLHYLKQVQYLNSFASEIKFDENGDPAAMYDLVNWQMN 464
*.* * : ***: . ::.**::: *::::: . :...: *:. .* . * ::**: .
PEDGSIVFKEVGYYN-VYAKKGERLFINEEKILWSGFSREVPFSN----CSRDCLAGTRK
QEDDSIVFEEVGYYN-VYAKVGERLFINESKILWNGFSREVGAGQEGLGAGQEGLGAGQK
PEDGSVVFEEVGFYN-MRAKRGVQLFIDNTKILWNGYNTEVPFSN----CSEDCEPGTRK
TEDGSVVFEEVGYYN-MHAKRGAKLFIDRTKILWNGYSTEVPFSN----CSEDCEPGTRK
S-DRSIRIHTVGVVS-EELEKGLMLTLDEDAIYWNFETKKPPQSV----CSESCPRGSRR
P-NGKIEFINIGKFDGMTGDVKQKLYIHEDIILWNGNRTRVPLSV----CSTICPPGTRK
: .: : :* .
.
* :.. * *.
.
.
..
. ::

Figure 7.10 Sequence alignment of CaSR ECD among different species.

552
556
537
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Predicted secondary structures of CaSR are highlighted in colors. Red: Helix structure;
Blue: Strand. Conserved Cysteines are highlighted in yellow; Green labeled cysteines are
cysteines unique in the CaSR ECD.

Cysteines are generally considered to be important in the disulfide bond formation and protein
folding. In order to facilitate the correct protein folding, we mutated non-conservative cysteines
and cysteines that are involved in intermolecular dimerization to alanines (Figure 7.11). Six
cysteines involved in three pairs of intramolecular disulfide bonds are kept in the sequence.
Query METABOTROPIC GLUTAMATE RECEPTOR SUBTYPE 1 (PDB: 1EWV)
Sbjct Human CaSR

Query 7
Sbjct 26
Query 60
Sbjct 84

ARMDGDVIIGALFSVHHQPPAE-----KVPER-KCGEIREQY-GIQRVEAMFHTLDKINA 59
A+ GD+I+G LF +H
A+
PE +C IR + G + ++AM +++IN+
AQKKGDIILGGLFPIHFGVAAKDQDLKSRPESVEC--IRYNFRGFRWLQAMIFAIEEINS 83
DPVLLPNITLGSEIRDSCWHSSVALEQSIEFIRDSLISIRDEKDGLNRCLPDGQTLPPGR 119 disordered Cys
P LLPN+TLG I D+C S ALE ++ F+ + I + + N C
+ +P
SPALLPNLTLGYRIFDTCNTVSKALEATLSFVAQNKIDSLNLDEFCN-C---SEHIPS-- 137

Query 120 TKKPIAGVIGPGSSSVAIQVQNLLQLFDIPQIAYSATSIDLSDKTLYKYFLRVVPSDTLQ 179
V+G S V+ V NLL LF IPQ++Y+++S LS+K +K FLR +P+D Q
Sbjct 138 ----TIAVVGATGSGVSTAVANLLGLFYIPQVSYASSSRLLSNKNQFKSFLRTIPNDEHQ 193

May be involved in dimerization,
but disordered in 1EWV

Query 180 ARAMLDIVKRYNWTYVSAVHTEGNYGESGMDAFKELAAQEGLCIAHSDKIYSNAGEKSFD 239 (free Cys)
A AM DI++ + W +V + + +YG G++ F+E A + +CI S+ I + E+
Sbjct 194 ATAMADIIEYFRWNWVGTIAADDDYGRPGIEKFREEAEERDICIDFSELISQYSDEEEIQ 253
Query 240 RLLRKLRERLPKARVVVCFCEGMTVRGLLSAMRRLGVVGEFSLIGSDGWADRDEV-IEGY 298
++ ++
A+V+V F G + L+ + R + G+ L S+ WA
+ + Y
Sbjct 254 HVVEVIQNS--TAKVIVVFSSGPDLEPLIKEIVRRNITGKIWL-ASEAWASSSLIAMPQY 310
Query 299 EVEANGGITIKLQSPEVRSFDDYFLKLRLDTNTRNPWFPEFWQHRFQCRL---------- 348
G I L++ ++ F ++ K+
+ N + EFW+ F C L
Sbjct 311 FHVVGGTIGFALKAGQIPGFREFLKKVHPRKSVHNGFAKEFWEETFNCHLQEGAKGPLPV 370

Mutated into
Alanine in our
constructs

Query 349 ---------PGHLLENPN--FKKVCTGNE---SLEENYVQDSKMGFVIN---AIYAMAHG 391
G
N + F+ +CTG+E S+E Y+ + +
N A+Y++AH
Sbjct 371 DTFLRGHEESGDRFSNSSTAFRPLCTGDENISSVETPYIDYTHLRISYNVYLAVYSIAHA 430
Query 392 LQNMHHALCPGH----VGLCDAMKPIDGRKLLDFLIKSSFVGVSGEEVWFDEKGDAPGRY 447
LQ+++ L PG
G C +K ++ ++L L +F
GE+V FDE GD G Y
Sbjct 431 LQDIYTCL-PGRGLFTNGSCADIKKVEAWQVLKHLRHLNFTNNMGEQVTFDECGDLVGNY 489
Query 448 DIMN 451
I+N
Sbjct 490 SIIN 493

Non-conserved Cys
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Figure 7.11 sequence alignment of mGluR1 and the CaSR ECD domain.
Intramolecular disulfide bonds are labeled with red arrows. Three cysteines that will be
mutated to alanines are circled in red.
7.2.7 Problems associated with the CaSR ECD expression using bacterial system.
One of the problems associated with the CaSR ECD expression using E. Coli is protein
degradation. As shown in Figure 7.12, the SDS page on the left indicated a dark band at around
70 kDa which is corresponding to the calculated CaSR ECD molecular weight. However, there
are smeared bands at lower molecular weights. Western bloton the right side, shows that the
smeared bands are at least partially due to the protein degradation. It is also possible that the
degradation may start during protein expression.

Figure 7.12 Protein degradation problem observed during protein expression and
purification
Left side: Coomassie blue staining of purified CaSR ECD collected from FPLC fractions.
Right side: western blot of the same fractions. Protein was blotted using anti-flag antibody
at 1:3000 dilution.
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In order to solve the issue, several conditions have been screened for increasing protein stability.
As shown in Figure 7.13, proteins aliquoted into six conditions started to degrading from Day 1.
There were no significant differences among these reagents. However, the results on Day 3
suggested dramatic variation among the six conditions. Caclium free buffer may prevent the
protein from severe degradation. Meanwhile, the decrease of the pH condition to 4.0 could also
help in slowing down the degradation process. Other conditions, including addition of protein
inhibitor (PMSF), mixing with 5% glycerol, as well as 20 M of La3+, help to increase the
stability of the protein to a certain extent, but not as promising compared to EDTA and an acidic
environment.
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Figure 7.13 Stability test of bacteria expressed CaSR ECD
Aliquots of CaSR ECD samples were prepared in different buffer conditions and incubated
at room temperature or -20C for upto 5 days. Samples are further loaded onto the SDS
page gels.
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Although some reagents might be helpful for preventing protein degradation, it would be better if
the CaSR ECD can be expressed with less degradation bands. Several methods are considered to
be feasible for dealing with this problem. First, deleting the cysteine rich domain as well as the
signal peptide at the beginning of CaSR ECD sequence might increase the yield and decrease the
misfolding of disulfide bonds during protein expression. Second, decreasing the expression
temerpature to 20 or 16 C can be helpful for the protein folding correctly. Third, we can switch
to different bacterial strains (e.g.SHuffle). SHuffle have DsbC prokaryotic disulfide bond
isomerases, which help disulfide bond formation and functions in bacterial cells.

7.2.8 Comparing the bacterial expressed protein with mammalian expressed CaSR ECDs
As can be seen from those aforementioned results, bCaSR ECD and hCaSR ECDs have few
similarities in their biophysical studies. First, all of them showed a blue shift from their intrinsic
Trp spectrum indicating the protein was at least partially in its native form. Second, all of their
secondary structures are dominanted by -helix (Table 7.1). Third, protein from either of the two
systems exhibited conformational changes upon their interaction with Ca2+ as well as Tb3+.

Table 7.1 Secondary structure comparison between bCaSR ECD and hCaSR ECD.
-Helix
Without Ca2+

With Ca2+

-Strands
Without Ca2+

With Ca2+

Turns
Without Ca2+

Unordered

With Ca2+

Without Ca2+

With Ca2+

bCaSR

47% ± 6%

48%± 1%

27% ± 5%

25%± 2%

7%± 2%

7%± 2%

21%± 1%

21%± 1%

mCaSR-WT

58% ± 1%

55% ± 6%

17% ± 1%

21% ± 4%

6% ± 2%

5% ± 1%

18% ± 4%

15% ± 4%

mCaSR-Lec1

52% ± 5%

60% ±4%

25% ± 3%

18% ± 1%

5% ± 1%

7% ± 2%

18% ± 3%

18% ± 3%
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Despite the fact that the CaSR ECDs expressed from bacterial and mammalian systems share
several similiarities, the properties of CaSR ECDs expressed from the two systems have quite a
few differences. The most apprarent difference is the size of the CaSR ECDs. The bCaSR ECD
showed a clear band at around 72 kDa; on the other hand, WT hCaSR ECD exhibited a smeared
band in the range from 100 kDa~130 kDa while the Lec1 mutant hCaSR has one single band
with a molecular weight of approximately 95 kDa. Under non-reducing conditions, the WT
hCaSR ECD and Lec1 hCaSR ECD have molecular weight at around 240 kDa and 200 kDa
respectively, corresponding to the calculated dimerization form of the receptor’s extracellular
domain. However, the bCaSR ECD forms oligormers (Figure 7.14).

The second difference is the glycosylation pattern and it is one of the major factors that affected
the thermal stability of the proteins. The melting point (Tm) of bCaSR ECD is around 80 C in
the absence of calcium. Interestingly, the WT hCaSR ECD demonstrated extraordinary thermal
stability as the signal at the given wavelength did not change. The high mannose form of the
hCaSR ECD, the Lec1 hCaSR ECD, showed a rapid disruption of the secondary structure at
92C (Figure 7.15).

Moreover, the calcium induced conformational changes of the CaSR ECDs expressed from the
two different systems are dissimilar. For bCaSR ECD, calcium caused less hydrophobic areas
interacting with ANS, resulting in a 34% decrease of the fluorescence peak value; on the
contrary, it induced exposure of more hydrophobic regions in the complex oligosaccharide form
(WT hCaSR ECD) as there was a 25% increase in the fluorescence signal. Similar intensity
enhancements, though to lesser extents (~10%), were detected in Lec1 hCaSR ECD.
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Figure 7.14 Bacterial expressed CaSR ECD under reducing and non-reducing condition
(Data adopted from Ling Wei). Immunoblotting using anti-CaSR antibody ADD shows
that bCaSR ECD formed oligomers under non-reducing condition (Left lanes).
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Figure 7.15 The thermal stability of CaSR ECDs from different expression systems.
Temperature dependence of the molar ellipticity at 222 nm for CaSR ECDs in 10 mM Tris,
pH 7.2 in the absence of calcium is shown in the figure. Square: bCaSR ECD; Open circle:
Lec1 hCaSR ECD; Closed circle: WT hCaSR ECD.

Fourth, the binding affinities calculated from the fitting curves for titration experiments with
bCaSR ECD and hCaSR ECDs are different. The observed Kds of hCaSR ECDs for Ca2+ were in
the range of mM, however, the Kd of bCaSR ECD for Ca2+ was in M range. It is also
worthwhile to notice that during the titration of calcium into the buffer containing 2 M bCaSR
ECD, protein precipitation was observed. This phenomenum may be due to the fact that bCaSR
ECD has less solubility compared with the hCaSR ECDs, which have glycosylation to increase
their solubility.
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7.3 Discussion
It has been suggested that the ECD of the mGluRs and CaSR share similar Venus Fly Trap
structure based on several conserved amino acids regions and predicted secondary structures
(Mei Bai 2004). However, there is limited structural and biochemical information available for
CaSR due to its large molecular weight (~70 kDa as monomer) and heterogeneous glycosylation.
Since the amino acid sequence of a protein determines its three-dimensional structure, it is
worthwhile to utilize the bacterial system to express the CaSR ECD. In the present study, the
target protein was expressed in the cytosol of bacteria and we were able to purify the bCaSR
ECD via affinity columns. It is known that CaSR functiona as a dimer on the surface of cell
membrane, the mammalian secreted ECD proteins, both the complex glycan form and the
homogenous high mannose form, also present in the culture medium as a dimer form (Chapter 5).
However, the bacterial expressed ECD forms an oligomer in the non-reducing environment.

Glycosylation is one of the most important posttranslational modifications occurring in protein
biosynthesis and secretory pathways. As expected, distinctive from the mammalian expression
system, the bCaSR ECD did not have glycosylation modifications. The thermodynamic
stabilization calculations indicate that the stability of a protein may be enhanced when a glycan
is covalently bound to the protein surface, which can be measured as an increase in melting
temperature (292). The ECD protein with heterogeneous saccharides was able to maintain its
secondary structure at high temperature (> 90C) (Chapter 5). On the other hand, bCaSR ECD,
which has no glycosylation modification, was comparatively less stable than its mammalian
expressed counterparts. These phenomena may be attributed to the differences of protein tertiary
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structures altered by the post-translational modification since their secondary structures were
relatively similar.

Calcium, as a predominant agonist for CaSR, is believed to induce conformational changes of the
receptor to convey the extracellular signal to intracellular messengers. However, the lack of
evidence to prove such change makes it worthwhile to analyze the alteration of the receptor’s
biophysical characteristics before and after the Ca2+ binding. One of the biophysical changes on
CaSR, upon the interaction with Ca2+, is the thermal stability of its ECD. The addition of calcium
altered the structural stability of CaSR-ECD, resulting in losing the secondary structure at a
much lower temperature. Another possible interpretation is the positive charges of the metal
accelerate the aggregation of the protein at higher temperatures.

The enthalpy change usually measures a change in the strength of the interactions between
molecules. However, the decreased Tm value of bCaSR ECD as well as Lec1 CaSR ECD, in the
presence of calcium, indicates that proteins could tend to aggregate with the addition of calcium.

Data from spectroscopy and NMR spectrum indicated that calcium induce conformational
changes in CaSR ECD. There are fourteen tryptophan residues on the ECD, among them four are
on the malleolar surface between lobe 1 and 2. The decrease of tryptophan intensity might be
explained by a close form of receptor resulting from calcium binding which could lead to a more
imbedded position of those tryptophan residues. However, the Trp spectrum relies on the
environment surrounding the Trp residues. Since those Trp residues are not only near the
predicted calcium binding site, but also spread out on the entire ECD, sensitivity to monitor the
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real binding process can be affected. Interestingly, the decreased ANS signal resulting from
calcium titration into the bCaSR ECD, revealed the difference between the bacterial expressed
protein and the mammalian expressed protein.
In our lab’s previous studies, when titrated with Tb3+, CaSR ECD subdomain 1, which includes
predicted Ca2+ binding site 1, site 2 and site 3, showed biphasic binding processes while
subdomain 2 (including Ca2+ binding site 2 &3) and subdomain 3 (including Ca2+ binding site 4
&5) had monophasic responses to Tb3+. However, in the present studies, bCaSR ECD presented
a sigmoidal curve, suggesting multiple metal binding sites in the ECD may work coorperatively
in order to accommodate the extracellular calcium concentration changes.
Overall, the present study provides further insights into the structure related CaSR functions and
should permit further studies to define which are the key residues involving the interaction with
the ligands for this receptor, including cations, nutrient amino acids, as well as antibiotics. This
information will be crucial to understanding how CaSR responds to a variety of stimuli and will
pave the way for future research of other members in GPCR family C.
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CHAPTER 8. CALMODULIN, AN ASSISTANT FOR THE RECEPTOR INSERTION ON
CELL MEMBRANE.
8.1 Introduction
The calcium sensing receptor (CaSR), which is predominately expressed in the parathyroid
glands and kidneys, is a major player in sensing fluctuations of the extracellular calcium
concentration [Ca2+]o and in maintaining calcium homeostasis by regulating parathyroid
hormone (PTH) secretion as well as renal Ca2+ reabsorption (38). Since 1995 when CaSR was
found universally in the gastrointestinal tract (41,166) and antral G cells (166), the exploration of
its physiological function has been extended.

In the digestive system, proteins from dietary intake can be ultimately transformed to free amino
acids which are essential molecules as they are the metabolic precursors of crucial substances
which could be ligands for receptors, for instance L-histidine for histamine, L-tryptophan for 5hydroxytryptamine (serotonin) , and L-tyrosine for dopamine, catecholamines and thyroid
hormone (165). Fluctuation of the plasma amino acid level can regulate the rate of hormone
synthesis and secretion as well as calcium metabolism through the control of cellular signal
transduction pathways (165).

It has been reported that aromatic amino acids can enhance the sensitivity of CaSR to
extracellular calcium, which could be one potential explanation for how dietary protein
modulates calcium homeostasis in normal individuals as well as patients with chronic renal
failure (165,167). However, the mechanisms by which these two nutrients, calcium and L-Phe,
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cooperatively regulate the function of the receptor are barely understood, other than the fact that
they activate the CaSR through Gq/11 and G12/13 respectively(121).

Recently, a novel concept which is termed “agonist-driven insertional signaling” (ADIS) has
been brought to the field of CaSR signaling by Dr.Breitwieser’s group(144). ADIS is considered
to be contributing to the high degree of the receptor’s cooperativity as well as lack of
desensitization(144). The subsequent insertion of additional CaSR upon the activation of plasma
membrane CaSRs is the fundamental feature of ADIS model. Since ADIS integrates the cell
signaling with protein trafficking, it would be interesting to analyze whether ADIS contributes to
the L-Phe modulated CaSR activity.

One of the scaffold proteins that have been reported to interact with the CaSR is filamin (80,81).
Filamin is ubiquitously expressed as a homodimer which is composed of monomers with 2647
amino acids forming 24 immune globulin-like repeats, two hinge regions, a dimerization domain
at the C terminus, and an actin-binding domain at the N terminus (300). Filamin crosslinks actin
to cell surface receptors, for instance, dopamine D2 receptor (a G protein-coupled
receptor), the Fc receptor, platelet glycoprotein Ib, 1 and 2 integrins, tissue factor, MAP
kinases, the tumor necrosis factor receptor-associated factor-2 (TRAF2), Rho GTPases, and
Smad proteins (301-304). Filamin is also involved in protein trafficking and cycling of proteins
by interacting with caveolin (305,306). Filamin binds to the c-tail of the CaSR as demonstrated
by yeast two hybrid assays, and there are two potential interaction regions, one 972-1031, and
the other 907-997.

220
CaM is a ubiquitously expressed protein in the cytosolic environment. It has been reported that
the interaction between the CaSR and CaM is essential for maintaining [Ca2+]i oscillations
triggered by [Ca2+]o(148). The previous study by our lab using a calmodulin binding domain
(CaMBD) peptide indicated that CaM could interacted with the potential CaMBD at the c-tail of
the CaSR in 1-8-14 class binding mode and it induced significant changes in the secondary and
tertiary structure of this region (148). Since it has been reported that CaM can modulate the
surface expression of other GPCR proteins (307), it is worthwhile to analyze how CaM, as one of
many proteins that interacting with CaSR (see Chapter 1 for details), can regulate the trafficking
as well as the function of this particular recpeotr. Calmodulin can stabilize the CaSR by
interacting with the c-terminal of the receptor, specifically in the region between amino acids
881-894 (148). Moreover, the presence of calmodulin (CaM) inhibitors can diminish the
extracellular calcium [Ca2+]o as well as the L-Phe induced intracellular calcium concentration
[Ca2+]i change(120). However, how CaM can regulate the the agonist triggered receptor function
as well as the following downstream signaling pathways is unclear.
In the present study, we report our observation that in the presence of L-Phe, the ADIS was
enhanced in HEK293 cells either expressing wild type CaSR or disease related loss-of-function
mutant CaSR, which possibly contributes to the L-Phe potentiated receptor activity. The deletion
of potential CaM and filamin interaction regions changed the [Ca2+]i oscillation patterns and
abolished the L-Phe promoted ADIS. Our findings may provide a novel angle to investigate how
calcium and L-Phe cooperatively work together to promote the function of the CaSR.
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8.2 Results
8.2.1 L-Phe can promote the function of CaSR by working cooperatively with Ca2+.
In the presence of L-Phe, the [Ca2+]i oscillation pattern was changed as the [Ca2+]i started
oscillating at lower [Ca2+]o, and a [Ca2+]i plateau required less [Ca2+]o to be reached to (Figure
8.1a). Next, we utilized immunostaining assay to analyze the Ca2+ triggered ADIS in CaSR
transfected HEK293 cells with or without the addition of L-Phe. The transfected CaSR has a flag
tag in the extracellular domain. Cells were first labeled with a rabbit monoclonal FLAG antibody
to block all plasma membrane FLAG epitopes, followed by stimulation with different calcium
concentration. Cells were then fixed with formaldehyde and incubated with a mouse monoclonal
FLAG antibody to identify newly exocytosed receptor. After permeabilization with triton, cells
were stained with goat anti-rabbit Alexa488 and goat anti-mouse Alexa568 to differentiate the
original surface CaSR and newly translocated CaSR. The immunostaining assay revealed that the
agonist driven receptor insertion phenomena induced by [Ca2+]o emerged at 3.0 mM [Ca2+]o with
the addition of L-Phe instead of 4.0 mM [Ca2+]o without L-Phe (Figure 8.1b). Quantitative
analysis of the surface receptor intensity using Image J was able to generate an ADIS-[Ca2+]o
response curve which correlated with their [Ca2+]i change (Figure 8.1c). Meanwhile, the results
of the biotin-cleavable western blot assay showed that the CaSR internalization in the presence
of both L-Phe and Ca2+ compared to Ca2+ only was similar (Figure 8.1d).
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Figure 8.1 L-Phe and [Ca2+]o influenced the activity and trafficking of CaSR.
(a.) Representative oscillation pattern from a single HEK-293 cell transfected with WT
CaSR. The [Ca2+]i was measured using Fura-2AM as described in methods. Each
experiment was carried out in 0.1% DMSO as W7 solvent control. Cells were first
submerged in Ca2+-free Ringer’s buffer followed by treatment with various [Ca2+]o buffers
until [Ca2+]i reached a plateau (up to 8 mM [Ca2+]o) in the presence or absence of 5 mM LPhe.(b.) HEK293 cells transiently expressing FLAG-CaSR were labeled with polyclonal
anti-FLAG antibody (pFLAG) for 1 hour (4°C), then incubated in various [Ca2+]o buffer
for 10 min (37°C). Cells were labeled with monoclonal anti-FLAG antibody (mFLAG) for
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1 hour (room temperature) after fixing with formaldehyde. Cells were permeabilized and
labeled with goat anti-rabbit Alexa488- and goat anti-mouse Alexa555-conjugated
secondary antibodies. Incubation in high [Ca2+]o buffer increased binding of monoclonal
anti-FLAG antibody (mFLAG) to CaSR, demonstrating ADIS. Images shown are
representative of N = 25 cells. (c.) Quantitative analysis of ADIS: The fluorescent intensity
from Alexa555 was measured by Image J which was further divided by the fluorescent
intensity from Alexa488. The values were calculated for all cells at each indicated [Ca2+]o
with (grid) or without (blank) L-Phe.(d.) Effects of L-Phe on internalization of the WT
CaSR. CaSR transfected HEK293 cells were labeled with disulfide-cleavable biotin in
calcium-free buffer for 30 min, and then stimulated with various [Ca2+]o for 10 mins. The
internalized CaSR was immunoprecipitated with the anti-FLAG antibody and detected by
streptavidin peroxidase. Top panel: Non-cleaved biotin labeled CaSR stands for
internalized receptor. Lower panel: total CaSR.

8.2.2 L-Phe enhanced the ADIS in inactive CaSR mutants.
We next examined whether this L-Phe enhanced ADIS existed in the disease related mutations.
The CaSR L173P and P221Q are two loss-of-function mutants recently reported by Hannan et. al.
The immunostaining results showed that the translocation of the mutated receptors from
cytosolic reservoir to cell membrane can also be facilitated by L-Phe (Figure 8.2). Although the
L-Phe enhanced the ADIS in mutant CaSRs, it did not increase the surface receptor
internalization as shown in Figure 8.3.
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Figure 8.2 L-Phe enhanced ADIS in disease related mutants.
Cells transfected with L173P and P221Q were exposed to various [Ca2+]o for the
measurement of ADIS as described in Figure 6.1(b). Quantitative analysis of ADIS was
shown in the scatter plot. The fluorescent intensity from Alexa555 (I555) and Alexa488 (I488)
was measured by Image J. The ratio of I555/I488 was further plotted against [Ca2+]o and
normalized to the intensity ratio when [Ca2+]o was at 1.0 mM. Open circle: without L-Phe;
Closed circle: in the presence of L-Phe.

Figure 8.3 Receptor internalization in disease related mutants.
CaSR mutants transfected HEK293 cells were labeled with disulfide-cleavable biotin in
calcium-free buffer for 30 min, and then stimulated with various [Ca2+]o for 10 mins. The
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internalized CaSR was immunoprecipitated with the anti-FLAG antibody and detected by
streptavidin peroxidase.

8.2.3 CaM inhibitor W7 affected the trafficking of the CaSRs.
Previously studies have reported that CaM plays a pivotal role in regulating the traffic of the
CaSRs (148) and it may also be involved in modulating the L-Phe triggered [Ca2+]i
oscillation(120). We further investigated whether CaM could also be involved in regulation of
the ADIS effects. We first incubated the cells with CaM inhibitor W7 followed by monitoring
the [Ca2+]o induced [Ca2+]i changes using Fura-2 AM in the presence or absence of L-Phe. As
shown in Figure 8.4, the [Ca2+]i oscillation has gone through dramatic pattern alterations. Most
cells exhibited transient peaks instead of continuous sinusoidal changes (Figure 8.4a). The
confocal images suggested the ADIS induced by Ca2+ was still observable (Figure 8.4b); on the
contrary, the L-Phe enhanced ADIS was abolished. Meanwhile, the ERK activity which once
could be promoted by L-Phe was also reduced by W7 (Figure 8.4c). The [Ca2+]o induced
internalization of the receptor had no significant change with the pretreatment of W7 either in the
presence or the absence of L-Phe (Figure 8.4d).
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Figure 8.4 W7 reduced the Ca2+ and L-Phe induced ADIS.
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(a.) Cells were pretreated with 50 M W7 or DMSO for 30 mins. Figures show
Representative oscillation pattern from a single pretreated WT CaSR transfected HEK-293
cell with or without L-Phe. Right panel: Statistic analysis of total responded cells. Empty
bar: DMSO only; Black: with 50 M W7; Red diagonal: with 5 mM L-Phe and DMSO;
Red solid: with 5 mM L-Phe, DMSO and 50 M W7. (b.) HEK293 cells transiently
expressing FLAG-CaSR were first treated with either W7 or DMSO for 30 mins at 37°C.
Cells were labeled with polyclonal anti-FLAG antibody (pFLAG) for 1 hour (4°C), then
incubated in various [Ca2+]o buffer with 5 mM L-Phe for 10 min (37°C). Cells were labeled
with monoclonal anti-FLAG antibody (mFLAG) for 1 hour (room temperature) after
fixing with formaldehyde. Cells were permeabilized and labeled with goat anti-rabbit
Alexa488- and goat anti-mouse Alexa555-conjugated secondary antibodies. Right panel:
Quantitative analysis of ADIS as described in Fig. 1c. (c.) W7 inhibited [Ca2+]o activated
ERK phosphorylation in CaSR-transfected HEK293 cells. HEK-293 cells transfected with
WT CaSR or its mutants were incubated in serum-free high glucose MEM medium
containing 0.2% BSA overnight. Cells were pretreated with DMSO alone or W7 in DMSO
for 30 mins, cells were then incubated in various Ca2+ concentrations (0.0-~8.0mM) for 10
min at 37 C. The incubations were stopped by exposure to the lysate buffer and processed
for SDS/PAGE and Western blotting as described in the Methods. The western blot results
were further quantified using Image J. Empty bar: without W7; Black bar: with W7. (d.)
Effects of W7 on Ca2+ and L-Phe triggered internalization of the WT CaSR. CaSR
transfected HEK293 cells were incubated with DMSO or W7 for 30 mins. Cells were then
labeled with disulfide-cleavable biotin in calcium-free buffer for 30 min, followed by
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immunoprecipitated with the anti-FLAG antibody and detected by streptavidin peroxidase.

8.2.4 Mutations on the CaM interaction region changed the L-Phe enhanced intracellular
calcium response pattern.
Since CaM is a ubiquitous molecule that participates in hundreds of intracellular signaling
pathways, the addition of W7 could affect other signal transductions besides the potential
disruption of the interaction between CaSR and L-Phe. In order to analyze the specific role of
CaM in the trafficking of the CaSR, we designed experiments with several CaSR C-tail mutants
(CaSR F881E/V894E, F881E/T888E, F881E/T888E/V894E) which their binding with CaM are
believed to be interrupted (148). The [Ca2+]i changes upon the [Ca2+]o stimulation were altered in
those mutants as shown in Figure 8.5. Majority of the cells transfected with C-tail mutants
F881E/V894E, F881E/T888E, F881E/T888E/V894E showed transient peaks as their responses
to the increase of [Ca2+]o. The addition of L-Phe could not change the [Ca2+]i response as the
way it changed the oscillation patterns in WT CaSR, i.e. starting oscillation at lower [Ca2+]o,
increasing the [Ca2+]i oscillation frequencies; instead, the [Ca2+]i responded in a special way in
the presence of L-Phe. Noticeably, the width of each transient peak became wider in the mutant
F881E/V894E, mutant F881E/T888E and mutant F881E/T888E/V894E as well. Moreover, the
peak descending rates were also decreased compare to WT CaSR.

Because the CaM CaSR interaction region also includes T888, which is a potential
phosphorylation site of CaSR, in order to rule out the possibility that mutations at the
phosphorylation site would complicate the conclusion, single mutation to the residue T888 was
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employed for an in depth analysis. As indicated in (Figure 8.5), the T888V mutation, which
abolished the phosphorylation site, forced the receptor to start oscillating at lower [Ca2+]o
compared with WT CaSR. However, with L-Phe, the oscillation patterns were changed likely as
in WT CaSR. Thus, the L-Phe caused peak transformation is more related to CaM other than
phosphorylation.
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Figure 8.5 The [Ca2+]i oscillation in cells expressing CaSR with mutations in the CaM
binding region.
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Representative oscillation patterns from a single cell. HEK-293 cells transfected with CaSR
or one of its mutants were loaded with Fura-2 AM for 15 min. The [Ca2+]i was assessed by
monitoring emission at 510 nm with excitation alternately at 340 or 380 nm as described in
methods. Each experiment carried out with or without 5 mM L-Phe began in Ca2+-free
Ringer’s buffer (10 mM HEPES, 140 mM NaCl, 5 mM KCl, and 1.0 mM MgCl2, pH 7.4)
followed by stepwise increases in [Ca2+]o until [Ca2+]i reached a plateau (up to 10 mM
[Ca2+]o).

8.2.5 Filamin A is involved in the CaM regulated CaSR trafficking.
The next question is how CaM could modulate the traffic of the receptor. The C-tail of the CaSR
has been reported to interact with the cytoskeleton protein, filamin. Truncation of these potential
binding domains on CaSR led to the weakened interaction with filamin as shown in (Figure 8.6).
Interestingly, the disruption of the CaSR-filamin interaction also influenced the communication
between CaM and CaSR. Notice that the molecular weight of CaM shown in the western blot
results indicated its existence as a dimer form. It is worthwhile to look into the [Ca2+]i oscillation
pattern in those mutants as well as the ADIS effects.
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Figure 8.6 Filamin A and CaM interacts with CaSR.
HEK293 cells expressing FLAG-CaSR or its Filamin truncation mutants (860/ 906998/907-999/860971) or CaM truncation mutants (880-894) or CaM interaction
mutation (3E3) were immunoprecipitated with anti-flag antibody. The input receptor
(CaSR), Filamin A and CaM were immunoblotted with their specific antibodies
respectively.

8.3 Discussion

In the present study, we characterized how the interaction between CaSR and CaM could
transduce the extracellular amino acids triggered signaling into the intracellular environment and
modulate the trafficking of the receptor. We have demonstrated that the disruption of the CaM
binding site on the C-tail of CaSR altered the L-Phe and [Ca2+]o cooperatively induced [Ca2+]i
oscillation patterns in the HEK293 cells transfected with the CaSR. The cross-talk between the
two proteins and filamin A appear to be critical in the L-Phe enhanced agonist-driven receptor
insertion signaling.

The addition of L-Phe can potentiate the responses of HEK293 cells transfected with the CaSR
to the changes of extracellular calcium concentration, characterizing by starting as well as
terminating [Ca2+]i oscillation at lower [Ca2+]o and an increase in the oscillation frequency at the
EC50 for [Ca2+]o. The data reported herein suggested that L-Phe also enhanced the [Ca2+]o driven
receptor insertion while stimulating more surface receptor underwent internalization. The CaSR
specific allosteric modulator NPS R-568 has been reported to have the similar ADIS(144). Since

233
the L-Phe induced [Ca2+]i change via the CaSR requires a minimum of 1.5 mM [Ca2+]o, the
potentiated ADIS effect was barely observable when the [Ca2+]o was in the physiological range.
This phenomenon was also detected in the disease related mutants and was well correlated with
their respective [Ca2+]i oscillation patterns, suggesting that both active and inactive receptors
could be modulated in the similar way as WT CaSR. On the other hand, the L-Phe enhanced
ADIS was diminished in the mutant L173P, of which the rescue ability of the L-Phe was
impaired possibly due to the sterically hindering by the Leu to Pro mutation, indicating the
appropriate interaction between the CaSR and the L-Phe should be crucial in transducing the
extracellular signaling into the cytosol. Considering the fact that the [Ca2+]i alterations responded
much faster than the ADIS, the oscillation patterns could be a necessary messenger for the
regulation the trafficking of the CaSR.

In the present study, we confirmed that not only the application of CaM inhibitor W7 but also the
mutations on the CaMBD, which interrupted the interaction with CaM could change the [Ca2+]i
oscillation patterns upon the step wise increase of [Ca2+]o. The reduced ADIS in these CaSR
mutants suggested a linkage between the two events. The addition of L-Phe failed to rescue the
[Ca2+]i oscillation as it would to WT CaSR indicating CaM probably involved in the L-Phe
regulation which is in a way correlated with the findings from Rey et. al. that CaM inhibitors
impaired the L-Phe induced [Ca2+]i changes(120). Meanwhile, the L-Phe enhanced ADIS was
also abolished suggesting CaM participates both in the [Ca2+]o stimulated ADIS as well as in the
L-Phe signaling.
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Based on the results, a model of the L-Phe enhanced Ca2+ induced ADIS was proposed as
presented in the schematic figure (Figure 8.7). CaM binds to the CaSR to stabilize the receptor
during its interaction with agonists. In the presence of Ca2+ the ADIS is predominately regulated
by 14-3-3 protein (144). The addition of W7 did not completely abolish the transferring of novel
receptor to the cell membrane. The L-Phe cooperatively regulated the CaSR with Ca2+,
meanwhile it activated Gi/o signal pathway other than Gq/. CaM is a crucial element in the LPhe regulated [Ca2+]i change. The disruption of its interaction with CaSR not only alter the
[Ca2+]o induced [Ca2+]i oscillation pattern but the [L-Phe] promoted [Ca2+]I responses. CaM may
participate in the L-Phe enhanced ADIS in a dimer form.

Ca2+

CaM

P

CaM

P
P

ERK

Ca2+

Figure 8.7 Schematic presentation of the L-Phe enhanced ADIS under the modulation of
CaM
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Phosphorylated CaM forms a dimer and binds to the C-tail of CaSR. The stimulation with
[Ca2+]o and L-Phe facilitates the phosphorylation of ERK. The later may accelerate the
opening of cytosolic CaSR reservoir and potentiate the exocytosis.

In the present study, we found that in the presence of L-Phe, the ADIS was enhanced in HEK293
cells transfected with either wild type CaSR or disease related loss-of-function mutant CaSR.
Further analysis with the calmodulin (CaM) inhibitor suggested CaM could be involved in
regulating the L-Phe enhanced ADIS. Studies on the CaSR with mutations at calmodulin binding
domain which interrupted CaM-CaSR interaction and the CaSR with Filamin A binding domain
truncation showed that not only the L-Phe induced intracellular calcium[Ca2+]i oscillation was
altered, but the L-Phe promoted receptor insertion phenomena was abolished. Thus, L-Phe
possibly regulates the receptor through CaM and Filamin A modulation.

Several experiments still need to be done in order to finalize the story. The interaction between
Filamin A and the c-tail of CaSR need to be confirmed either using pull down assay or
immunofluorescence study. Whether Filamin A is truly involved in the CaM modulated CaSR
trafficking needs to be further investigated. The relationship among CaM stabilized surface
receptor and

receptor internalization as well as the ADIS might be much clearer with

bungotoxin linked SEP-CaSR. Our approach will shed light on understanding the mechanisms
underlying the agonist regulated receptor trafficking for other GPCR family members and will
provide new strategies for drug designing targeting at various GPCR proteins.
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CHAPTER 9. PROBING THE CORRELATION BETWEEN THE [Ca2+]ER AND THE
TRAFFICKING OF CASR
9.1 Introduction
The endoplasmic reticulum (ER) is considered as a major storage reservoir and a crucial
regulator of intracellular Ca2+ as it stores more than 90% of the Ca2+ in the cells, although its
volume is less than one tenth of the total cell (308-310). ER is also the most important
suborganelle for global protein maturation, as approximately one third of all open reading frames
code for proteins that enter the ER in human. A polypeptide starts with translocation across or
into the ER membrane before its secretory pathway. It will not be transported via the Golgi
apparatus to the cell surface unless it is folded and modified correctly in the ER. The ER lumen
has a unique environment for the proper folding of protein, including complex pathways, tons of
folding factors like Hsp90, Cyp, FKBP, PDI, UGGT etc., quality control, recycling (e.g. ER-toGolgi intermediate compartment (ERGIC)), Especially for membrane proteins, which usually
contain glycosylation sites, the ER provides a good compartment for proper modification such as
glycosylation and disulfide bond formation to stabilize their conformation before they are
secreted out and exposed to extracellular milieu (311). In this case, protein folding and secretion
can be related with the ER calcium concentration. An accurate way for quantifying the ER Ca2+
concentration is thus in great need.

Certain mutations on CaSR can lead to reduced receptor surface expression on the cell
membrane. The treatment with the CaSR specific positive allosteric modulators can increase its
surface expression while the negative allosteric modulators have the opposite effects. Since ER is
one of the major subcellular organelles involving the synthesis, modification and transportation
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of proteins, it would be worthwhile to test how those allosteric modulators can affect ER, mainly
focusing on the ER calcium concentration.
How these allosteric modulators can change the receptor expression level is still obscure. One of
the hypotheses is that the drug treatment can influence the ER calcium concentration change
thereby affecting the foldings of the receptors and the following trafficking pathways.
In order to analyze the ER calcium concentration, an ER targeted calcium sensor should be an
essential tool

Currently, there are two major generations of ER Ca2+ sensors. The first one is small molecular
based Ca2+ dye, Mag-fura-2 which can majorly measure Ca2+ concentration in calcium stors (e.g.
mitochondria or ER) due to its small size and low affinity to Ca2+. The other type is based on
fluorescent proteins consisting of a Ca2+ regulated protein such as calmodulin or troponin
C(181,312,313). The advantage of those protein based Ca2+ indicators is that they can target
subcellular organelles with high spatial and temporal resolution (9). However, they still have
some limitations during the application in excitable cells (18). Our group has engineered a new
type of Ca2+ sensors, named CatchER(calcium sensor for detecting high concentration in the ER),
based on the green fluorescence protein. CatchER has an ER retention sequence KDEL and its
EGFP based property allows it to have intensity change upon calcium binding. CtachER meets
the requirements for a better Ca2+ indicator such as accurate targeting to certain cellular
compartments, the ability to quantitatively measure the ER Ca2+ concentrationand, fast release
kinetics, and minimized quenching problems (185).
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Although CatchER has been successfully applied for detecting the Ca2+ release in mouse muscle
sarcoplasmic reticulum (SR), the lower temperature requirement for the expression of CatchER
in HEK293 cells limited its further application, e.g. co-expression with other proteins in cells.
Our lab further improved this calcium sensor to ensure its chromophore formation at 37 C and
named it CatchERT.

In the present study, we aim to answer how ER Ca2+ signaling regulates CaSR functional
cooperativity via modulation of receptor surface expression. Either CatchER or CatchERT were
co-transfected with CaSR and the ER calcium concentration changes were monitored using these
designed calcium sensors after treating with various drugs. We found that the positive allosteric
modulator NPS R-568 could increased the calcium concentration in ER, while NPS 2134 had
minimum effect on the ER.
9.2 Results
9.2.1 The CaSR allosteric regulators can influence the receptor expression level.
It has been reported that the not only the addition of proteasome inhibitor e.g. GM132 can
increase the amount of the CaSR expressed at the cell surface, but also overnight incubation with
positive allosteric CaSR modulator NPS R-568 can increase the expression of the receptor
(268). Here we confirmed that the 0.1%DMSO as solvent only treatment did not change the
expression level of WT CaSR while the negative regulator NPS-2143 down regulated the total
amount of CaSR and the positive modulator NPS-R568 had the opposite effect.
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Figure 9.1 Total CaSR expression in HEK293 cells with various treatments.
After transfection with CaSR for 48 hours, HEK293 cells were treated with 10 M CaSR
positive allosteric modulator NPS R-568 in 0.1% DMSO or 10 M negative allosteric
modulator NPS 2143 in 0.1% DMSO or 0.1%DMSO (as solvent control) for 16 hours. Cells
were collected and lysed in RIPA buffer. The total CaSR was detected by anti-Flag
antibody. GAPDH was used as internal control.
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9.2.2 Monitoring the [Ca2+]ER using calcium sensor CatchER.
In the present study, we coexpressed Catcher and the CaSR in HEK293 cells in order to detect
the extracellular calcium induced intracellular calcium concentration change as well as the
corresponding calcium concentration alteration occurring in sub cellular organelles. Because
CatchER has to be expressed at 30C while the CaSR exhibited best expression at 37C, we used
two different protocols to optimize the condition for co-expression of the two proteins
simultaneously. Figure 9.2 shows the first protocol in which cells were initially cultured at 37C
for 12 hours after transfection followed by 12 hours incubation at 30C. Cells were continued in
culture for another 4 hours before proceeding to the imaging experiments. The green line
represents the fluorescent intensity from CatchER while the red line represents the signal from
Rhod-2, which is a calcium sensing dye to measure the cytosolic calcium concentration, from the
same single cell. Cells responded to upon the addition of extracellular calcium indicating the
CaSR had been expressed. However the dynamic range of CatchER is relatively small compared
with Rhod-2. Figure 9.3 indicated the intracellular responses using the second protocol.
Apparently the CaSR did not properly fold and express on the cell surface as suggested by
impaired the intracellular calcium responses. After comparing the two methods, the expression
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Figure 9.2 Monitoring the [Ca2+]ER using CatchER (first method).
After co-transfection with CaSR and CatchER, cells were first incubated at 37 C
overnight then the temperature was reduced to 30C for continuing expression another 12
hours. Cells were further moved to a 37C incubator for another 4 hours prior to
experiments. The calcium concentration is indicated above the lined bar. Ionomycin is used
as ionopore to transport the extracellular calcium to the intracellular enviroment. Red:
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Figure 9.3 Monitoring the [Ca2+]ER using CatchER (second method).
After co-transfection with CaSR and CatchER, cell were first incubated at 30 C for 2 days
then the temperature was increased to 37C for continuing 1 day expression. Red: cytosolic
calcium changes measured using Rhod-2. Green: signals from CatchER.
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9.2.3 Measuring the drug induced [Ca2+]ER in CaSR transfected HEK293 cells using CatchER.
We next analyzed the intracellular responses upon the treatment with different CaSR
modulators. HEK293 cells co-transfected with CatchER and CaSR were treated with the CaSR
positive modulator NPS R-568, the negative modulator NPS 2143 or DMSO as solvent control
overnight at 37C. As shown in Figure 9.4, 3.0 mM of [Ca2+]o can trigger the increase of
cytosolic calcium concentration. Some of the cells started to show [Ca2+]i oscillation (Figure
9.4B) while some of the cells responded as transient peak of cytosolic [Ca2+] (Figure 9.4A). The
incubation with 0.1% DMSO barely had any influence on the extracellular induced intracellular
calcium change. Incubation with NPS 2143 diminished the cytosolic calcium oscillation
frequency as well as the peak amplitude. On the other hand, NPS R568 had the opposite effect.
The calcium alterations in the ER were less pulsatile compared with its cytosolic changes. Only a
sudden decrease of the [Ca2+]ER was able to be detected when cells were exposed to 3.0 mM
[Ca2+]o and the [Ca2+]ER started to increase when the [Ca2+]o mM dropped to 1.0 mM. 1.5 M of
ionomycin was introduced as a positive control. The addition of ionomycin induced a [Ca2+]i
climbing and a similar [Ca2+]ER descending was able to be detected. Although the fluorescence
quenching phenomenon is quite notable, the overall [Ca2+]ER responses were able to be recorded.
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Figure 9.4 [Ca2+]ER measurement in HEK293 cells treated with various CaSR allosteric
modulators.
Cells were seeded on coverslips and transfected with CatchER T and CaSR simultaneously.
Cells were continuously cultured for another 48 hours at 37C and further treated with
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various drugs for 16 hours. After loading with Rhod-2, the coverslip was mounted onto the
microscope working stage. The chamber was first perfused with 3 mM Ca2+, followed by
calcium free washing buffer. Then cells were then treated with 1.5 M ionomycin. The
cytosolic calcium concentration was measured using Rhod-2 (Red), while the [Ca2+]ER was
analyzed using CatchER-T(Green). A. WT CaSR expressed cells as controls. B. Cells were
treated with DMSO. C. Cells were incubated with NPS-2143, which is a negative allosteric
modulator for CaSR. D. Cells were treated with NPS R-568, which positively regulated
CaSR.

Next, we measured the [Ca2+] in subcellular organelles using Mag-Fura-2 and CatchER. The
former compartmentalizes in the ER, mitochondria as well as cytoplasm while the latter targets
to the ER only. The calibration using Mag-fura-2 suggested an increase in the subcellular
organelles [Ca2+] after incubation with the CaSR positive modulators NPS R-568. Further
analysis using CatchER showed an increase in the [Ca2+]ER upon the treatment with NPS R-568.
Other treatments did not have significant influences on the [Ca2+] ER.
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Figure 9.5 Calibration of ER calcium concentration using Mag-fura 2.
The [Ca2+]ER was calculated using [Ca2+]i = Kd(F − Fmin)/(Fmax − F) (314) and the results
from different drug treatments were further normalized to WT. The calcium binding
constant for Mag-Fura-2 is around 25M.
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Figure 9.6 Calibration of ER calcium concentration using CatchER.
The [Ca2+]ER was calculated using [Ca2+]ER = Kd(F − Fmin)/(Fmax − F) The Kd of CatchER
was 0.18 mM and the results from different drug treatments were further normalized to
WT.

9.2.4 Insertion of Furin tag in CaSR functional mutants.
White et.al has categorized CaSR loss-of-function mutants into four types: Class Ia mutants have
little expression on the plasma membrane regardless of the presence of proteasomal inhibitor
MG132. They went through the mature glycosylation process and traverse from ER to the Golgi;
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Class Ib mutants are also not significantly localized to the plasma membrane, but they are
targeted for degradation from the ER or ER-Golgi intermediate compartment (ERGIC). Class IIa
can be expressed on the cell membrane without MG132 and their function can be rescued by
CaSR positive allosteric regulator NPS R-568. Class IIb CaSR mutants can locate on the plasma
membrane but their function is barely rescued by NPS R-568. Figure 9.7 shows the schematic
diagram of the four types of mutants. The pro-protein convertase furin cleavage sequence
“ARRRKKRGLDV” was cloned right behind flag-tag in our pcDNA-CaSR (Figure 9.8). Furin is
a trans-Golgi network (TGN)-resident type I membrane protease with a catalytic site facing the
Golgi lumen (Furin at the cutting edge: from protein traffic to embryogenesis and disease.).
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Figure 9.7 Schematic diagram of the trafficking pathways of the disease related mutants
(315).
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Figure 9.8 Schematic diagram of Furi-CaSR constructions.
A. Furi sequence inserted into pcDNA CaSR. B. Furi sequence inserted into pEGFP CaSR.
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9.2.5 Analysis of the constructed Furin-CaSR and its mutants
A few CaSR loss-of-function mutants from each subclass have been selected for the present
studies. As shown in Figure 9.10, the furin tagged WT CaSR, either constructed in the pcDNA
plasmid or in the pEGFP plasmid, traversed from ER to Golgi would be cleaved by furin
resulting in an additional band at 50 kDa in reduced environment on a denatured SDS-page gel.
P39A and G778D are two inactive mutants that can not traffic to the Golgi, therefore they
maintained in an intact form. In the absence of -mercaptoethanol, WT Furin-CaSR was still
able to keep all the fragments together even though it interacted with pro-protein convertase.
Further analysis of other mutants confirmed this phenomenon (Fig. 8.11) as majority of the
mutants had an intense western blot band with fragment molecular weight at 50 kDa except for
L174R which also belongs to class Ib as P39A and G778D.

The pull down experiment using anti-flag antibody revealed similar results compared with the
experiment directly using cell lysates in terms of the band at 50 kDa (Fig. 8.12). Multiple bands
are observed under the reducing environment due to the fact that the secondary antibody not only
recognizes the primary anti-CaSR ADD antibody but also the anti-flag antibody which was used
to pull down the receptor.
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Figure 9.9 Schematic illustration of location of CaSR loss-of-function mutations.
Mutations involved in the present studies are highlighted with frames.CaSR contains 1078
amino acids. The amino-terminal, ECD is comprised of a VFTD, divided into lobes I
(horizontal bars) and II (vertical bars), and a CysRD (diagonal bars). The TMD contains
seven helices (gray boxes). Extra- and intracellular loops and carboxyl terminus are
white.Yellow: Class Ia, Green: Class IIa, Red: Class Ib, Blue: Class IIb.
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Figure 9.10 Western blot of Furin-CaSR constructions with or without reducing reagent
(R). (-G) represent plasmids constructed in pEGFP vectors.
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Figure 9.11 Western blot of disease related mutations in pcDNA-Furin-CaSR constructs.
Forty-eight hours after transfected with different mutants, cells were lysated and
underwent western blot. R: with the addition of reducing reagent (-mercaptoethanol).
Yellow: Class Ia, Green: Class IIa, Red: Class Ib, Blue: Class IIb. (The clone of R227Q was
not correct).
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Figure 9.12 Pull down assay analysis of disease related mutations in pcDNA-Furin-CaSR
constructs.
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Forty-eight hours after transfection with different mutants, cell lysate was coimmunoprecipitated with anti-flag antibody overnight at 4C. Proteins were further eluted
from beads with sample buffer and underwent western blot. R: with the addition of
reducing reagent (-mercaptoethanol). Yellow: Class Ia, Green: Class IIa, Red: Class Ib,
Blue: Class IIb.
9.3 Discussion
How the calcium concentration in the endoplasmic reticulum (ER) change during cytosolic
calcium oscillation is a question that has puzzled scientists for a long time. The absence of a
proper ER calcium indicator is one of the major barriers. The development of CatchER enables
us to monitor the ER calcium concentration change in living cells due to its engineered ER
targeting peptide and the relative weak binding affinity (0.19 ± 0.02 mM) (185). The fact that we
only observed a decrease in the [Ca2+]ER during the [Ca2+]i oscillation should not be attributed to
the failure of dissociation of calcium from CatchER since the koff rate of CatchER is 700 s-1. To
our knowledge, it is the fastest off-rate of all reported Ca2+ sensors. The [Ca2+]ER is thea
consequence of the entrance and exit of calcium from the organelle while the cytosolic calcium
concentration reflects the dynamics calcium change as a result of various membrane pumps and
calcium inlets. The potential increases of [Ca2+]ER contributed by the presumed SERCA pump
and other factors may not be dramatic enough to be captured by the ER calcium indicator during
[Ca2+]i oscillation.

The calibration of the [Ca2+]ER suggested the positive allosteric modulator NPS R-568 can
increase [Ca2+]ER which is expected as a potential explanation that the addition of the NPS R-568
can facilitate the expression of the CaSR. Similar findings have been reported by Ong et al on the
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study of glucocerebrosidase (316). Their group found out that increasing the ER calcium
concentration can regulate the post-tranlational protein folding pathway which can facilitate the
chaperone system to fold misfolding-prone enzymes and increase folded protein population.

In the present study, we first documented how the dynamics of [Ca2+]ER changed upon the
extracellular induced intracellular calcium oscillation. Second, we analyzed the influence of
CaSR allosteric regulators on the intracellular calcium store. Third, this approach can be applied
to other receptors located on the cell membrane.
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CHAPTER 10.

MAJOR CONCLUSIONS AND SIGNIFICANCE

Overall, these series of studies provide a mechanistic view to understand how CaSR
integrates the Ca2+ as well as amino acids -mediated signaling and depict the molecular basis for
diseases associated CaSR mutations resulting in alterations in Ca2+ homeostasis. We have met
different challenges, nevertheless, we are able to achieved the goal via addressing the following
five major questions.
1, How CaSR functional cooperativity is regulation by extracellular binding of Ca2+ and amino
acids?
2. How the disease associated CaSR mutants can affect the functional cooperativity mediated by
Ca2+ and amino acids?
3. How can we determine the binding of Ca2+ and L-Phe to the CaSR ECDs and detect the
potential conformational change induced by the interaction?
4. How the multifunctional intermediate messenger protein--- CaM regulates the CaSR
trafficking and signaling?
5. How ER Ca2+ signaling regulates CaSR functional cooperativity via modulation of receptor
surface expression?

A. In Chpater 3, we focused on the regulation of CaSR functional cooperativity by
extracellular binding of Ca2+ and amino acids.
Although previous lab members predicted five potential Ca2+ binding sites using
computational algorithm as well as grafting approaches, how these Ca2+ binding sites are
correlate with each other in tuning the function of CaSR is still a mystery. Calcium binding sites
are usually invisible even in determined structures of the ECD such as mGluR1. Combined with
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the challenge, the lack of direct binding methods for determinging cooperativity in its responses
to Ca2+ and amino acids and the high off rates of these binding ligands associated with their
weak binding affinities discourage the structural and functional study of the CaSR.
The major findings in the chapter are summarized in the following figure (see Fig. 3.10 for
details).

The studies in Chapter 3 are important and novel for several reasons:
First, we have documented for the first time the predicted Ca2+-binding site 1 within the
hinge region of the CaSR’s ECD plays a central role of molecular connectivity in tuning the
positive cooperativity caused by changes in [Ca2+]o. Second, We also identified a potential L-Phe
binding pocket in the hinge region of CaSR ECD which plays a key role in regulating the
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heterotropic cooperativity of CaSR. Third, we were able to demonstrate of the interplay among
extracellular Ca2+, amino acids and the CaSR via molecular connectivity that modulates the
positive homotropic and heterotropic cooperativity of CaSR-mediated intracellular Ca2+
signaling. The positive cooperative co-activation of the CaSR by Ca2+ and L-Phe and the
importance of the positive homotropic and heterotropic cooperativity, respectively, exhibited by
the two agonists may be further extended to other members of the family C GPCRs to facilitate
an understanding of the molecular basis for related human disorders and the development of new
therapeutic strategies.

B. In Chapter 4 & 5, we analyzed how the disease associated CaSR mutants can affect the
functional cooperativity mediated by Ca2+ and amino acids.
Several naturally occurring mutations in the CaSR are located in the extracellular domain of
CaSR. However, due to the lack of structure information about this receptor, it is not clear how
calcium modulates those CaSR mutants as well as the molecular basis of those clinical disorders
associated with this receptor. By collaborating with Prof. Thakker’s group at University of
Oxford, we have demonstrated the importance the predicted Ca2+-binding sites play in regulating
the function of the receptor. Among the thirty-four VFTD missense mutations we have identified,
18 mutations were located within 10 Angstroms of one or more of the Ca2+ binding sites,
particularly at the calcium binding site 1, which is the principal site of Ca2+ binding. Moreover,
our studies strongly suggested that the Ca2+ binding site 1, which is encoded in the VFTD, is the
key for connecting the other calcium binding sites and regulting the receptor activity. Two
residues 173 and 221 located at the entrance to the VFTD cleft binding site, were associated with
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both receptor activation (L173F, P221L) and inactivation (L173P, P221Q), thereby highlighting
the importance of the molecular connectivity linked by the Ca2+ binding site 1 . We also found
that the heterotropic cooperativity introduced by L-Phe can be limited by gain-of-function
mutants.Both in silico and in vivo results indicated that the residue Leu173, which is close to
residues that are part of the L-Phe-binding pocket, exhibited impaired heterotropic cooperativity
in the presence of L-Phe.
The following schematic figure summarizes our work in Chapter 4 and 5.
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These naturally occurring mutations, therefore, may be useful for further probing the
functions of Ca2+-binding site 1 and the adjacent L-Phe binding site in producing the positive
cooperative interactions that are critical for the capacity of the CaSR to sense both mineral ions
and amino acids. Last but not least, our findings may provide key insights into molecular
mechanisms shared with other members of the class C GPCRs, including metabotropic glutamate
receptors (mGluRs), GABAB receptors, pheromone receptors, and taste receptors, that are
regulated by Ca2+o.

C. In Chapter 6 and 7, we have probed the Ca2+ and L-Phe binding affinity, cooperativity,
and related conformational change of both mammalian and bacteria expressed ECD by
various biophysical methods.
The challenges associated with probing the key question, how CaSR senses the alterations of
calcium concentration, are multifaceted. First, the full length of CaSR is huge (260 kDa), even
the extracellular domain of the CaSR is comparably larger (~70 kDa based on sequence only )
than most of the proteins that can be expressed and purified using bacterial system (< 60 kDa). In
order to get the protein within its native conformation, eukaryotic system may be the best choice.
Second, the multiple glycosylation sites (11) in the ECD can cause difficulties in crystallization.
Besides, those glycans also introduce structural heterogeneity into the entire system make the
protein in infavorable condition for structure studies using NMR. Third, despite extensive
functional studies of CaSR by different groups, how calcium and L-Phe interact with the
extracellular domain is still under debate due to the lack of structural information. Fourth, the
direct visualization of interaction of Ca2+ and Phe to the receptor ECD has also been hampered
by the high off rate associated with weak binding during X-ray crystallography. Last but not least,
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direct monitoring of such interactions in solution and characterization the biophysical properties
of the large size protein and collection of structurally related information using spectroscopic
methods also requires a large amount of homogenous native protein.
In these two chapters, we demonstrated our progress in coping with the challenges stated in
the last paragraph. By collaboration with Dr. Kelley W. Moremen, we expressed and purified the
CaSR ECD, which was shown to play important role in intracellular calcium responses, using
bacteria and mammalian expression systems. The native conformation of the bacterial expressed
protein was compared to the mammalian expressed protein using by immunoblotting technique
and metal binding FRET assay. The secondary structures of the purified proteins were verified
using circular dichroism. Using various spectroscopic methods, we have shown that both protein
variants bind Ca2+ with a to Kd of 3.0~5.0 mM, which were hardly affected by the level of
glycosylation. We have demonstrated for the first the direct interaction between the CaSR and its
ligands. The calcium binding induced local conformational changes of the protein can be
visualized by NMR with both uniformly labeled and specific 15N Phe-labeled ECDs. By utilizing
the saturation transfer difference (STD) NMR technique, we report for the first time the direct
interaction between the CaSR ECD and its positive allosteric modulator L-Phe. We further
demonstrate that L-Phe increases the binding affinity of the CaSR ECD for Ca2+. This current
study provides valuble molecular basis for studying the connectivity between different calcium
binding sites. Our findings also present new insights into the mechanism of how Ca2+ and amino
acids regulate the CaSR and other proteins in the G protein coupled receptors (GPCR)
superfamily and may pave the way for exploration of the structural properties of CaSR.
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D. In Chapter 8, we have studied the molecular mechanism underlying receptor trafficking
upon the interaction with various agonists.
Given the fact that the CaSR has low affinity for Ca2+ or allosteric regulators such as amino
acids, small peptides (in the range from M to mM), structural and functional studies about this
receptor are mainly through mutagenesis induced changes. And the regulation about the CaSR is
largely from signaling readouts of intracellular calcium, lipids or mitogen-activated protein
kinase (MAPK) pathways. The complex and hysterestic regulation of the downstream signaling
pathways independent of the activated recptors, combined with receptor desensitization,
contribute to the difficulties to describe the responses exclusively to the CaSR. Understanding
the factors that regulate the life cycle of the receptor in the context of physiological condition is
crucial for developing strategies to regulate CaSR activities.
In our previous study, we have demonstrated a CaM-binding domain (CaMBD) located
within the C terminus of CaSR (residues 871–898) interacting with CaM in a Ca2+-dependent,
stoichiometric way. Our studies suggest a wrapping around 1–14-like mode of interaction that
involves global conformational changes in both lobes of CaM with concomitant formation of a
helical structure in the CaMBD. More importantly, the Ca2+-dependent association between CaM
and the C terminus of CaSR is critical for maintaining proper responsiveness of intracellular Ca2+
responses to changes in extracellular Ca2+ and regulating cell surface expression of the receptor.
In chapter 8, we particularly investigated how calmodulin regulates of the CaSR mediated
cytosolic Ca2+ signaling and the receptor cell surface expression. We found that in the presence
of L-Phe, the agonist driven insertion signaling (ADIS) was enhanced in HEK293 cells
transfected with either wild type CaSR or disease related loss-of-function mutant CaSR. Further
analysis with the calmodulin (CaM) inhibitor suggested CaM could involve in regulating the L-
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Phe enhanced ADIS. Studies on the CaSR with mutations at calmodulin binding domain which
interrupted CaM-CaSR interaction and the CaSR with Filamin A binding domain truncation
showed that not only the L-Phe induced intracellular calcium[Ca2+]i oscillation was altered, but
the L-Phe promoted receptor insertion phenomena was abolished. Thus, L-Phe possibly regulates
the receptor through CaM and Filamin A modulation. Our working model is summarized in the
following figure (see Fig. 8.7 for details)

Ca2+

CaM

P

CaM

P
P

ERK

Ca2+

The significance of the work relyis on the fact that CaM not only interact with the CaSR, but
also its activity is prevalently involved in the function of other GPCR family members. Since
GPCRs meet at least a subset of the criteria for the ADIS mechanism, such as a large
intracellular pre-Golgi pool of receptors, chronic or extended exposure to agonist during receptor
life cycle, relatively low steady-state plasma membrane amounts of receptor and a CaM binding
domain at C-tail, our findings may be a relevant regulatory mechanism for other GPCRs, include
mGluRs, adrenergic, dopamine and cannabinoid receptors etc.
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E. In Chapter 9, we have investigated the regulation of CaSR functional cooperativity by
modulation of surface expression via [Ca2+]ER signaling.
Ca2+ signaling is one of the most ubiquitous cellular events in living organisms. It regulates
tremendous amount of biological functions. The endoplasmic reticulum (ER) lumen, which
occupies less than 10% of cell volume, stores >90% of intracellular Ca2+ and is crucial in
controlling Ca2+ signaling. Directly monitoring fast ER Ca2+ dynamics in living cells is still a
new field, and understanding how the ER [Ca2+] can regulate the trafficking of receptors is a
challenging project.
In Chapter 9, we reported that our lab has used the ER calcium probe developed in our lab -- CatchER as well as the commercial available ratiometric dye Mag-Fura 2 to investigate how
[Ca2+]ER regulates the expression of the receptor. The working model is summarized in the
following schematic diagram.
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The significances are in several layers. First, we first documented how the dynamics of
[Ca2+]ER upon the extracellular induced intracellular calcium oscillation. Second, we analyzed
the influence of CaSR allosteric regulators on the intracellular calcium store. Third, this
approach can be applied to other receptors located on the cell membrane.
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APPENDICES
Appendix A: EMOC, a Novel Endoplasmic Reticulum Protein that Regulates Cell Growth
and Ca2+ Store-Operated Entry
INTRODUCTION
The endoplasmic reticulum (ER) is a key organelle involved in controlling major cellular
functions including protein synthesis and modification as well as intracellular Ca2+ homeostasis
[1, 2]. In recent years, the role of ER in the regulation of intracellular signal transduction is
beginning to become clear. A number of ER-associated proteins are known to modulate
intracellular Ca2+ signaling, including, for example, calreticulin, glucose-regulated protein 78
(Grp78/Bip), 94(Grp94), and calsequestrin [reviewed in 3]. Other types of ER-associated
proteins are ER-membrane calcium channels; for example, the ER Ca2+ uptake channels, formed
by sarcoplasmic/ER Ca2+-transporting ATPases (SERCAs), and the Ca2+-releasing channels,
constituted by the inositol-1,4,5-triphosphate receptor (InsP3R) or ryanodine receptors (RYRs)
[3].

Many of these proteins are known to regulate several cellular processes including

proliferation, adhesion, motility, metabolism, differentiation, gene expression and apoptosis [4,
5].
Store-operated calcium (SOC) channels play important roles in regulation of a series of
distinct cellular processes including cell migration, gene expression, cell growth and apoptosis
[reviewed in 6, 7]. Store-operated Ca2+ entry (SOCE) is evoked by depletion of Ca2+ from the ER.
It has been noted that depletion of intracellular calcium store triggers the opening of plasma
membrane Ca2+ channels that leads to Ca2+ influx [6-8]. Although the phenomenon of SOCE was
noted many years ago, little is known about proteins that regulate SOCE process. Recent studies
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have identified two proteins, STIM1 (stromal interaction molecular 1) and Orai1 (also named
CRACM1) that are believed to work together to regulate SOCE. While STIM1 functions as the
ER Ca2+ sensor [9-11], Orai1 is an essential pore-forming subunit of the plasma membrane Ca2+
release-activated Ca2+ (CRAC) [11-14]. Several lines of evidence suggest that when the ER Ca2+
stores are replete, STM1 predominantly localizes in the ER-membrane, however, in the event
that ER Ca2+ stores are depleted, STIM1 forms oligomers and redistributes to ER-plasma
membrane junctions as STIM1 clusters (aggregates) [9, 15, 16]. Evidence also suggests that
STIM1 recruits ORAI1 protein to the regions directly opposite of the STIM1 clusters and
STIM1-ORAI1 interactions activate ORAI1 channels resulting in Ca2+ influx through the ORAI1
channels [8, 15, 17-19]. While these findings significantly enhance our understanding of how
SOCE is regulated, several questions still remain unanswered and warrant further investigations.
Chief among those are how STIM1 and ORAI1 are regulated and whether other cellular protein(s)
is/are also involved in the regulation of SOCE process.
In the present study, we report the characterization of a novel ER membrane protein named
EMOC (ER Membrane protein Overexpressed in Cancer). Our study shows that EMOC is an
integral ER membrane protein that harbors two transmembrane domains. Our study also shows
that EMOC forms oligomers and binds to Ca2+. Importantly, we have also provided evidence that
EMOC is linked to controlling of cell growth and appears to play a role in regulation of SOCE.
Thus, our studies indicate EMOC to be another cellular protein involved in the regulation of the
SOCE process.

EXPERIMENTAL PROCEDURES
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Measurements of intracellular calcium concentration: Measurement of intracellular Ca2+ was
performed as described [39]. Briefly, Hela and 293T cells with scrambled RNAi or EMOC
RNAi were seeded on coverslips and further cultured for 48 hrs. The cells on the coverslips were
subsequently loaded using 4 μM Fura-2 AM in 2 mL physiological saline buffer (10 mM
HEPES, 140 mM NaCl, 5 mM KCl, 0.55 mM MgCl2, 1 mM CaCl2 and pH 7.4) for 15 mins.
Then cells were washed with ringer buffer and coverslips were mounted in a bathing chamber on
the stage of a Leica DM6000 fluorescence microscope. The Fura-2 emission signals at 510 nm
from cells excited at 340 or 380 nm were recorded in real time during the experiments as 500 nM
thapsigargin was added and the concentration of extracellular Ca2+ was changed to 2 mM. The
data representing relative intracellular Ca2+ change were plotted as 340/380 fluorescence ratios.

The Mn2+ Quench Assay: The Mn2+quench assay was performed as described [9]. In brief, cells
were seeded on 13.5 × 20 mm coverslips. Before experiments, 4 mM fura-2/AM was loaded into
cells. After 20 mins, the remaining extracellular Fura-2/AM was washed out with Ringer buffer
and the coverslips were transferred to a fluorescence cuvette. Before data acquisition, 2 mM
Mn2+ in HBSS buffer was added to the cuvette. Thapsigargin was added 50 seconds later, and the
experiment was continued for another 300 seconds. Quenching of Fura-2 fluorescence signal was
measured at 510 nm with excitation at 360 nm.
RESULTS

EMOC plays a role in regulation of store-operated calcium influx: Because our results
indicate that EMOC is an ER-membrane Ca2+-binding protein, next, we examined the effect of
EMOC on cellular Ca2+ homeostasis. To this end, we employed a lentiviral shRNA-mediated
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knockdown (KD) approach to deplete EMOC and to determine the effect of EMOC on Ca2+
release from ER and on Ca2+ influx after intracellular Ca2+ store depletion. First, we performed
EMOC knockdown and Figure 8A shows that EMOC expression was sufficiently depleted by the
lentilvirus-mediated EMOC shRNA. Next, we performed “Ca2+ add-back” experiments, in which
the ER Ca2+ stores were first depleted by treating cells with thapsigargin (TG) in the absence of
extracellular Ca2+,

then 2 mM extracellular Ca2+ was added back to trigger intracellular Ca2+

depletion-induced store operated calcium (SOC) influx. Ca2+ release from the ER and
extracellular Ca2+ influx were monitored in whole cell population by Furo-2-based assays. As
shown in Figure 8B, there was no significant difference in TG-evoked Ca2+ transient (1st peak)
observed in the EMOC knockdown cells and in control scrambled RNAi cells. These results
indicate that EMOC may not have a strong effect on ER Ca2+ store and release because when no
extracellular Ca2+ is added, TG-evoked Ca2+ transient is mainly contributed by Ca2+ released
from the ER. By contrast, when ER Ca2+ was depleted by TG and extracellular Ca2+ was added,
the intracellular Ca2+ transient signal (2nd peak) was significantly lower (by 40-60%) in the
EMOC knocked down cells (Figure 8B). We also similarly performed the “Ca2+ add-back”
experiments using another cell line 293T, and as shown in Figure 8C and D, EMOC depletion
also led to a reduced Ca2+ transient signal in EMOC knockdown cells when extracellular Ca2+
was added after ER Ca2+ was depleted by TG. These results indicate that the absence of EMOC
protein significantly alters Ca2+ transient. Because the suppression of Ca2+ signal in the EMOC
knockdown cells seen in Figure 8 could be due to a mechanism involving a decreased Ca2+ influx
from the store operated-channel or due to a mechanism that is involved in an accelerated plasma
membrane Ca2+ extrusion, we performed the Mn2+ quench assays to further differentiate these
two possible mechanisms. Like Ca2+, Mn2+ can enter cells via the SOC influx channels to form a
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non-florescence complex with Fura-2. Thus, the Mn2+ quench assay is widely used to investigate
the regulation of SOC influx [9, 30]. We reasoned that, if EMOC were involved in the regulation
of SOC influx, we should be able to observe a difference in intracellular Ca2+ transient monitored
by Fura-2 in cells depleted with the EMOC expression when extracellular Mn2+ was present. As
shown in Figure 9A&B, Hela EMOC knockdown cells (EMOC RNAi) exhibited significantly
reduced Mn2+ quench-rate evoked by TG (Figure 9A and B) compared with cells expressing the
control RNAi (Scr. RNAi).
In addition, EMOC depletion also has similar effect in influencing SOC influx in 293T cells
(Fig. 9C&D). Thus, these results indicate that EMOC depletion significantly reduces the rate of
Mn2+ entrance through the SOC channels and that EMOC plays a role in the regulation of SOC
influx.
Interestingly, this behavior of EMOC in regulation of SOC influx appears to be similar to
that of STIM1 protein, a key SOCE Ca2+ sensor in the ER [9, 10, 31]. Furthermore, EMOC also
has additional STIM1-like features including, for example, EMOC is an integral ER membrane
protein that binds to Ca2+ and forms oligomers. Whether EMOC functions in a manner similar to
STIM1 in regulation of SOCE is an interesting and important issue that remains to be
investigated.
In summary, the present studies have characterized a novel ER transmembrane protein, EMOC.
EMOC protein binds to Ca2+ and regulates Ca2+ homeostasis. Our mechanistic studies also
indicate that EMOC is involved in the regulation of the store-operated calcium influx. Thus, our
data suggest EMOC is a new and critical factor, in addition to STIM1 and ORAI1, involved in
regulating the SOCE process.
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Figure 8. Depletion of EMOC expression significantly reduces thapsigargin (TG)- and
extracellular Ca2+-induced transient [Ca2+]i (intracellular Ca2+ concentration) increase.
A&B, results obtained from Hela cells. C&D, results obtained from 293T cells. For these
assays, TG (500 nM) was first added to deplete ER-stored Ca2+ in the absence of
extracellular Ca2+. CaCl2 (2 mM) was introduced after intracellular calcium concentration
reached to a plateau to trigger calcium influx. The ratio of emission signals at 510 nm from
cells excited at 340 or 380 nm were recorded in real time respectively for scrambled RNAi
expressing cells (black line) or for EMOC RNAi expressing cells (red line). For Hela cells
(A and B), results shown are the average Ca2+ responses of 16 control (Scr. RNAi) and 18
EMOC-KD (EMOC RNAi) single cells; and for 293T cells, results shown are the average
response of 46 control (Scr. RNAi) and 14 EMOC KD (EMOC RNAi) single cells. A and C
are results of one representative experiment performed in Hela cells (A) or 293T cells (C).
B and D, bar graphs represent averaged Ca2+ influx peak (ΔF340/F380 ratio) ± s.e.m. of
three-independent experiments in Hela cells (B) or in 293T cells (D). Expression of EMOC
mRNA in control and EMOC knockdown cells determined by RT-PCR assay is also shown
(B and D).
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Fig. 9. EMOC knockdown significantly suppresses the store-operated channel entry
demonstrated by the Mn2+ quench assay. The Mn2+ quench assay was performed as
described in the Materials and Methods. A&B, results obtained from Hela cells. C&D,
results obtained from 293T. The relative Fura-2 fluorescence intensity was measured with
360 nm excitation as a function of time in the control (Scr. RNAi, black line) and EMOC
knockdown cells (red line). Mn2+ quench rate (ΔF/F) measured in the scrambled RNAi and
EMOC RNAi expressing cells in the absence (clear bars) or in the presence of thapsigargin
(TG) (dark bars).
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Appendix B: Enhancing Near IR Luminescence of Thiolate Au nanoclusters by Thermo
Treatments and Heterogeneous Subcellular Distributions
INTRODUCTION

Soluble gold nanoclusters can be categorized as very small gold nanoparticles. Unlike other
nanomaterials normally described by size and shape, a definitive chemical composition of Au
nanoclusters could be elucidated regarding the number of Au atoms forming an Au core and the
number of chemically bonded molecules on core surface forming a monolayer of stabilizing
ligands. Novel physicochemical properties distinct from larger Au nanoparticles have been
discovered, which render the Au nanoclusters broad applications in fundamental research and
biomedical and energy applications. Of particular relevance to this report is the intrinsic
photoluminescence in near IR wavelength range from aqueous soluble Au nanoclusters with core
diameter smaller than 2 nm stabilized by a monolayer of thiolate ligands. The small overall
dimension makes them biocompatible, readily accessible to subcellular domains and ultimately
body-clearable, while an emission maximum longer than 650 nm is highly advantageous for cell
imaging due to drastically reduced background absorption, autofluorescence and other
interferences. If the quantum efficiency (QE) of the near IR emission could be further enhanced
and approach the QEs of organic dyes or semiconductor quantum dots, those aforementioned
advantages of Au nanoclusters will make them superior candidates in studying the dynamic and
heterogeneous cellular processes for biomedical applications over other counterparts. The
luminescence properties of Au-thiolate nanoclusters have been studied from fundamental
perspective and applied for bioimaging applications.1 An optical energy gap between the highest
occupied and lowest unoccupied orbitals is required to observe appreciable photoluminescence,
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albeit the emission energy does not match the band gap of the Au nanoclusters in most cases.2, 3
A large Stokes shift exists between the visible excitation and near IR emission. The observation
suggests significant energy relaxation that is also supported by the long lifetime at nano to micro
seconds.4 An upper threshold in core size of 2.2 nm was determined by transient optical
measurements from hexanethiolate stabilized Au nanoclusters.5, 6 Strong dependence on ligand
polarity of the luminescence QE was initially reported via the comparisons through ligand
exchanged and directly synthesized Au nanoclusters.7, 8 Possible charge interactions between
the Au core and the ligands were further studied on well-defined monodispersed Au25
nanoclusters.9 Optimization of those parameters leads to enhanced QE of the near IR emission
(i.e. emission max > 650-700 nm) at ca. 1% for aqueous soluble and ca. 8% for non-aqueous
soluble Au nanoclusters. To make the near IR emitting Au nanoclusters competitive with organic
dyes and nanoclusters that display intense visible emissions, further enhancement in QE would
be favorable. Recently, a synthetic procedure involving heating induced aggregation was
reported to generate Au nanoclusters displaying bright emission centered at ca. 600 nm.10 For
the preformed Au nanoclusters, heating in the presence of excess thiols as ligands arguably
reduced the core size, known as core etching process.11,12 An annealing procedure was
developed to improve the electrochemical properties of the Au nanoclusters.13 It generally
adopts milder conditions compared with etching, using limited amount of excess thiols (same as
those ligands already on the Au nanoclusters) and lower temperatures. The nanomaterials quality
is improved presumably by the elimination of those less thermodynamically stable species, or by
the optimization of the thiolate-Au bonding,14-16 or both. Besides the introduction of
multidentate dithiol ligands to tailor the core-ligand interfaces and particularly the
luminescence,17-19 we have reported the observation of the individual Au nanoclusters and their
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distribution inside fixed HeLa cells under confocal microscope via luminescence intensity and
lifetime imaging.20 Au is FDA approved materials due to its non- or low toxicity. Various Au
nanoclusters and Au complexes have been used in basic biomedical research and as diagnostic
and therapeutic tools.21-23 Fundamental understanding regarding the fate of such small
nanoclusters in cells is rather diffusive.24-29 One of the essential questions related to those
contradictory reports is whether the nanoclusters could efficiently enter cell and nucleus, and
what internalization pathway is responsible for the dynamic processes. Apparently, labeling
nanomaterials with fluorescent probes adds additional variables and complicates the analysis.
Ex-situ measurements by mass spectrometry, electron microscopy, or sedimentation etc. are less
capable to capture living cell dynamics and heterogeneity, information essential for living
subjects.22, 30 This report establishes a universal approach to enhance the near IR luminescence
of Au nanoclusters with different sizes (less than 2 nm) and different protecting ligand molecules.
Because the surface chemistry is known to be critical in the nano-bio interactions, a
generalizable method to enhance the QE of Au nanoclusters with different surface functionalities
could enable in-situ dynamic cellular studies previously inaccessible. Two types of monothiols,
mercaptosuccinic acid (MSA) and tiopronin (Tio), were employed to synthesize different Au
nanoclusters under a variety of conditions. Heating each batch of the purified Au nanoclusters in
the presence of the corresponding thiols was found to drastically enhance the emission QE by ca.
5-10 folds. After the incubation with live human embryonic kidney (HEK) cells, confocal
microscope analysis demonstrates the heterogeneous distribution of Au nanoclusters inside the
fixed HEK cells. Furthermore, co-distribution with nucleus stain dye reveals their presence
inside cell nucleus.
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EXPERIMENTAL SECTION

Confocal Fluorescence Microscopy. Human embryonic kidney 293 (HEK) cells were incubated
with Au-MSA-PEG at 37 °C in cell culture media over 24 hours. The cells were then washed in
triplicate with PBS buffer followed by fixation with 4% ice cold 100% methanol in -20 °C for
5~10 minutes. Subsequently, cells were mounted on glass slides using Prolong Gold Antifade
reagent with DAPI (P36391; Invitrogen) followed by triplicate washing with PBS prior to
confocal imaging.
RESULTS

Confocal Fluorescence Imaging A key concern for the usage of nanomaterials as medicine or
contrast enhancing agents for diagnostics and therapeutics is the prolonged body retention and
subsequent potential toxicity. Effective renal clearance has been reported for nanoparticles with
an overall dimension of 5 nm or smaller combined with proper surface chemistry design.35, 36
Because the kidneys play a major role in nanoparticles body retention and clearance, in this
report, the distribution of the luminescent Au nanoclusters in kidney cells is investigated to offer
fundamental insights at cell and subcellular levels for potential in-vitro and in vivo applications.

The enhanced QE of Au nanoclusters enables direct imaging using commercial confocal
fluorescence microscope, albeit only a small portion of the emitted photons could be captured by
the PMT detectors. Heterogeneous subcellular distribution inside individual HEK cells can be
readily resolved in Figure 6, information inaccessible by ex-situ and ensemble measurements
such as mass spectrometry, ICP OES. The membrane boundaries of individual HEK cells can be
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seen under bright field. A fluorescent dye DAPI, widely used to stain DNA due to its high
binding affinity to A-T, is co-distributed to highlight cell nucleus region. The blue and red
channels record the shorter wavelength emission from DAPI and the near IR emission from the
Au nanoclusters respectively. The co-distribution of the Au NCs inside the cells is further
demonstrated in the two overlay panels. In comparison, Au NCs without heat treatments could
not be observed in similar imaging studies at comparable dosage. Those treated Au NCs without
PEGlation, though detectable directly under the PMT detectors, could not be observed inside the
cells under comparable conditions.

To affirm that the Au NCs are inside cell nucleus, a series of z-stack images are presented in
panel B (i.e. from the top toward the bottom of the cells). It is obvious that the emissions from
both DAPI and Au nanoclusters become more intense toward the center of the cell. The features
strongly suggest that the Au NCs are inside cell and cell nucleus instead of being adsorbed on
membranes, which would otherwise display ring-like features along the membrane peripheries
within focus, especially at middle z positions. Further, the Au NCs distribute heterogeneously
both within individual cells and between different cells: some cells show very low intensity from
Au NCs both in cytoplasm and in nucleus; some show high intensity in cytoplasm but low in
nucleus; while other cells have a high intensity both in cytoplasm and nucleus. The more intense
clustered red emission signals in cytoplasm suggest confinement or enriched Au NCs within
unidentified organelles, presumably endosomes.
The kinetics and pathways of the cell internalization of nanomaterials are known to be
heterogeneous and require more systematic studies.37 Internalization will differ at different
phases of cell life cycle,38 which could explain the heterogeneous distributions observed.
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Furthermore, the Au nanoclusters are not functionalized with specific biomarkers, and thus are
expected to non preferentially distribute inside the cell if internalized. Due to the small
dimension, passive diffusion is possible across the cell membrane and maybe nucleus
membrane.26, 28, 37, 39 The kinetics of internalization and sub-cellular distribution of the Au
NCs at different dosage and other conditions are under further investigation. Regardless, the
consistent presence of Au nanoclusters at the center of multiple individual cells clearly
demonstrated that these Au nanoclusters penetrated both the cytoplasm and nucleus of HEK cells
that enable further cell dynamics and function studies.
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Figure 6. Confocal images of fixed HEK293 cells. The cells were exposed to 50 μg/mL AuMSA-PEG NCs (60% of original QE prior PEGlation) for 24 hours prior fixture. Panel A:
clockwise from left: Au-MSA-PEG; Bright field; DAPI; Composite emissions from DAPI
and Au-MSA-PEG; Composite image of bright field, DAPI and Au-MSA-PEG. The images

330
correspond to frame 10 in panel B. Panel B: Z-stack images of composite emissions from
DAPI and Au-MSA-PEG. The images were taken in a series of 15-step 1-μm-step-size
measurements, starting from above the cell (TOP) toward the bottom of the cell.
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Appendix C: CaSR May Play A Role In Osteoclastogenesis.
The bone turnover is a process that continuously exists throughout life. Osteoclasts which are a
group of cells responsible for bone resorption and osteoblasts which take in charge of bone
formation work collaboratively to ensure the old bones degradation and the new bones formation
(317). The bone remodeling process is believed to be initiated by the recruitment of
monoucleated osteoclast precursors from circulation (318). The osteoclast precursors then fused
with these cells after them infiltrating the bone lining cell layer, thus forming multinucleated
osteoclasts(319). The apoptosis of osteoclast ends the phase of resorption but begins the bone
formation phase by recruiting osteoprogenitor cells to the resorption surface(320).

The skeleton is considered as a major reservoir of calcium and phosphorus. These bone derived
products attract various cell types to the bone environment (321). For instance, Olszak et al.
found that Ca2+ promote the migration of peripheral blood monocyte cells (PBMC)(322,323).
Since Ca2+ can form great concentration gradient in the bone environment (up to 40
mM)(324,325), it is reasonable to hypothesize Ca2+ is one of the signals that involving the
physiological and pathological process of bone modeling.

Arthritis is a form of joint disorder due to the inflammation on one or more joints. Osteoarthritis
is the most common form of arthritis. Patients with arthritis could suffer from constant pain
located to the joint affected, causing swelling, stiffness and limited movements. The basic
treatment involves physical therapy and prescription of anti-inflammation drugs. However, only
a few arthritis-related disorders can be completely cured, most of the rest are chronic conditions.
It has been reported that the mean serum calcium level are lower in patients with rheumatoid
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arthritis than health(326). Nevertheless how calcium concentration can affect the disease state is
barely understood.

Calcium sensing receptor can sense the variation of calcium concentration and regulate the
secretion of the parathyroid hormone (PTH) and calcitonin. By analyzing the receptor’s function
in RAW264.7 cells, a well established osteoclast precursor model, recent studies have found that
CaSR are intimately involved in regulating osteoclastic activities(57). Boudot et.al. reported in
2010 that CaSR could be a possible candidate for the initiation of the basic multicellular units
(BMU), which is a temporary anatomical structures during the bone remodeling(321). However,
little is known about how CaSR plays a role in the process of Arthritis.
In this study, we analyzed the CaSR expression level in RAW264.7 cells and carried out
preliminary researches on the differentiation of the CaSR knock down RAW264.7 cells. A few
tissue samples from mice with or without rheumatoid arthritis were tested with CaSR specific
antibodies.
Preliminary Results
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RANKL D6 4 mM Ca2+

Control 4 mM Ca2+

RANKL D6 1.5 mM Ca2+

Control 1.5 mM Ca2+

RANKL D6 4 mM Ca2+

Control 4 mM Ca2+

RANKL D6 1.5 mM Ca2+

Control 1.5 mM Ca2+

Figure. C-1 High [Ca2+]o and RANKL could promote the CaSR expression in RAW264.7
cells. Cells were incubated either in normal [Ca2+]o medium or 4.0 [Ca2+]o culture medium
with or without the addition of RANKL. The mRNA was then extracted from those cells
with various treatments. RT-PCR was performed to analyze the CaSR expression level.
GAPDH was used as internal control.
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Figure C-2 High [Ca2+]o and RANKL stimulate the expression of CaSR. Cells were lysated
in RIPA buffer after incubation in 1.5 mM [Ca2+]o or 4.0 mM [Ca2+]o in the presence or
absence of RANKL. Subsequent to membrane transference, the membrane was incubated
anti-CaSR specific antibody (ADD) or internal control antibody (GAPDH) overnight at
4C. Upper panel: CaSR; Lower panel: GAPDH.
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Figure C-3 Immunostaining of CaSR in RAW264.7 cells. A. Brightfield image of control
group cells. B. Cells were fixed and further stained with anti-CaSR specific antibody
(ADD). C. Bright field image of cells treated with 100 ng of RANKL for 6 days. D After
treatment with RANKL for 6 days, cells were fixed and permeabilized with 0.2%
tritonX100. Red: anti-CaSR antibody staining; Blue: DAPI staining.
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Figure C-4. The proliferation of RAW264.7 cells in normal and high [Ca2+]o medium. Cells
were cultured for 5 continuous days in either 1.5 mM [Ca2+]o medium or 4.0 mM [Ca2+]o
medium. The total cell numbers were determined using a hemocytometer.
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Figure C-5. RT-PCR of CaSR knock down in RAW264.7 cells.
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Figure C-6 CaSR knock down reduced the osteoclasts induced by RANKL. The CaSR
knock down cells and the control group were subjected with 100ng/L of RANKL for 5
continuous days. A. Brightfield images of RANKL treated RAW264.7 cells. Red arrows:
osteoclast like cells. B. Quantitative analysis of the number of osteoclasts after normalized
to the control group.
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Figure C-7 HE Staining of CaSR in physiological and pathological tissue samples. A. Paw
tissues from normal mouse stained with anti-CaSR antibody (ADD) at 1:1000. B. Tissues
from rheumatoid arthritis mouse model stained with the same antibody.
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Appendix D: Sequence alignment of CaSR in various species
Rattus
Mus
Homo
Bos
Capra

MASYSCCLALLAL-AWHSSAYGPDQRAQKKGDIILGGLFPIHFGVAAKDQDLKSRPESVE
MAWFGYCLALLAL-TWHSSAYGPDQRAQKKGDIILGGLFPIHFGVAAKDQDLKSRPESVE
MAFYSCCWVLLAL-TWHTSAYGPDQRAQKKGDIILGGLFPIHFGVAAKDQDLKSRPESVE
MALYSCCWILLAFSTWCTSAYGPDQRAQKKGDIILGGLFPIHFGVAVKDQDLKSRPESVE
MALNSCCWILLAFSTWCTSAYGPDQRAQKKGDIILGGLFPIHFGVAAKDQDLKSRPESVE
** . * ***: :* :****************************.*************

59
59
59
60
60

Rattus
Mus
Homo
Bos
Capra

CIRYNFRGFRWLQAMIFAIEEINSSPSLLPNMTLGYRIFDTCNTVSKALEATLSFVAQNK
CIRYNFRGFRWLQAMIFAIEEINSSPALLPNMTLGYRIFDTCNTVSKALEATLSFVAQNK
CIRYNFRGFRWLQAMIFAIEEINSSPALLPNLTLGYRIFDTCNTVSKALEATLSFVAQNK
CIRYNFRGFRWLQAMIFAIEEINSSPALLPNMTLGYRIFDTCNTVSKALEATLSFVAQNK
CIRYNFRGFRWLQAMIFAIEEINSSPALLPNMTLGYRIFDTCNTVSKALEATLSFVAQNK
**************************:****:****************************

119
119
119
120
120

Rattus
Mus
Homo
Bos
Capra

IDSLNLDEFCNCSEHIPSTIAVVGATGSGVSTAVANLLGLFYIPQVSYASSSRLLSNKNQ
IDSLNLDEFCNCSEHIPSTIAVVGATGSGVSTAVANLLGLFYIPQVSYASSSRLLSNKNQ
IDSLNLDEFCNCSEHIPSTIAVVGATGSGVSTAVANLLGLFYIPQVSYASSSRLLSNKNQ
IDSLNLDEFCNCSEHIPSTIAVVGATGSGISTAVANLLGLFYIPQVSYASSSRLLSNKNQ
IDSLNLDEFCNCSEHIPSTIAVVGATGSGISTAVANLLGLFYIPQVSYASSSRLLSNKNQ
*****************************:******************************

179
179
179
180
180

Rattus
Mus
Homo
Bos
Capra

YKSFLRTIPNDEHQATAMADIIEYFRWNWVGTIAADDDYGRPGIEKFREEAEERDICIDF
FKSFLRTIPNDEHQATAMADIIEYFRWNWVGTIAADDDYGRPGIEKFREEAEERDICIDF
FKSFLRTIPNDEHQATAMADIIEYFRWNWVGTIAADDDYGRPGIEKFREEAEERDICIDF
FKSFLRTIPNDEHQATAMADIIEYFRWNWVGTIAADDDYGRPGIEKFREEAEERDICIDF
FKSFLRTIPNDEHQATAMADIIEYFRWNWVGTIAADDDYGRPGIEKFREEAEERDICIDF
:***********************************************************

239
239
239
240
240

Rattus
Mus
Homo
Bos
Capra

SELISQYSDEEEIQQVVEVIQNSTAKVIVVFSSGPDLEPLIKEIVRRNITGRIWLASEAW
SELISQYSDEEEIQQVVEVIQNSTAKVIVVFSSGPDLEPLIKEIVRRNITGRIWLASEAW
SELISQYSDEEEIQHVVEVIQNSTAKVIVVFSSGPDLEPLIKEIVRRNITGKIWLASEAW
SELISQYSDEEKIQQVVEVIQNSTAKVIVVFSSGPDLEPLIKEIVRRNITGRIWLASEAW
SELISQYSDEEEIQQVVGVIQNSTAKVIVVFSSGPDLEPLIKEIVRRNITGRIWLASEAW
***********:**:** *********************************:********

299
299
299
300
300

Rattus
Mus
Homo
Bos
Capra

ASSSLIAMPEYFHVVGGTIGFGLKAGQIPGFREFLQKVHPRKSVHNGFAKEFWEETFNCH
ASSSLIAMPEYFHVVGGTIGFGLKAGQIPGFREFLQKVHPRKSVHNGFAKEFWEETFNCH
ASSSLIAMPQYFHVVGGTIGFALKAGQIPGFREFLKKVHPRKSVHNGFAKEFWEETFNCH
ASSSLIAMPEYFHVVGGTIGFGLKAGQIPGFREFLQKVHPRKSVHNGFAKEFWEETFNCH
ASSSLIAMPEYFHVVGGTIGFGLKAGQIPGFREFLQKVHPRKSVHNGFAKEFWEETFNCH
*********:***********.*************:************************

359
359
359
360
360

Rattus
Mus
Homo
Bos
Capra

LQEGAKGPLPVDTFVRSHEEGGNRLLNSSTAFRPLCTGDENINSVETPYMDYEHLRISYN
LQDGAKGPLPVDTFVRSHEEGGNRLLNSSTAFRPLCTGDENINSVETPYMGYEHLRISYN
LQEGAKGPLPVDTFLRGHEESGDRFSNSSTAFRPLCTGDENISSVETPYIDYTHLRISYN
LQEGAKGPLPVDTFLRGHEEGGARLSNSPTAFRPLCTGEENISSVETPYMDYTHLRISYN
LQEGAKGPLPVDTFLRGHEEGGARISNSSTAFRPLCTGEENISSVETPYMDYTHLRISYN
**:***********:*.***.* *: **.*********:***.******:.* *******

419
419
419
420
420

Rattus
Mus
Homo
Bos
Capra

VYLAVYSIAHALQDIYTCLPGRGLFTNGSCADIKKVEAWQVLKHLRHLNFTNNMGEQVTF
VYLAVYSIAHALQDIYTCLPGRGLFTNGSCADIKKVEAWQVLKHLRHLNFTNNMGEQVTF
VYLAVYSIAHALQDIYTCLPGRGLFTNGSCADIKKVEAWQVLKHLRHLNFTNNMGEQVTF
VYLAVYSIAHALQDIYTCIPGRGLFTNGSCADIKKVEAWQVLKHLRHLNFTSNMGEQVTF
VYLAVYSIAHALQDIYTCIPGRGLFTNGSCADIKKVEAWQVLKHLRHLNFTSNMGEQVTF
******************:********************************.********

479
479
479
480
480

Rattus
Mus
Homo
Bos

DECGDLVGNYSIINWHLSPEDGSIVFKEVGYYNVYAKKGERLFINEEKILWSGFSREVPF
DECGDLVGNYSIINWHLSPEDGSIVFKEVGYYNVYAKKGERLFINEGKILWSGFSREVPF
DECGDLVGNYSIINWHLSPEDGSIVFKEVGYYNVYAKKGERLFINEEKILWSGFSREVPF
DECGDLAGNYSIINWHLSPEDGSIVFKEVGYYNVYAKKGERLFINDEKILWSGFSREVPF

539
539
539
540

345
Capra

DECGDLAGNYSIINWHLSPEDGSIVFKEVGYYNVYAKKGERLFINDEKILWSGFSREVPF 540
******.**************************************: *************

Rattus
Mus
Homo
Bos
Capra

SNCSRDCQAGTRKGIIEGEPTCCFECVECPDGEYSGETDASACDKCPDDFWSNENHTSCI
SNCSRDCQAGTRKGIIEGEPTCCFECVECPDGEYSGETDASACDKCPDDFWSNENYTSCI
SNCSRDCLAGTRKGIIEGEPTCCFECVECPDGEYSDETDASACNKCPDDFWSNENHTSCI
SNCSRDCLAGTRKGIIEGEPTCCFECVECPDGEYSDETDASACDKCPDDFWSNENHTSCI
SNCSRDCLAGTRKGIIEGEPTCCFECVECPDGEYSDETDASACDKCPDDFWSNENHTSCI
******* ***************************.*******:***********:****

599
599
599
600
600

Rattus
Mus
Homo
Bos
Capra

AKEIEFLAWTEPFGIALTLFAVLGIFLTAFVLGVFIKFRNTPIVKATNRELSYLLLFSLL
AKEIEFLAWTEPFGIALTLFAVLGIFLTAFVLGVFIKFRNTPIVKATNRELSYLLLFSLL
AKEIEFLSWTEPFGIALTLFAVLGIFLTAFVLGVFIKFRNTPIVKATNRELSYLLLFSLL
AKEIEFLSWTEPFGIALTLFAVLGIFLTAFVLGVFIKFRNTPIVKATNRELSYLLLFSLL
AKEIEFLSWTEPFGIALTLFAVLGIFLTAFVLGVFIKFRNTPIVKATNRELSYLLLFSLL
*******:****************************************************

659
659
659
660
660

Rattus
Mus
Homo
Bos
Capra

CCFSSSLFFIGEPQDWTCRLRQPAFGISFVLCISCILVKTNRVLLVFEAKIPTSFHRKWW
CCFSSSLFFIGEPQDWTCRLRQPAFGISFVLCISCILVKTNRVLLVFEAKIPTSFHRKWW
CCFSSSLFFIGEPQDWTCRLRQPAFGISFVLCISCILVKTNRVLLVFEAKIPTSFHRKWW
CCFSSSLFFIGEPQDWTCRLRQPAFGISFVLCISCILVKTNRVLLVFEAKIPTSFHRKWW
CCFSSSLFFIGEPQDWTCRLRQPAFGISFVLCISCILVKTNRVLLVFEAKIPTSFHRKWW
************************************************************

719
719
719
720
720

Rattus
Mus
Homo
Bos
Capra

GLNLQFLLVFLCTFMQILICIIWLYTAPPSSYRNHELEDEIIFITCHEGSLMALGSLIGY
GLNLQFLLVFLCTFMQIVICIIWLYTAPPSSYRNHELEDEIIFITCHEGSLMALGSLIGY
GLNLQFLLVFLCTFMQIVICVIWLYTAPPSSYRNQELEDEIIFITCHEGSLMALGFLIGY
GLNLQFLLVFLCTFMQIVICAIWLNTAPPSSYRNHELEDEIIFITCHEGSLMALGFLIGY
GLNLQFLLVFLCTFMQIVICAIWLNTAPPSSYRNHELEDEIIFITCHEGSLMALGFLIGY
*****************:** *** *********:******************** ****

779
779
779
780
780

Rattus
Mus
Homo
Bos
Capra

TCLLAAICFFFAFKSRKLPENFNEAKFITFSMLIFFIVWISFIPAYASTYGKFVSAVEVI
TCLLAAICFFFAFKSRKLPENFNEAKFITFSMLIFFIVWISFIPAYASTYGKFVSAVEVI
TCLLAAICFFFAFKSRKLPENFNEAKFITFSMLIFFIVWISFIPAYASTYGKFVSAVEVI
TCLLAAICFFFAFKSRKLPENFNEAKFITFSMLIFFIVWISFIPAYASTYGKFVSAVEVI
TCLLAAICFFFAFKSRKLPENFNEAKFITFSMLIFFIVWISFIPAYASTYGKFVSAVEVI
************************************************************

839
839
839
840
840

Rattus
Mus
Homo
Bos
Capra

AILAASFGLLACIFFNKVYIILFKPSRNTIEEVRSSTAAHAFKVAARATLRRPNISRKRS
AILAASFGLLACIFFNKVYIILFKPSRNTIEEVRSSTAAHAFKVAARATLRRPNISRKRS
AILAASFGLLACIFFNKIYIILFKPSRNTIEEVRCSTAAHAFKVAARATLRRSNVSRKRS
AILAASFGLLACIFFNKVYIILFKPSRNTIEEVRCSTAAHAFKVAARATLRRSNVSRQRS
AILAASFGLLACIFFNKVYIILFKPSRNTIEEVRCSTAAHAFKVAARATLRRSNVSRQRS
*****************:****************.*****************.*:**:**

899
899
899
900
900

Rattus
Mus
Homo
Bos
Capra

SSLGGSTGSIPSSSISSKSNSEDRFPQ--PERQKQQQPLSLTQQEQQQ---QPLTLHPQQ
SSLGGSTGSNPSSSISSKSNSEDRFPQ--PERQKQQQPLALTQQEQQQ---QPLTLQPQQ
SSLGGSTGSTPSSSISSKSNSEDPFPQ--PERQKQQQPLALTQQEQQQ---QPLTL-PQQ
SSLGGSTGSTPSSSISSKSNSEDPFPQQQPKRQKQPQPLALSPHNAQQPQPRPPSTPQPQ
SSLGGSTGSTPSSSISSKSNSEDPFPQQQPERQKQPQPLALSPHNAQQPQPRPPSTPQPQ
********* ************* *** *:**** ***:*: :: **
:* :
*

954
954
953
960
960

Rattus
Mus
Homo
Bos
Capra

QQQPQQPRCKQKVIFGSGTVTFSLSFDEPQKNAMAHRNSMRQNSLEAQRSNDTLGRHQAL
QQQPQQPRCKQKVIFGSGTVTFSLSFDEPQKNAMAHRNSMRQNSLEAQKSNDTLNRHQAL
QRSQQQPRCKQKVIFGSGTVTFSLSFDEPQKNAMAHRNSTHQNSLEAQKSSDTLTRHQPL
PQSQQPPRCKQKVIFGSGTVTFSLSFDEPQKTAVAHRNSTHQTSLEAQKNNDALTKHQAL
PQSQQPPRCKQKVIFGSGTVTFSLSFDEPQKSAVAHRNSTHQTSLEAQKNNDALTKHQAL
:. * *************************.*:***** :*.*****:..*:* :**.*

1014
1014
1013
1020
1020

Rattus
Mus
Homo
Bos

LPLQCADADSEMTIQETGLQGPMVGDHQPEMESSDEMSPALVMSTSRSFVISGGGSSVTE
LPLQCAEADSEMTIQETGLQGPMVGDHQPEIESPDEMSPALVVSTSRSFVISGGGSSVTE
LPLQCGETDLDLTVQETGLQGPVGGDQRPEVEDPEELSPALVVSSSQSFVISGGGSTVTE
LPLQCGETDSELTSQETGLQGPVGEDHQLEMEDPEEMSPALVVSNSRSFVISGGGSTVTE

1074
1074
1073
1080

346
Capra

LPLQCGETDSELTAQETGLQGPVSEDHQLEMEDPEEMSPALVVSNSRSFVISGGGSTVTE 1080
*****.::* ::* ********: *:: *:*..:*:*****:*.*:*********:***

Rattus
Mus
Homo
Bos
Capra

NVLHS
NILHS
NVVNS
NMLRS
NMLRS
*::.*

1079
1079
1078
1085
1085
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Appendix E: Synergistic Effect
Simplified concept for synergy:
Drug A and Drug B are both agonists for Target T.
Assume: the effect of A only to T equals 1; the effect of B only to T equals 1
Then combination of the following conditions will be defined accordingly:
If A + B > 2; Synergism
If A + B = 2: Additive Effect
If A + B < 2; Antagonism

For a more detailed description, please see the manual of Calcusyn
In the present study,
A= Ca2+
B= L-Phe (or other CaSR agonists)
T=CaSR
Our readout will be the average [Ca2+]i.
Procedure:
First, measure the Calcium (Drug A) only induced receptor activity:
In the WT CaSR transfected HEK293 cells, Fura-2 AM will be loaded using the aforementioned
protocol (normal loading). The intracellular calcium readout will be measured using Leica
microscope.
Change the [Ca2+]o stepwise from 0.0 mM to 10.0 mM for WT and upto 30.0 mM for inactive
mutants, and record the ratio of F340/F380. In the current study, the 0.0 mM, 1.0 mM, 2.0 mM,
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3.0 mM, 4.0 mM, 5.0 mM, 7.5 mM and 10.0 mM were chosen for measuring the Ca2+ dosageresponse
Second, measure the L-Phe (Drug B) only induced receptor activity:
Change the [L-Phe]o stepwise from 0.0 mM to 10.0 mM, and record the ratio of F340/F380. In
the current study, the 0.0 mM, 1.0 mM, 2.0 mM, 3.0 mM, 4.0 mM, 5.0 mM, 6.0 mM, 7.0 mM,
8.0 mM 9.0 mM and 10.0 mM were chosen for measuring the L-Phe dosage-response.
For the CaSR project, the activation of L-Phe requires the presence of minimum 1.0 mM Ca2+,
otherwise, there will be no change for the intracellular calcium readout.
The basal Ca2+ can be varied among different CaSR mutants. For instance, for analyzing WT
CaSR, [Ca2+]o was fixed at 2.0 mM while changing the L-Phe concentration; on the other hand,
7.5 mM of [Ca2+]o was chosen for analyzing the E297I CaSR during the stepwise increase of LPhe. The ratio of F340/F380 was recorded for further analysis. The choice of fixed [Ca2+]o is
depended on the [Ca2+]o of the mutant CaSR to start oscillating.
Third, measure the combination effect (Drug A & B) induced receptor activity:
The L-Phe concentration was fixed at either 5.0 mM or 10.0 mM, [Ca2+]o was increased stepwise
from 0.0 mM to 10.0 mM for WT and from 0.0 mM to 30.0 mM for inactive mutants. The
average intracellular calcium change at each level of [Ca2+]o was recorded accordingly.
Using CalcuSyn for analyzing the synergistic effect:
Choose “Drug wizard” for adding effects for individual drugs; choose “Drug manually” for input
combined effects.
Because the software requires that the input drug effects shall be < 1, so the average intracellular
calcium readout is subtracted from the basal fluorescence ratio value. For example, if the average
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intracellular calcium level is 1.3 under 4 mM [Ca2+]o , and the initial readout for calcium level is
1.03, the number for inputting into the software as the drug effects shall be 1.3-1.03 = 0.27.

Results:

WT and Control
800
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Control

700
1.0 mM

[Ca

2+

], nM
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5.0 mM

20 mM
8.0 mM
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400
300
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2
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6
8
Time (Min)
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Figure E-1 Representative [Ca2+]i oscillation pattern from single-cell study. WT: calcium
concentration increased stepwise. Control: typical [Ca2+]i

response of non-CaSR

transfected HEK293 cells upon the stimulation with extracellular calcium. Similar
phenomena will be seen with increase of L-Phe in the absence of calcium.
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2
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Ratio 340/380
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Figure E-2 Representative [Ca2+]i oscillation pattern from single-cell study. WT: L-Phe
concentration increased stepwise in the presence of 2.0 mM Ca2+.
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Figure E-3 Representative [Ca2+]i oscillation pattern from single-cell study. WT: calcium
concentration increased stepwise in the presence of 5.0 mM L-Phe.

Similar experiments have been done for the CaSR mutants.
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Figure E-4 Representative [Ca2+]i oscillation pattern from single-cell study. E297I: L-Phe
concentration increased stepwise in the presence of 7.5 mM Ca2+.
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5 mM L-Phe

2.4
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Figure E-5 Representative [Ca2+]i oscillation pattern from single-cell study. E297I: Ca2+
concentration increased stepwise in the presence of 5.0 mM Ca2+.
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C

A

Hill number = 5.2 ± 0.2

Hill number = 3.0 ± 0.1

D

B

Hill number = 1.8 ± 0.1

Hill number = 2.5 ± 0.1

Figure E-6 Intracellular calcium response curve upon titration with calcium or L-Phe.
Plots are fitted using Hill equations. A. WT CaSR transfected cellular response to the
extracellular calcium concentration change in the presence of 5.0 mM of L-Phe. B. WT
CaSR transfected cellular response to the extracellular L-Phe concentration change in the
presence of 2.0 mM of calcium. C. E297I CaSR transfected cellular response to the
extracellular calcium concentration change in the presence of 5.0 mM of L-Phe. D. E297I
CaSR transfected cellular response to the extracellular L-Phe concentration change in the
presence of 7.5 mM of calcium.
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a

b
Test for Synergistic Effect on WT
F(mM)
Ca(mM)
CI
1.0
2.0
271.3
1.0
3.5
121.8
1.0
4.0
6296.7
1.0
5.0
8737.2
1.0
7.5
20400.0
1.0
8.0
27100.0
1.0
10.0
135000.0
5.0
1.0
2.5
5.0
1.5
2.1
5.0
2.0
1.8
5.0
3.0
1.5
5.0
3.5
1.5
5.0
4.0
1.5
5.0
5.0
1.2
5.0
7.5
1.4
5.0
8.0
1.7
5.0
10.0
1.8

Test for Synergistic Effect on E297I
F (mM)
1
1
1
1
1
1
5
5
5
5
5
5
5

Ca (mM)
5.0
7.5
10.0
15.0
20.0
25.0
5.0
7.5
8.0
10.0
15.0
20.0
25.0

CI
886.3
6.9
6.3
3.6
1.6
1.5
1.3
1.2
1.1
1.0
1.0
0.9
0.7

Table E-1. Analysis of possible synergy using CalcuSyn in the sensing of calcium and L-Phe
to WT CaSR and mutant E297I. After transfection with WT CaSR for 48 hours, [Ca2+]i
was recorded upon incremental increases in [Ca2+]o in the presence of 1 mM L-Phe or upon
incremental increases in L-Phe in the presence of 2 mM [Ca2+]o. A similar experiment
carried out in cells transfected with mutant E297I in the presence of 1 mM, 5 mM or 10
mM L-Phe. A CI number > 1.0 indicates lack of a synergistic effect of the two ligands in
WT CaSR and mutant E297I.

